

January 2011

The Role of IKK β in Osteoclastogenesis and Inflammatory Osteolysis

Jesse Otero

Washington University in St. Louis

Follow this and additional works at: <https://openscholarship.wustl.edu/etd>

Recommended Citation

Otero, Jesse, "The Role of IKK β in Osteoclastogenesis and Inflammatory Osteolysis" (2011). *All Theses and Dissertations (ETDs)*. 268.
<https://openscholarship.wustl.edu/etd/268>

This Dissertation is brought to you for free and open access by Washington University Open Scholarship. It has been accepted for inclusion in All Theses and Dissertations (ETDs) by an authorized administrator of Washington University Open Scholarship. For more information, please contact digital@wumail.wustl.edu.

WASHINGTON UNIVERSITY IN ST. LOUIS

Division of Biology and Biomedical Sciences

Molecular Cell Biology

Dissertation Examination Committee:

Yousef Abu-Amer, Chair

Roberto Civitelli

Anthony Muslin

Deborah Novack

Phillip Osdoby

Steven Teitelbaum

Dwight Towler

THE ROLE OF IKK β IN OSTEOCLASTOGENESIS
AND INFLAMMATORY OSTEOLYSIS

by

Jesse E. Otero

A dissertation presented to the
Graduate School of Arts and Sciences
of Washington University in
partial fulfillment of the
requirements for the degree
of Doctor of Philosophy

May 2011

Saint Louis, Missouri

ABSTRACT OF THE DISSERTATION

The Role of IKK β in Osteoclastogenesis and Inflammatory Osteolysis

by

Jesse E. Otero

Doctor of Philosophy in Biology and Biomedical Sciences

Molecular Cell Biology

Washington University in St. Louis, 2011

Professor Yousef Abu-Amer, Chairperson

Bone homeostasis is essential for health and is altered in many pathological conditions. A balance in the activity of osteoblasts (bone-building cells) and osteoclasts (bone-resorbing cells) determines the state of bone metabolism, and a tip in this balance toward either cell type is detrimental to health. In clinical settings, the most common bone diseases favor increased osteoclast activity and include osteoporosis and rheumatoid arthritis. Heightened osteoclast differentiation and activation in these conditions causes bone loss which results in increased fracture risk, bone pain, and deformity. Understanding the mechanisms by which osteoclasts develop will elucidate important targets for therapy in these conditions. Osteoclasts differentiate from monocyte precursors when stimulated by the Ligand for Receptor Activator of NF- κ B (RANKL). Recent research has identified many transcription factors that are activated by RANKL

and are important for osteoclast differentiation. One such family of transcription factors is NF- κ B. We hypothesized that activators of NF- κ B are necessary for RANKL-induced osteoclast differentiation. The Inhibitory kappaB Kinase (IKK) Complex, which consists of two catalytically active subunits, IKK α and IKK β , and one regulatory subunit, NEMO, is the main stimulator of NF- κ B downstream of RANK in osteoclast progenitors. Our lab and others show that this activation is critical for stimulation of NF- κ B and osteoclastogenesis. We sought to further characterize the role of the IKK complex in osteoclastogenesis by conditionally deleting IKK β from osteoclast precursors. Using this mouse model, we demonstrated that IKK β is critical for differentiation of osteoclasts *in vivo* and *in vitro*, and that IKK β supports osteoclastogenesis at the levels of differentiation and survival. Our model provided a useful tool to study the structural components of IKK β which are important for its function in osteoclast differentiation. Retroviral rescue experiments in which IKK β KO monocytes were reconstituted with mutant forms of IKK β revealed that activation loop serines are critical for IKK β to support osteoclast differentiation. These experiments led to the discovery that constitutive activation of IKK β results in spontaneous, RANK-independent osteoclast differentiation *in vitro* and osteolysis *in vivo*. Our work demonstrates that IKK β is central to osteoclast differentiation and is therefore an important target in therapy for osteoclast-mediated disease.

ACKNOWLEDGEMENTS

I am indebted to my wife, Emily, for her encouragement, patience, understanding, and love during my training. The countless nights and weekends in the lab were more difficult for her than for me, and her strength and perseverance were truly inspirational. I must thank my son, Gentry, for making my work his play. Mundane details, he saw as magic, and his awe and wonder renewed my sense of purpose and reverence for nature. His inquisitiveness grounded me and reminded me of the big picture. When he sensed that I began to love the osteoclast, he would look into the microscope and clarify, “The big cells are the bad ones, right?” I must thank my daughters, Samantha and Leyla, for allowing me to watch them develop while inspiring in me a desire for beauty and truth.

I would like to thank Gary Ulaner for showing me science in its purest form and for teaching me that meticulous attention to detail and effort in the lab is worth more than hours spent. I thank Gary for igniting the spark of motivation that has continued to drive my career goals today. I thank Andrew Hoffman, my undergraduate mentor, for nurturing my immature conceptions and supporting me while I stumbled over the idea of pursuing a career as a physician-scientist. I would like to thank Steven Weintraub for showing me the inner workings of the mind of a philosopher-scientist.

I am indebted to the MSTP administration, especially Christy Durbin, Brian Sullivan, and Andrew Richards for making the process streamlined behind the scenes so that I could focus on my work. I must thank Anna Cook-Linsenman and Shirley McTigue for helping

me with my Ruth L. Kirschstein National Research Service Award fellowship and for ensuring that my funding was secured.

I would like to thank Simon Dai for his invaluable teaching in the lab and for showing me how to think small and big. I thank Muhammad Alhawagri for managing my mouse colonies, including breeding, observing, and genotyping. Without his assistance, I would have lived in the lab. I thank Isra Darweh for making my day-to-day life in the lab manageable. I would like to thank Karon Hertlein for helping me obtain my materials and reagents, for her encouraging chats, and for fueling me with caffeine to get through big days. I thank Koon Lai for displaying discipline and organization and for being there to talk about anything.

I thank Yousef Abu-Amer for taking a chance on entrusting a portion of his work to a beginner. He taught me that observations are as important as knowledge, and he taught me what hard work in science looks like. I thank Yousef for loosening the reigns and allowing me to explore and discover in his lab and for throwing out my tab of broken and wasted materials. His patience allowed me to become confident in science. He was always a step ahead of me in hypothesizing, so I continuously matured in my thinking. His focus on the greater goal of our work perfectly balanced my concern with detail so that our work always moved forward.

I would like to thank the members of my thesis committee, Steven Teitelbaum, Deborah Novack, Anthony Muslin, Roberto Civitelli, Philip Osdoby, and Dwight Towler for encouragement and stimulating discussions. I would also like to thank the NIH for funding my training through the MSTP training grant.

To my loving family, Emily, Gentry, Samantha, and Leyla

To my Grandfather, Ross J. Sinkey

To my supportive parents, Charlie and Donna Otero

TABLE OF CONTENTS

| | |
|-----------------------------------|---------|
| Abstract of the Dissertation..... | ii-iii |
| Acknowledgements..... | iv-vi |
| Dedication..... | vii |
| Table of Contents..... | viii-ix |
| List of Figures..... | x-xi |

CHAPTER 1: INTRODUCTION

| | |
|--|-------|
| Rationale and Objective of Thesis..... | 2-3 |
| Background..... | 3-8 |
| References..... | 9-15 |
| Figure Legends..... | 16-18 |
| Figures..... | 19-24 |

CHAPTER 2: DEFECTIVE OSTEOCLASTOGENESIS BY IKK β -NULL PRECURSORS IS A RESULT OF RANKL-INDUCED JNK-DEPENDENT APOPTOSIS AND IMPAIRED DIFFERENTIATION

| | |
|----------------------------|-------|
| Abstract..... | 26-27 |
| Introduction..... | 27-29 |
| Materials and Methods..... | 29-35 |
| Results..... | 35-41 |
| Discussion..... | 41-45 |
| References..... | 46-49 |
| Figure Legends..... | 50-54 |
| Figures..... | 55-63 |

CHAPTER 3: IKK β ACTIVATION IS SUFFICIENT FOR RANK-INDEPENDENT OSTEOCLAST DIFFERENTIATION AND OSTEOLYSIS

| | |
|-----------------------|---------|
| Summary..... | 65-66 |
| Introduction..... | 66-69 |
| Results..... | 69-78 |
| Discussion..... | 78-83 |
| Methods..... | 83-93 |
| Acknowledgements..... | 93 |
| References..... | 94-100 |
| Figure Legends..... | 101-108 |
| Figures..... | 109-121 |

CHAPTER 4: INFLAMMATORY CYTOKINE SECRETION AND OSETOCLAST DIFFERENTIATION INDUCED BY ACTIVATION OF IKK β IN MACROPHAGES ARE UNCOUPLED EVENTS

| | |
|---------------------|---------|
| Abstract..... | 123 |
| Introduction..... | 124-126 |
| Results..... | 126-129 |
| Discussion..... | 129-130 |
| Methods..... | 131-135 |
| References..... | 136-140 |
| Figure Legends..... | 141-143 |
| Figures..... | 144-147 |

CHAPTER 5: ACTIVATION OF THE ALTERNATIVE NF- κ B PATHWAY BY CONSTITUTIVELY ACTIVE IKK β

| | |
|---------------------|---------|
| Introduction..... | 149-150 |
| Results..... | 151-152 |
| Methods..... | 153-155 |
| References..... | 156-158 |
| Figure Legends..... | 159 |
| Figures..... | 160-162 |

CHAPTER 6: CONCLUSION

| | |
|-------------------------|---------|
| Summary of Results..... | 164-171 |
| Future Directions..... | 171-173 |
| Perspectives..... | 174 |
| References..... | 175-178 |

LIST OF FIGURES

CHAPTER 1

| | |
|---|----|
| Figure 1: Schematic of Osteoclast Differentiation..... | 19 |
| Figure 2: Osteoclastogenic Signaling..... | 20 |
| Figure 3: Classical NF- κ B Signaling Pathway..... | 21 |
| Figure 4: Alternative NF- κ B Signaling Pathway..... | 22 |
| Figure 5: Schematic Structure of IKK β | 23 |
| Figure 6: Generation of Mice with a Conditional Deletion of IKK β in Osteoclast Precursors..... | 24 |

CHAPTER 2

| | |
|---|----|
| Figure 1: Mice with IKK β -deleted osteoclast precursors possess a defect in <i>in vivo</i> and <i>in vitro</i> osteoclastogenesis..... | 55 |
| Figure 2: OCP ^{ΔIKKβ} are defective in osteoclast differentiation and demonstrate increased susceptibility to apoptosis..... | 56 |
| Figure 3: Apoptosis contributes to the <i>in vivo</i> deficiency of osteoclasts in OCP ^{ΔIKKβ} mice..... | 57 |
| Figure 4: Loss of IKK β in OCP's results in a gain-of-function in JNK phosphorylation..... | 58 |
| Figure 5: Inhibition of RANKL-mediated JNK-induced apoptosis rescues osteoclastogenesis defect in OCP's deficient in IKK β | 59 |
| Figure 6: Inhibition of JNK in OCP ^{ΔIKKβ} cells rescues bone resorption..... | 60 |
| Supplementary Figure 1: Deletion of IKK β in multiple hematopoietic tissues..... | 61 |
| Supplementary Figure 2: OCP ^{ΔIKKβ} with insufficient suppression of IKK β mRNA show defective osteoclast phenotype <i>in vitro</i> despite normal induction of osteoclast markers..... | 62 |
| Supplementary Figure 3: Requirement for early inhibition of JNK for rescue of osteoclastogenesis in OCP ^{ΔIKKβ} | 63 |

CHAPTER 3

| | |
|---|-----|
| Figure 1: IKK β ^{SSEE} Induces <i>bona fide</i> Osteoclasts from Bone Marrow, Spleen, and Fetal Liver Progenitors..... | 109 |
| Figure 2: IKK β ^{SSEE} -induced Osteoclastogenesis does not Require RANKL/RANK Upstream Signals..... | 110 |
| Figure 3: IKK β ^{SSEE} Induces Osteoclastogenesis Independent from NEMO Association..... | 111 |
| Figure 4: IKK β ^{SSEE} Induction of Osteoclasts does not Require IKK α | 112 |

| | |
|---|-----|
| Figure 5: IKK β ^{SSEE} Induction of Osteoclastogenesis Requires Coordinated NF- κ B Signaling..... | 113 |
| Figure 6: Active IKK β is Sufficient for Osteolysis..... | 114 |
| Supplementary Figure 1: High Resolution Image Demonstrating RANKL-Independent Osteoclastogenic Effect of IKK β ^{SSEE} in the Absence of Endogenous IKK β | 115 |
| Supplementary Figure 2: IKK β ^{SSEE} -Transduced cells 30 min. Post-Plating..... | 116 |
| Supplementary Figure 3: Resorption of Artificial Matrix by Osteoclasts Generated by Expression of IKK β ^{SSEE} | 117 |
| Supplementary Figure 4: High Resolution Image of Resorption Pits Generated by RANKL and IKK β ^{SSEE} – Induced Osteoclasts..... | 118 |
| Supplementary Figure 5: Constitutive I κ B α Processing Induced by IKK β ^{SSEE} in Control and NF- κ B dKO Cells..... | 119 |
| Supplementary Figure 6: Adenoviral Gene Transfer <i>in vivo</i> | 120 |
| Supplementary Figure 7: Kinase Activity is responsible for IKK β ^{SSEE} -induced osteoclastogenesis..... | 121 |

CHAPTER 4

| | |
|--|-----|
| Figure 1: Constitutively Active IKK β Induces NF- κ B Nuclear Translocation..... | 144 |
| Figure 2: Induction of Osteoclastogenesis and Inflammatory Cytokine Secretion by IKK β ^{SSEE} | 145 |
| Figure 3: TNF α Autocrine Stimulation is not Responsible for IKK β ^{SSEE} – Induced Osteoclastogenesis..... | 146 |
| Figure 4: IL-1 Receptor Autocrine Stimulation is not an Essential Mediator of the Osteoclastogenic Effect of Constitutively Active IKK β | 147 |

CHAPTER 5

| | |
|--|-----|
| Figure 1: Expression of IKK β ^{SSEE} in Monocytes results in RelB Activation..... | 160 |
| Figure 2: IKK β ^{SSEE} induces p100 processing to p52..... | 161 |
| Figure 3: IKK α – independent p52 production by IKK β ^{SSEE} | 162 |

CHAPTER 1
INTRODUCTION

RATIONALE AND OBJECTIVE OF THESIS

Arthritis is a medical condition defined as inflammation of the joints and surrounding connective tissue. Currently, it is estimated that over 46 million Americans suffer from arthritis, and in 2003, total direct and indirect costs attributable to the condition were approximately \$128 billion ¹. Arthritis and its medical complications represent the leading cause of disability in the United States, and it has been projected that by the year 2020, more than 60 million Americans will suffer from the condition ². For this reason, it has been a priority of basic science research to understand the mechanisms underlying the onset and progression of arthritis and its complications in order to direct and guide implementation of preventative and therapeutic strategies.

The most devastating complication of arthritis is the destruction of bone associated with inflammation of joints (osteolysis) which results in pain, deformity, and immobility. Osteolysis in arthritis is triggered by inflammatory mediators and accomplished by osteoclasts, cells that resorb bone ³. The discovery that osteoclasts are required for bone destruction associated with inflammatory conditions ^{4,5} has led to an intense effort to characterize the cell and the mechanisms involved in its differentiation and activity. Indeed, drugs targeting the osteoclast have been demonstrated to improve arthritis-associated osteolysis and are now being considered in the therapy for osteolytic conditions ⁶.

The objective of this thesis is to investigate the molecular mechanisms utilized by the osteoclast focusing on the NF- κ B pathway (see Background) as a means to better understand the process of osteoclast differentiation and to offer insight that will guide therapy of pathological conditions in which the osteoclast is the culprit.

BACKGROUND

Arthritis and the Osteoclast

Arthritis is the leading cause of disability in the United States. Bone-loss associated with certain types of arthritis is a well-recognized relationship^{7,8} and contributes greatly to the joint pain, deformation, and immobility which often accompanies arthritis. The discovery of bone-resorbing osteoclasts in arthritic joint tissue led to the hypothesis that osteoclasts are the culprits in arthritic osteolysis⁹. Since this discovery, genetic studies in mice have confirmed that inflammatory cytokines present in inflamed joint tissue contribute to the hyperactivation of osteoclasts in this setting^{5,10,11}, and therapy targeting the osteoclast in patients with rheumatoid arthritis reduces the osteolysis associated with their condition⁶. It is therefore critical to gain a deeper understanding of the osteoclast and the molecular mechanisms it utilizes to differentiate and become active in order to more effectively treat arthritis-associated osteolysis.

Osteoclast Biology

The osteoclast is a multinucleated bone-resorbing cell which differentiates from monocyte precursors under the control of stimulation by two cytokines, Macrophage Colony Stimulating Factor (M-CSF) ¹² and Ligand for the Receptor Activator of NF- κ B (RANKL) ¹³. Mice devoid of either cytokine suffer from severe osteopetrosis owing to failure of osteoclast differentiation, which has become a well-established phenotype in animals that possess genetic defects in osteoclast differentiation and activity ¹⁴. The identification of genes whose dysfunction results in osteopetrosis has contributed tremendously to the understanding of the osteoclast.

The mature osteoclast forms through stimulation of monocytes with M-CSF and RANKL which triggers a differentiation program leading to fusion of precursors, attachment to bone matrix, release of protons and proteases, and degradation of bone material ¹⁴. Inhibition of each of these parameters involved in formation and function of osteoclasts results in impairment of osteoclast activity. For example, mice devoid of the v_0 v-ATPase ¹⁵ or DC-STAMP ¹⁶, which are critical in osteoclast precursor fusion display impaired osteoclast activity and increased bone mass. Deficiency in β_3 -Integrin results in an osteoclast which is unable to attach effectively to bone, and therefore is ineffective in resorbing bone substrate ¹⁷. Further, mice with a deficiency in Cathepsin K (Cath K), a protease released by active osteoclasts demonstrate high bone mass ¹⁸. Moreover, failure to acidify secretory vesicles in osteoclasts results in inefficient bone resorption ¹⁹ (Figure 1). Identification of additional proteins which contribute to the

functions of osteoclasts will likely yield a more complete understanding of osteoclast biology.

Differentiation of the mature osteoclast from monocyte precursors involves integration of complex signaling cascades activated by RANKL, through TRAF6^{20,21}, including ERK and p38 MAP Kinases²², PI3K²³, Akt²⁴, c-Src²⁵, PKC²⁶, and JNK²⁷ (Figure 2). Cooperation of these signals leads to a hierarchy of transcriptional regulation that results in osteoclast differentiation from precursors. Research has identified several transcription factors, such as NF- κ B²⁸, AP-1^{27,29}, and NFATc1³⁰ whose deficiency results in impaired differentiation of osteoclasts from monocyte progenitors. It is now believed that the interplay between these transcription factors is critical for osteoclast differentiation³¹.

The most important transcription factor for the differentiation of the osteoclast is NF- κ B. NF- κ B is activated by RANKL, and several murine genetic models have demonstrated that NF- κ B signaling defects result in impaired differentiation^{28,32-39}. Furthermore, NF- κ B appears to be the most upstream transcriptional regulator involved in osteoclast differentiation³¹. Therefore, understanding NF- κ B signaling in the context of osteoclast differentiation will likely contribute to new therapeutic approaches in the treatment of osteoclast mediated disease.

NF- κ B Signaling

NF- κ B is a transcription factor activated primarily through receptor stimulation by extracellular ligands. NF- κ B signaling is divided for convenience into two separate pathways, classical (or canonical) and non-canonical (alternative) ⁴⁰ which have both recently been shown to play a role in osteoclast differentiation ^{32,33}. In the classical pathway, signals such as RANKL, TNF- α , IL-1, and LPS result in activation of the Inhibitory κ B Kinase (IKK) complex, the catalytic complex which is responsible for activation of NF- κ B. The classical IKK complex consists of two kinases, IKK α and IKK β , and a regulatory subunit, NEMO (or IKK γ). Once activated, IKK phosphorylates I κ B α ⁴¹, which normally sequesters the NF- κ B heterodimers p50/p65 in the cytosol in an inactive state. Phosphorylation of I κ B α results in its ubiquitination and proteasomal degradation ⁴², which releases p50/p65(RelA) NF- κ B heterodimers in the nucleus to activate gene transcription (Figure 3). In the alternative NF- κ B pathway ⁴³, extracellular signals such as RANKL, CD40L, and Lymphotoxin β stimulate activation of IKK α homodimers which phosphorylate the C-terminus of *NF- κ B2*(p100) which serves an I κ B function for RelB, holding it inactive in the cytosol. This phosphorylation results in proteasomal processing of p100 to p52, which partners with RelB to enter the nucleus and activate gene transcription as the alternative NF- κ B pathway heterodimer (Figure 4).

Efforts to define the relative contribution of each of these pathways to osteoclastogenesis have led to disparate conclusions. For example, mice devoid of active IKK α and alternative NF- κ B activation by RANKL demonstrate no apparent bone phenotype and

are susceptible to inflammatory osteolysis ³⁷. However, mice lacking RelB, the transactivating NF- κ B member of the alternative pathway, show impaired osteoclast differentiation *in vitro*, and are resistant to pathological bone destruction induced by tumor metastasis and TNF injection ³². The reason for this discrepancy most likely rests in the individual systems used to challenge the osteoclast. Nevertheless, it is well accepted that the classical NF- κ B pathway is indispensable for osteoclast differentiation, since deficiency of IKK β or RelA results in impaired osteoclastogenesis and inflammatory osteolysis ^{33,37,38}. Therefore investigation of classical NF- κ B signaling downstream of RANKL will yield valuable insight into the basic mechanisms utilized by differentiating osteoclasts.

The Kinase IKK β

IKK β is the kinase responsible for activation of the classical NF- κ B signaling pathway ^{43,44}. It is a 756-amino acid cytosolic serine kinase with three general domains, a kinase domain important for catalytic activity, a leucine zipper domain which is important for protein-protein interactions, and a helix-loop-helix domain which regulates the molecule's kinase activity ⁴⁵. Activation of IKK β requires its association with NEMO through two Tryptophan residues (739 and 741) located in a carboxyl terminal domain termed the NEMO-binding Domain (NBD) ^{46,47}. Phosphorylation of two activation loop Serines (177 and 181) on IKK β by an unknown kinase results in full activation of IKK β ⁴⁸ which phosphorylates I κ B α leading to NF- κ B activation. Pharmacologic inhibition of IKK β association with NEMO through the use of decoy peptides blocks activation of NF-

κ B, inhibits osteoclastogenesis, and prevents arthritis and associated bone loss in mice^{35,36}. Phosphomimetic mutation of IKK β by mutating Serines 177 and 181 to Glutamic Acid results in constitutive activation, and mutation of Lysine 44 of IKK β abrogates kinase activity⁴⁹ (Figure 5).

IKK β in the Osteoclast

In order to determine the precise role of IKK β in osteoclastogenesis, we created a mouse with a conditional deletion of IKK β in osteoclast precursors by breeding mice possessing a loxP-flanked IKK β gene⁵⁰ and mice transgenically expressing Cre recombinase under the control of the CD11b promoter⁵¹. Conditional IKK β knockout mice generated in this manner displayed many phenotypic anomalies including aberrant bone metabolism as a result of defective osteoclastogenesis (Figure 6). The primary goal of this thesis was to characterize the osteoclast phenotype of these mice, to use the model to study the structure function relationship of IKK β in the differentiating osteoclast, and to draw conclusions regarding the importance of IKK β in arthritic osteolysis.

REFERENCES

1. CDC. National and state medical expenditures and lost earnings attributable to arthritis and other rheumatic conditions--United States, 2003. *MMWR - Morbidity & Mortality Weekly Report* **56**, 4-7 (2007).
2. Meenan, R.F., Callahan, L.F. & Helmick, C.G. The National Arthritis Action Plan: a public health strategy for a looming epidemic. *Arthritis Care & Research* **12**, 79-81 (1999).
3. Teitelbaum, S.L. Osteoclasts; culprits in inflammatory osteolysis. *Arthritis Research & Therapy* **8**, 201 (2006).
4. Pettit, A.R. et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. *Am J Pathol* **159**, 1689-99 (2001).
5. Redlich, K. et al. Osteoclasts are essential for TNF- α -mediated joint destruction. *Journal of Clinical Investigation* **110**, 1419-1427 (2002).
6. Cohen, S.B. et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial.[see comment]. *Arthritis & Rheumatism* **58**, 1299-309 (2008).
7. Firestein, G.S. Evolving concepts of rheumatoid arthritis. *Nature* **423**, 356-61 (2003).
8. McInnes, I.B. & Schett, G. Cytokines in the pathogenesis of rheumatoid arthritis. *Nature Reviews. Immunology* **7**, 429-42 (2007).

9. Bromley, M. & Woolley, D.E. Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint. *Arthritis & Rheumatism* **27**, 968-75 (1984).
10. Lam, J. et al. TNF induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. *J Clin Invest* **106**, 1481-1488 (2000).
11. Wei, S., Kitaura, H., Zhou, P., Ross, F.P. & Teitelbaum, S.L. IL-1 mediates TNF-induced osteoclastogenesis. *J Clin Invest* **115**, 282-90 (2005).
12. Yoshida, H. et al. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. *Nature* **345**, 442-4 (1990).
13. Kong, Y.Y. et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. *Nature* **397**, 315-23 (1999).
14. Teitelbaum, S.L. Osteoclasts: what do they do and how do they do it? *American Journal of Pathology* **170**, 427-35 (2007).
15. Lee, S.H. et al. v-ATPase V0 subunit d2-deficient mice exhibit impaired osteoclast fusion and increased bone formation.[see comment]. *Nature Medicine* **12**, 1403-9 (2006).
16. Yagi, M. et al. DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells. *The Journal of Experimental Medicine* **202**, 345-351 (2005).
17. McHugh, K.P. et al. Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts. *The Journal of clinical investigation* **105**, 433-40 (2000).

18. Li, C.Y. et al. Mice lacking cathepsin K maintain bone remodeling but develop bone fragility despite high bone mass. *Journal of Bone & Mineral Research* **21**, 865-75 (2006).
19. Tolar, J., Teitelbaum, S.L. & Orchard, P.J. Osteopetrosis. *New England Journal of Medicine* **351**, 2839-49 (2004).
20. Wong, B. et al. TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-src. *Mol. Cell* **4**, 1041-1049 (1999).
21. Walsh, M.C., Kim, G.K., Maurizio, P.L., Molnar, E.E. & Choi, Y. TRAF6 Autoubiquitination-Independent Activation of the NF κ B and MAPK Pathways in Response to IL-1 and RANKL. *PLoS ONE* **3**, e4064 (2008).
22. Lee, S.E. et al. The phosphatidylinositol 3-kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation. *Bone* **30**, 71-7 (2002).
23. Munugalavadla, V. et al. The p85 $\{\alpha\}$ Subunit of Class IA Phosphatidylinositol 3-Kinase Regulates the Expression of Multiple Genes Involved in Osteoclast Maturation and Migration. *Molecular and cellular biology* **28**, 7182-98 (2008).
24. Sugatani, T. & Hruska, K.A. Akt1/Akt2 and mammalian target of rapamycin/Bim play critical roles in osteoclast differentiation and survival, respectively, whereas Akt is dispensable for cell survival in isolated osteoclast precursors. *The Journal of biological chemistry* **280**, 3583-9 (2005).

25. Schwartzberg, P.L. et al. Rescue of osteoclast function by transgenic expression of kinase-deficient Src in src^{-/-} mutant mice. *Genes & development* **11**, 2835-44 (1997).
26. Lee, S.W. et al. Participation of protein kinase C beta in osteoclast differentiation and function. *Bone* **32**, 217-27 (2003).
27. David, J.P., Sabapathy, K., Hoffmann, O., Idarraga, M.H. & Wagner, E.F. JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms. *Journal of Cell Science* **115**, 4317-4325 (2002).
28. Iotsova, V. et al. Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. *Nature medicine* **3**, 1285-9 (1997).
29. Grigoriadis, A.E. et al. c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. *Science (New York, N.Y.)* **266**, 443-8 (1994).
30. Takayanagi, H. et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. *Dev Cell* **3**, 889-901 (2002).
31. Yamashita, T. et al. NF-kappaB p50 and p52 regulate receptor activator of NF-kappaB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1. *The Journal of biological chemistry* **282**, 18245-53 (2007).
32. Vaira, S. et al. RelB is the NF-kappaB subunit downstream of NIK responsible for osteoclast differentiation. *Proceedings of the National Academy of Sciences of the United States of America* **105**, 3897-902 (2008).

33. Vaira, S. et al. RelA/p65 promotes osteoclast differentiation by blocking a RANKL-induced apoptotic JNK pathway in mice. *The Journal of clinical investigation* **118**, 2088-97 (2008).
34. Chaisson, M.L. et al. Osteoclast differentiation is impaired in the absence of I κ B kinase- α . *J Biol Chem* **279**, 54841-8 (2004).
35. Dai, S., Hirayama, T., Abbas, S. & Abu-Amer, Y. The I κ B kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks osteoclastogenesis and bone erosion in inflammatory arthritis. *The Journal of biological chemistry* **279**, 37219-22 (2004).
36. Jimi, E. et al. Selective inhibition of NF- κ B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. *Nature medicine* **10**, 617-24 (2004).
37. Ruocco, M.G. et al. I κ B kinase- β , but not IKK- α , is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss. *J. Exp. Med.* **201**, 1677-1687 (2005).
38. Otero, J.E. et al. Defective osteoclastogenesis by IKK β -null precursors is a result of receptor activator of NF- κ B ligand (RANKL)-induced JNK-dependent apoptosis and impaired differentiation. *The Journal of biological chemistry* **283**, 24546-53 (2008).
39. Abu-Amer, Y., Dowdy, S., Ross, F., Clohisy, J. & Teitelbaum, S. TAT fusion proteins containing tyrosine 42-deleted I κ B α arrest osteoclastogenesis. *J Biol Chem* **276**, 30499-30503 (2001).

40. Bonizzi, G. & Karin, M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. *Trends in Immunology* **25**, 280-8 (2004).
41. Ghosh, S. & Baltimore, D. Activation in vitro of NF-kappa B by phosphorylation of its inhibitor I kappa B. *Nature* **344**, 678-82 (1990).
42. Henkel, T. et al. Rapid proteolysis of I kappa B-alpha is necessary for activation of transcription factor NF-kappa B. *Nature* **365**, 182-5 (1993).
43. Senftleben, U. et al. Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. *Science* **293**, 1495-9 (2001).
44. Zandi, E., Rothwarf, D.M., Delhase, M., Hayakawa, M. & Karin, M. The IkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta, necessary for IkappaB phosphorylation and NF-kappaB activation. *Cell* **91**, 243-52 (1997).
45. Kwak, Y.T., Guo, J., Shen, J. & Gaynor, R.B. Analysis of Domains in the IKK-alpha and IKK-beta Proteins That Regulate Their Kinase Activity. *Journal of Biological Chemistry* **275**, 14752-14759 (2000).
46. May, M.J. et al. Selective inhibition of NF-kappaB activation by a peptide that blocks the interaction of NEMO with the IkappaB kinase complex. *Science* **289**, 1550-4 (2000).
47. May, M.J., Marienfeld, R.B. & Ghosh, S. Characterization of the Ikappa B-kinase NEMO Binding Domain. *Journal of Biological Chemistry* **277**, 45992-46000 (2002).

48. Delhase, M., Hayakawa, M., Chen, Y. & Karin, M. Positive and negative regulation of IkappaB kinase activity through IKKbeta subunit phosphorylation. *Science (New York, N.Y.)* **284**, 309-13 (1999).
49. Mercurio, F. et al. IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation. *Science (New York, N.Y.)* **278**, 860-6 (1997).
50. Pasparakis, M. et al. TNF-mediated inflammatory skin disease in mice with epidermis-specific deletion of IKK2. *Nature* **417**, 861-6 (2002).
51. Ferron, M. & Vacher, J. Targeted expression of Cre recombinase in macrophages and osteoclasts in transgenic mice. *Genesis* **41**, 138-45 (2005).

FIGURE LEGENDS

Figure 1: Schematic of Osteoclast Differentiation

Osteoclasts differentiate from monocyte precursors when stimulated by M-CSF and RANKL, two cytokines secreted by osteoblast cells in normal bone metabolism. Stimulation of the receptors, c-fms and RANK, by M-CSF and RANKL, respectively, triggers the activation of the transcription factors, NF- κ B, AP-1, and NFATc1 in the differentiating pre-osteoclast. These transcription factors coordinate the osteoclast differentiation program resulting in expression of proteins necessary for fusion of precursors (DC-STAMP), for bone attachment (β 3-Interin), for cytoskeletal organization (c-Src), and for degradation of bone matrix (Cathepsin K and MMP9). Calcitonin Receptor and Tartrate-Resistant Acid Phosphatase (TRAP) are useful biomarkers for the mature osteoclast.

Figure 2: Osteoclastogenic Signaling

Stimulation of the receptor, RANK, by its ligand, RANKL, leads to activation of several kinases including IKK, JNK, ERK, p38, and Akt. These signals require association of the E3 Ubiquitin Ligase, TRAF6, with the RANK receptor. Interference with each of these kinases, as well as loss of TRAF6, results in impaired osteoclast differentiation. IKK activates NF- κ B which induces the transcription factor, c-fos. NFATc1, considered the master regulator of osteoclastogenesis, is activated downstream of NF- κ B and AP-1.

Figure 3: Classical NF- κ B Signaling Pathway

The Classical NF- κ B heterodimer, p50/p65(RelA), is bound in an inactive state in the cytosol by I κ B α . Extracellular Signals lead to activation of the classical IKK complex consisting of IKK α , IKK β , and IKK γ (NEMO). IKK β phosphorylates I κ B α leading to its ubiquitylation and rapid degradation by the proteasome. As a result, P50/p65 (RelA) heterodimers translocate into the nucleus to activate gene transcription.

Figure 4: Alternative NF- κ B Signaling Pathway

RelB, the transactivating factor of the alternative pathway, is sequestered in the cytosol by NF- κ B p100. Extracellular signals result in activation of IKK α homodimers. IKK α phosphorylates p100 resulting in its proteasomal processing to p52. p52/RelB heterodimers then translocate into the nucleus to regulate gene transcription.

Figure 5: Schematic Structure of IKK β

IKK β consists of an N-terminal kinase domain (Kinase) which transfers phosphate from ATP to target serine and Threonine residues of substrate proteins, a Leucine Zipper domain (LZ) important for protein-protein interactions, a Helix-Loop-Helix domain (HLH) which modulates IKK β kinase activity, and a C-terminal domain (NBD) that is critical for binding to NEMO. Binding of IKK β to NEMO, through Tryptophan residues 739 and 741, results in phosphorylation by an upstream kinase of Serines 177 and 181 in the activation loop in the kinase domain of IKK β , leading to activation of IKK β . Lysine

44 is the ATP-binding residue in IKK β , and its mutation results in a kinase-inactive, dominant-negative molecule.

Figure 6: Generation of Mice with a Conditional Deletion of IKK β in Osteoclast Precursors

We generated mice with a conditional loss of IKK β in osteoclast precursors (OCP Δ IKK β) by crossing mice possessing loxP-flanked (floxed) IKK β with mice harboring a Cre recombinase transgene under the control of the CD11b promoter. Resultant knockout mice (OCP Δ IKK β) displayed dense femurs (arrows) on X-ray compared with control littermates suggesting that IKK β is critical for osteoclast differentiation from precursors.

FIGURES

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5





Figure 6



CHAPTER 2

**DEFECTIVE OSTEOCLASTOGENESIS BY IKK β -NULL PRECURSORS IS A
RESULT OF RANKL-INDUCED JNK-DEPENDENT APOPTOSIS AND
IMPAIRED DIFFERENTIATION**

This chapter is published: Otero J, *et al.* J Biol Chem. 2008 Sep 5;283(36):24546-53.

**DEFECTIVE OSTEOCLASTOGENESIS BY IKK β -NULL PRECURSORS IS A
RESULT OF RANKL-INDUCED JNK-DEPENDENT APOPTOSIS AND
IMPAIRED DIFFERENTIATION***

Jesse E. Otero¹, Simon Dai¹, Domenica Foglia¹, Muhammad Alhawagri¹, Jean Vacher³,
Manolis Pasparakis⁴, and Yousef Abu-Amer^{1,2¶}

From Department of Orthopaedic Surgery¹, Department of Cell Biology & Physiology²
Washington University School of Medicine, St. Louis, Missouri 63110

From Institut de Recherches Cliniques de Montreal³, Quebec, Canada

From University of Cologne⁴, Germany

Running Head: JNK-Dependent Apoptosis in OCP's lacking IKK β

Address correspondence to: Yousef Abu-Amer, Ph.D. Washington University

Orthopedics, One Barnes-Jewish Hospital Plaza, Suite 11300 Box 8233, St. Louis, MO
63110. Fax: (314) 362-0334. E-mail: abuamery@wudosis.wustl.edu

It has previously been reported that IKK β supports osteoclastogenesis through NF- κ B-mediated prevention of apoptosis. This finding suggests that the ligand for Receptor Activator of NF- κ B (RANKL), the master osteoclastogenic cytokine, induces apoptosis of osteoclast precursors (OCP's) in the absence of IKK β /NF- κ B competency. To validate this hypothesis, we sought to determine the pro-apoptotic signaling factors induced by RANKL in IKK β -null osteoclast OCP's and to rescue osteoclast differentiation in the absence of IKK β through their inhibition. To accomplish this, we generated mice which lack IKK β in multiple

hematopoietic lineages including OCP's. We found that these mice possess both *in vitro* and *in vivo* defects in osteoclast generation, in concurrence with previous reports, and that this defect is a result of susceptibility to RANKL-mediated apoptosis as a result of gain-of-function of JNK activation. We demonstrate that differentiation of OCP's depends on IKK β since reduced IKK β mRNA expression correlates with impaired induction of osteoclast differentiation markers in response to RANKL stimulation. We further show that fine-tuned inhibition of JNK activation in these cells inhibits RANKL-induced apoptosis and restores the ability of IKK β -null OCP's to become mature osteoclasts. Our data highlight the pro-osteoclastogenic and anti-apoptotic roles of IKK β in OCP's and identify a pro-apoptotic mechanism activated within the RANK signalosome.

INTRODUCTION

Osteoclasts develop from bone marrow macrophage precursors under the control of two cytokines, Receptor Activator of NF- κ B Ligand¹ (RANKL) (1) and m-CSF (2). RANKL induces osteoclast commitment and development by signaling downstream to several transcription factors, the most important of which is NF- κ B (3). NF- κ B is a family of transcription factors whose activity coordinates a major component of the cellular inflammatory program, and its function is essential for osteoclastogenesis (4,5). NF- κ B signaling involves two distinct but cooperating pathways, one canonical and one

alternative pathway (6), which has recently been shown to be critical in osteoclast biology (7).

NF- κ B is activated by the inhibitory κ B kinase (IKK) complex, which is crucial for osteoclastogenesis. The IKK complex is composed of two catalytically active members, IKK α and IKK β , and a regulatory subunit IKK γ /NEMO. IKK α mediates activation of the alternative pathway by phosphorylation of NF- κ B2/p100 (6), while IKK β is important for activation of the canonical pathway through phosphorylation of I κ B (8). The importance of the signaling activity of the IKK complex in osteoclasts is demonstrated by the defect in osteoclastogenesis noted in mice lacking IKK α (9) or IKK β (10). Despite the sequence homology of these two kinases, their relative importance in osteoclastogenesis is strikingly different. For example, osteoclasts devoid of active IKK α only demonstrate an *in vitro* defect in osteoclastogenesis, while the bone phenotype of the mouse is remarkably normal. On the other hand, mice with an inducible osteoclast precursor-specific deletion of IKK β demonstrate both *in vitro* and *in vivo* defects in osteoclastogenesis and are resistant to inflammatory osteolysis (10). Given these findings, it is evident that investigating the mechanism by which IKK2 supports osteoclastogenesis will improve our understanding of osteoclast biology and diseases attributable to overactive osteoclasts.

We and others have shown that diverse methods of IKK blockade arrest osteoclastogenesis by induction of apoptosis (10-12). We were interested in the pro-apoptotic signals downstream of RANKL in the absence of IKK β , and we hypothesized that inhibition of these signals would be sufficient to rescue the osteoclast defect of cells

lacking IKK β . Our findings reveal that loss of IKK β in osteoclast precursors (OCP's) results in a gain-of-function of JNK activation in response to RANKL that results in apoptosis. Furthermore, fine-tuned inhibition of this gain-of-function in JNK activation is sufficient to rescue osteoclastogenesis in OCP's lacking IKK β . This finding demonstrates that the necessity of IKK β for osteoclastogenesis may be evaded by inhibiting the pro-apoptotic effects of RANKL and designates JNK activation in the osteoclast as a potential means to induce cell death in OCP's.

MATERIALS AND METHODS

Reagents- Antibodies against IKK β , IKK α , NEMO, Actin, JNK, p38, Akt, MKP1, phospho-c-jun, and c-jun as well as horseradish peroxidase-conjugated secondary antibodies were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Antibodies against phospho-JNK, phospho-p38, phospho-Akt, and PARP were purchased from Cell Signaling Technologies, Inc. (Danvers, MA). Antibody against MKP5 was purchased from Abcam (Cambridge, MA). Cytokines were purchased from R&D Systems (Minneapolis, MN). TAT-TI-JIP was purchased from EMD Biosciences, Inc. (La Jolla, CA). Enhanced Chemiluminescence kit was purchased from Pierce Biotechnology, Inc (Rockford, IL). All other chemicals were purchased from Sigma (St. Louis, MO) unless otherwise indicated.

Animals- CD11b Cre Y-chromosomal transgenic and floxed IKK β mice on a C57BL/6 background were reported previously (12, 13). Male Cre⁺ Floxed IKK β homozygotes were generated by crossing the above mice.

Cell Culture- Osteoclast precursors were enriched from bone marrow of 2-3-week-old mice. Briefly, whole marrow was flushed from long bones into α -MEM and was centrifuged at 453 rcf. Marrow pellets were resuspended in whole media (α -MEM with penicillin/streptomycin, 10% heat-inactivated fetal bovine serum) supplemented with 10 ng/mL m-CSF. Cell suspensions were plated onto petri dishes at 37 °C in 5% CO₂ for 5 days and then were plated according to experimental conditions.

Osteoclast Formation Assay- Osteoclast precursors were plated in triplicate at a density of 3.0×10^4 cells in 200 μ L whole media supplemented with 10 ng/mL m-CSF and RANKL in 96-well tissue culture plates. TAT-TI-JIP was added at the time of cell plating (day 1). TNF- α and LPS were added at day 4 of the assay. Mature osteoclasts form between day 5 and day 6 of culture, at which point, the cells are fixed and stained for Tartrate-Resistant Acid Phosphatase (TRAP) to visualize osteoclasts (Leukocyte Acid Phosphatase Kit, Sigma, St. Louis, MO). TRAP-positive multinucleated cells with 3 or more nuclei were scored as osteoclasts.

Protein Phosphorylation Assay- Osteoclast precursors were plated onto tissue culture dishes overnight in whole media supplemented with m-CSF. Cells were then serum

starved for 4-6 hours and stimulated with the indicated cytokine for a planned time course. At the allotted time, cells were lysed in cell lysis buffer containing (20 mM Tris HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 2.5 mM NaPyrophosphate, 1 mM β -Glycerophosphate, 1% Triton, 1 mM Na_3VO_4 , 1 $\mu\text{g/mL}$ Leupeptin, 1 mM NaF, 1 mM PMSF, and distilled deionized H_2O). Protein concentration was measured by standard BCA assay (Pierce). 10-20 μg of total cell protein was used for Western blot. See below.

Apoptosis Assay- Osteoclast precursors were plated onto tissue culture dishes overnight in whole media supplemented with m-CSF. Cells were serum starved for 6 hours and stimulated with 10 ng/mL RANKL for the indicated time. At the allotted time, cells were lysed as described above, protein was normalized, and samples were analyzed by Western blot. See below.

Rescue of Apoptosis- Osteoclast precursors were plated onto tissue culture dishes for 24 hours in whole media supplemented with m-CSF. Four groups of two plates of cells were plated in this assay. Each group was treated with either sterile PBS, 0.4 μM , 1.0 μM , or 2.0 μM TAT-TI-JIP. Also at the time of plating, one plate from each group was stimulated with either sterile PBS or 20 ng/mL RANKL. After 24 hours, cells were lysed as described above, protein was normalized, and samples were analyzed by Western Blot. See below.

Osteoclast Differentiation Assay- Osteoclast precursors were plated in whole media supplemented with m-CSF. Cells were either not stimulated, or were stimulated with 10 ng/mL RANKL for 5 days. Total RNA was isolated from cells using TRIzol reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's standard protocol.

Reverse Transcription- 1.0 µg total RNA was subjected to reverse transcription under the following conditions. 1.0 µg RNA and 1.0 µg random hexamer primer in 10 µL nuclease-free deionized H₂O in PCR tubes were heated to 70 °C for 5 minutes, cooled to 42 °C, and set on ice. The following components were then added at the indicated amounts or concentrations for a total reaction volume of 20 µL: 1 x RT AMV buffer (Roche, Palo Alto, CA), 40U RNaseIn (Promega, San Luis Obispo, CA), 1.25 mM dNTP's, 5 mM NaPyruvate, 5 U Reverse Transcriptase Enzyme, AMV (Roche). To produce cDNA, tubes were placed in a thermocycler programmed as follows. 42 °C for 60 minutes, 50 °C for 10 minutes, 95 °C for 5 minutes, and 4 °C to hold.

Bone Resorption Assay- Bone marrow osteoclast precursors were plated onto BD Biocoat Osteologic tissue culture slides (BD Biosciences, San Jose, CA) in the presence of 10 ng/ml m-CSF and RANKL with or without 0.4 µM TAT-TI-JIP for the indicated times. Resorption pits were determined as clear areas in the osteologic matrix. Representative photographs were taken at 10X magnification.

Real-Time PCR- Triplicate samples of 4 μ L cDNA product (5X diluted), 10 μ L Sybr Green PCR Master Mix (Applied Biosystems, Inc. Foster City, CA), 0.1 μ L each of 10 μ M forward and reverse primer stocks, and 6 μ L nuclease-free deionized H₂O were subjected to real time PCR according to the following program in a 7300 AB Real Time PCR System: 50 °C for 2 minutes, 95 °C for 10 minutes, (95 °C for 15 seconds, 60 °C for 1 minute) x 40 cycles. Results were analyzed using AB RQ Study Software. Real Time PCR primers were designed using Primer Express Software (Applied Biosystems, Inc.)

| | | | | |
|---|-------|---------------------|---------|-----|
| mouse Actin Forward 5'-CTTCTACAATGAGCTGCGTG-3', | mouse | TRAP | Forward | 5'- |
| TCATGAGGTAGTCTGTCAGG-3', | mouse | TRAP | Reverse | 5'- |
| CGACCATTTGTTAGCCACATACG-3', | mouse | TRAP | Reverse | 5'- |
| CACATAGCCCACACCGTTCTC-3', | mouse | Calcitonin Receptor | Forward | 5'- |
| CAAGAACCTTAGCTGCCAGAG-3', | mouse | Calcitonin Receptor | Reverse | 5'- |
| CAAGCACGCGGACAATGTTG-3', | mouse | MMP9 | Forward | 5'- |
| CAGGGAGATGCCCATTTTCG-3', | mouse | MMP9 | Reverse | 5'- |
| GGGCACCATTTGGAGTTTCCA-3', | mouse | A20 | Forward | 5'- |
| CAGAAAAAAGTGGTGAAGGTGTGA-3', | mouse | A20 | Reverse | 5'- |
| CCAGGCTCTGACCTCTGTTACA-3', | mouse | cIAP1 (birc2) | Forward | 5'- |
| GTGATGGTGGCTTGAGATGTTG-3', | mouse | cIAP1 (birc2) | Reverse | 5'- |
| CAAGAACTCACACCTTGGAACC-3', | mouse | cIAP2 (birc3) | Forward | 5'- |
| GAAGTGGGCTGCGGTATCA-3', | mouse | cIAP2 (birc3) | Reverse | 5'- |
| GCGCTGTCTTGAACCATGTTC-3', | mouse | Bcl-x _L | Forward | 5'- |
| GCGGCTGGGACACTTTTG-3', | mouse | Bcl-x _L | Reverse | 5'- |

| | | | | |
|------------------------------|-------|--------------------|---------|-----|
| CAGAACCACACCAGCCACAGT-3', | mouse | XIAP | Forward | 5'- |
| CGGATCGTTACTTTTGGAAACATG-3', | mouse | XIAP | Reverse | 5'- |
| CGCCTTCACCTAAAGCATAAAATC-3', | mouse | Cathepsin K | Forward | 5'- |
| GGAAGAAGACTCACCAGAAGC-3', | mouse | Cathepsin K | Reverse | 5'- |
| GTCATATAGCCGCCTCCACAG-3', | mouse | β_3 Integrin | Forward | 5'- |
| TTACCCCGTGGACATCTACTA-3', | mouse | β_3 Integrin | Reverse | 5'- |
| AGTCTTCCATCCAGGGCAATA-3', | mouse | GAPDH | Forward | 5'- |
| CTTCACCACCATGGAGAAGGC-3', | mouse | GAPDH | Reverse | 5'- |
| GACGGACACATTGGGGGTAG-3'. | | | | |

Western Blot Assay- Total cell lysates were boiled in the presence of an equal volume of 2X SDS sample buffer consisting of (0.5 M Tris-HCl, pH 6.8, 10% (w/v) SDS, 10% glycerol, 0.05% (w/v) bromphenol blue, 3% β -Mercaptoethanol, and distilled water) for 5 min and subjected to electrophoresis on 8–10% SDS-PAGE. The proteins were transferred to nitrocellulose membranes using a semi-dry blotter (Bio-Rad, Hercules, CA) and incubated in blocking solution (10% skim milk prepared in phosphate-buffered saline containing 0.05% Tween 20) to reduce nonspecific binding. The membranes were washed with phosphate-buffered saline/Tween buffer and exposed to primary antibodies (16 h at 4 °C), washed again four times, and incubated with the respective secondary horseradish peroxidase-conjugated antibodies (1 h at room temperature). The membranes were washed extensively (4 X 15 min), and an ECL detection assay was performed following the manufacturer's directions.

Western Blot Quantification-Where indicated, protein expression was quantified using Quantity One 1-D Analysis Software, BioRad (Hercules, CA).

Histology- Long bones were collected from mice and fixed in 10% buffered formalin for 24 hours. Bones were then decalcified for 7 days in decalcification buffer consisting of (14% (w/v) EDTA, H₄NOH pH 7.2), dehydrated in graded ethanol (30%-70%), cleared through xylene, and embedded in paraffin. Paraffin sections were stained histochemically for TRAP to visualize osteoclasts or immunohistochemically for TdT-mediated dUTP Nick End Labeling (TUNEL) with the ApopTag Peroxidase *In Situ* Apoptosis Detection Kit (Millipore/Chemicon International, Temecula, CA) to detect apoptotic cells.

RESULTS

Mice with an Osteoclast Precursor- IKK β -Deficiency Demonstrate in vitro and in vivo Defects in Osteoclastogenesis

IKK β has been shown to be necessary for osteoclast formation (10). To define the mechanism through which IKK β supports osteoclastogenesis, we generated mice with a deficiency of IKK β in multiple hematopoietic lineages including OCP's by crossing CD11b Cre recombinase transgenic mice (13) with mice possessing floxed IKK β (14) (Supplementary Figure 1). In this study, we focus on the osteoclast phenotype, so we will refer to the resultant knockout (Cre-positive floxed/floxed IKK β) mice as OCP ^{Δ IKK β} or Cre⁺ f/f. OCP ^{Δ IKK β} mice possess a hampered ability to generate osteoclasts *in vivo* as

evidenced by a significantly reduced number of TRAP-positive osteoclasts compared with controls observed by histochemical staining for TRAP in long bones (fig. 1A). This is further supported by lack of IKK β protein in osteoclast precursors of OCP ^{Δ IKK β} mice (fig. 1B). We demonstrate that this defect is cell-autonomous by culturing bone marrow-derived OCP's in the presence of m-CSF and RANKL. OCP ^{Δ IKK β} cells form significantly fewer multinucleated osteoclasts (fig. 1C, panel g) compared with Cre-positive IKK β wild-type/wild-type (wt/wt) (fig. 1C, panel a) and Cre-positive IKK β wild-type/floxed (wt/f) heterozygous littermate controls (fig. 1C, panel d). Furthermore, stimulation with TNF- α or LPS (fig. 1C, panels h and i) is insufficient to rescue the osteoclast defect of OCP ^{Δ IKK β} cells. Compared with WT cells, Cre-positive IKK β (wt/f) OCP's also show decreased IKK β protein expression (fig. 1B), but this difference does not result in impaired osteoclastogenesis (fig. 1C, panels d-f).

OCP ^{Δ IKK β} are Prone to RANKL-Induced Apoptosis and Display Defective Osteoclast Differentiation

IKK β has previously been demonstrated to protect OCP's from TNF- α -mediated apoptosis (10). We sought to determine whether IKK β -deficient OCP's are similarly susceptible to apoptosis in response to RANKL and to test whether the absence of IKK β results in defective osteoclast differentiation. To accomplish this, we cultured OCP ^{Δ IKK β} and control OCP's in the presence of m-CSF and RANKL for zero or five days to induce osteoclast differentiation. We measured by real-time PCR the expression of several markers for osteoclast differentiation. We observe a significant decrease in the

expression of m-RNA for the osteoclast markers β_3 Integrin (Fig. 2A), Cathepsin K (Fig. 2 B), Calcitonin Receptor (Fig. 2C), Matrix Metalloproteinase 9 (Fig. 2D), and TRAP (Fig. 2E) in RANKL-stimulated OCP ^{Δ IKK β} cells compared with controls. This failure to express osteoclast markers in osteoclastogenic conditions correlates with up to an 81% reduction in expression of IKK β mRNA in OCP ^{Δ IKK β} cells compared with controls (Fig. 2F). Interestingly, in OCP ^{Δ IKK β} cells that express higher levels of IKK β mRNA- 63% reduction compared with control OCP's- osteoclast marker expression after RANKL stimulation is not affected, yet they still fail to form multinucleated osteoclasts in *in vitro* culture (Supplementary Figure 2). This finding indicates that IKK β also serves a differentiation-independent function to support osteoclastogenesis. These observations lead us to surmise that IKK β is essential at various stages for differentiation and survival of RANKL-stimulated OCP's.

Therefore, we tested whether OCP ^{Δ IKK β} cells were more susceptible to apoptosis than control cells. First, we cultured OCP ^{Δ IKK β} and control OCP's in the presence of whole media supplemented with fetal bovine serum and m-CSF to promote survival and measured by real-time PCR the expression of mRNA for several NF- κ B-controlled anti-apoptotic proteins (15). We note significant reduction in expression of mRNA for A20, cellular inhibitor of apoptosis 2 (c-IAP2), c-IAP1, Bcl-x_L, and X-linked inhibitor of apoptosis (XIAP) in OCP ^{Δ IKK β} compared with control cells (fig. 2G).

To determine whether OCP ^{Δ IKK β} undergo apoptosis in response to RANKL, we exposed serum-starved OCP ^{Δ IKK β} and control OCP's to RANKL for a time-course of four hours. We detected the kinetics of poly-ADP Ribose Polymerase (PARP) cleavage by

Western blot as a molecular signature of apoptosis. We note disappearance of full-length PARP in OCP ^{Δ IKK β} cells after 1 hour while in control cells, the integrity of full-length PARP is preserved over the time-course of RANKL exposure (fig. 2H), which indicates that RANKL has a pro-apoptotic effect on osteoclast precursors deficient in IKK β . We conclude that IKK β is necessary for osteoclast differentiation and the survival of osteoclast precursors exposed to RANKL.

In order to determine whether apoptosis of osteoclasts or OCP's from OCP ^{Δ IKK β} mice contributes to the paucity of osteoclasts observed *in vivo*, we stained sections of long bones of OCP ^{Δ IKK β} and control mice immunohistochemically with the TUNEL method to detect apoptosis. We note a significantly greater number of TUNEL-positive peritrabecular nuclei resembling apoptotic osteoclasts and OCP's in OCP ^{Δ IKK β} compared with control long bones (fig. 3A and B). Based on our data, we conclude that apoptosis contributes to the osteoclast defect in OCP ^{Δ IKK β} mice.

OCP ^{Δ IKK β} Possess a Gain-of-Function in JNK Activation

We were interested in potential pro-apoptotic signals induced by RANKL in differentiating IKK β -deficient OCP's. To address this, we performed a phospho-protein screen by Western blot analysis in OCP ^{Δ IKK β} and control OCP's after stimulation with a time course of RANKL or TNF- α . We postulated that OCP ^{Δ IKK β} kinase signaling would possess a signature which would favor apoptosis. We noted several aberrations in the pattern of protein phosphorylation in OCP ^{Δ IKK β} compared with control cells. Of particular interest was an increase and prolongation of JNK phosphorylation in response to RANKL

(fig. 4A and B) and TNF- α (fig. 4A) in OCP ^{Δ IKK β} compared with control OCP's. Interestingly, p38 (fig. 4A) and Akt (fig. 4B) phosphorylation remain unaffected in the absence of IKK β , suggesting that JNK downregulation is a specific function of IKK β . We observe that MAP Kinase Phosphatase 1 (MKP1) protein resynthesis after degradation and MKP5 protein synthesis are dampened after RANKL stimulation of OCP ^{Δ IKK β} cells compared with controls. In particular, MKP1 and MKP5 protein levels maximize after 30 minutes of RANKL stimulation of control OCP's (fig. 4C). This time point correlates with downregulation of JNK phosphorylation after RANKL stimulation (fig. 4A and B). In OCP ^{Δ IKK β} cells, JNK phosphorylation is sustained at 30 minutes of RANKL stimulation (fig. 4A and B), which correlates with the absence of detectable MKP1 and MKP5 protein at this time point in OCP ^{Δ IKK β} cells (fig. 4C). Since MKP1 (16) and MKP5 (17) serve as JNK phosphatases, MKP induction may serve as an IKK β -dependent mechanism for JNK downregulation after RANKL stimulation. We postulated that the gain-of-function of JNK activation may result in apoptosis of OCP ^{Δ IKK β} cells.

Inhibition of JNK Blocks RANKL-Induced Apoptosis of Osteoclast Precursors and Rescues Osteoclastogenesis in IKK β -Deficient Osteoclast Precursors

JNK activation has been linked to RANKL-induced apoptosis of differentiating osteoclasts (15). We hypothesized that since OCP ^{Δ IKK β} cells are susceptible to RANKL-induced apoptosis, inhibition of RANKL-mediated JNK activation in these cells would rescue osteoclastogenesis. We took advantage of a cell-permeable peptide (TAT-TI-JIP) to specifically inhibit JNK activation (18) after RANKL stimulation. In WT OCP's,

TAT-TI-JIP peptides inhibit osteoclastogenesis at concentrations above 1 μ M (not shown). This finding is expected given the established importance of c-jun in osteoclast differentiation (19,20). Surprisingly, TAT-TI-JIP peptides enhance osteoclastogenesis in WT cells at a concentration of 0.4 μ M (fig. 5B panel b). We hypothesized that this concentration of TAT-TI-JIP is sufficient to block the pro-apoptotic action of JNK without affecting the activity of JNK toward c-jun after RANKL stimulation. Indeed, 0.4 μ M of TAT-TI-JIP blocks RANKL-induced PARP cleavage without dramatically altering RANKL-induced phosphorylation of c-jun (fig. 5A). At a concentration of 1 μ M, TAT-TI-JIP inhibits RANKL-induced PARP cleavage in OCP's, but it also inhibits c-jun phosphorylation (fig. 5A), which explains the inhibitory affect of this concentration on osteoclastogenesis. These results suggest that JNK serves two distinct functions in osteoclast differentiation and survival. Since low dose TAT-TI-JIP inhibits apoptosis of OCP's induced by RANKL stimulation without affecting c-jun activation, we tested this concentration for its potential to rescue osteoclastogenesis of OCP's in the absence of IKK β . Indeed, in the *in vitro* osteoclastogenesis assay, 0.4 μ M TAT-TI-JIP peptide rescues osteoclastogenesis of OCP ^{Δ IKK β} cells (fig. 5B). For example, OCP ^{Δ IKK β} cells (fig. 5B, panel c) treated with RANKL produce less than 5% of the number of TRAP-positive osteoclasts produced by control OCP's (fig. 5B, panel a). However, TAT-TI-JIP treatment of OCP ^{Δ IKK β} cells (fig. 5B, panel d) results in slightly, but statistically not significant, higher number of TRAP-positive osteoclasts compared with non-TAT-TI-JIP-treated controls (fig. 5B, panel a). Importantly, JIP peptide-treated control OCP's (fig. 5B panel b) produced more osteoclasts in *in vitro* culture than JIP peptide-treated

IKK β deficient OCP's (fig. 5B panel d), indicating that OCP Δ IKK β possess defects in osteoclast differentiation that are independent of JNK-mediated apoptosis.

Finally, we sought to determine whether rescue of osteoclastogenesis in OCP Δ IKK β through JNK inhibition results in a concomitant rescue of bone resorption. To accomplish this, we plated WT and OCP Δ IKK β osteoclast precursors on an artificial bone substrate in osteoclastogenic conditions in the presence and absence of 0.4 μ M TAT-TI-JIP. Resorption pits created by RANKL-treated OCP Δ IKK β cells (fig.6, panel b) were significantly smaller (22 \pm 3% resorption area compared with controls) than those created by control osteoclasts (fig. 6, panel a), indicating that OCP Δ IKK β are defective in resorbing bone. However, when we treated OCP Δ IKK β cells with TAT-TI-JIP (fig. 6, panel d), we restored resorption pit size over that noted in WT non-TAT-TI-JIP treated cells (165 \pm 7% of control) (Fig. 6, panel a). Consistent with our *in vitro* osteoclastogenesis assay data shown in figure 5, resorption pit size of TAT-TI-JIP-treated WT osteoclasts (fig. 6, panel c) is two fold larger than that of TAT-TI-JIP-treated OCP Δ IKK β (210 \pm 14%) indicating that IKK β also acts through mechanisms independent of JNK inhibition to support osteoclastogenesis.

DISCUSSION

In previous studies, we and others have shown that IKK-NF- κ B function is necessary for osteoclastogenesis (4,10,12). The diverse activities of the individual IKK and NF- κ B members suggest that each molecule plays a unique role in the overall program of osteoclast development. It has been demonstrated that IKK β protects OCP's from

apoptosis in response to TNF- α (10). While this finding is consistent with previous reports regarding the function of IKK β in other settings (21), its precise role downstream of RANK during osteoclastogenesis has remained unclear. The most likely possibility is that IKK β serves some capacity in osteoclastogenesis that is dependent upon NF- κ B-p65 action. However, the exact function of p65 in the osteoclast remains to be elucidated. It has been suggested that IKK β may be important for the survival and differentiation of OCP's (10). We show that OCP's deficient in IKK β display a defect in osteoclast differentiation, which is consistent with impaired induction of mRNA for the osteoclast markers: β_3 Integrin, Cathepsin K, Calcitonin Receptor, MMP9, and TRAP after RANKL stimulation.

We also show that IKK β -deficient OCP's are susceptible to apoptosis in response to RANKL stimulation. Based on our real-time PCR data, this phenomenon is likely to partially result from impaired NF- κ B-mediated transcription of anti-apoptotic genes. However, the pro-apoptotic function of RANKL in osteoclast precursors has not been fully described. Importantly, in OCP $^{\Delta IKK\beta}$ cells which expressed higher levels of IKK β mRNA, induction of osteoclast differentiation markers was not affected, although impaired *in vitro* osteoclastogenesis was still observed (Supplementary Figure 2). We examined the expression of mRNA for DC-STAMP (22) and ATP6v0d2 (23), two genes known to be important in osteoclast fusion, in these cells to determine whether a fusion deficiency was responsible for the defect. Induction of these markers was equivalent to controls in this population of OCP $^{\Delta IKK\beta}$ cells (data not shown). Although induction of other unknown osteoclast fusogenic genes may be impaired in RANKL-treated OCP $^{\Delta IKK\beta}$

cells, our data suggests that RANKL-induced apoptosis is a major contributor to the osteoclast defect in these cells.

We hypothesized that the kinase signaling environment downstream of RANK in OCP^{ΔIKKβ} cells would reveal pro-apoptotic signaling changes. Among several observed signaling aberrations, we noted in particular that JNK displayed a more robust and prolonged phosphorylation profile after RANKL stimulation in OCP's which lack IKKβ. Since JNK activation has been correlated with RANKL-induced apoptosis previously (15), we postulated that OCP^{ΔIKKβ} cells undergo apoptosis as a result of RANKL mediated JNK activation. Indeed, by inhibiting JNK-dependent apoptosis, we rescued osteoclastogenesis in OCP^{ΔIKKβ} cells.

We believe that OCP^{ΔIKKβ} cells undergo RANKL-induced JNK-dependent apoptosis early after RANKL stimulation, at a stage prior to the mature osteoclast, for two reasons. First, the number of multinucleated osteoclasts of RANKL-stimulated OCP^{ΔIKKβ} cells never approaches that of controls cells (unpublished observations). Second, TAT-TI-JIP only rescues the osteoclast defect of OCP^{ΔIKKβ} if added to the culture at the same time as RANKL stimulation (Supplementary Figure 3, panel c). When treated with TAT-TI-JIP 48 hours after RANKL stimulation, JNK-inhibition does not fully rescue osteoclastogenesis of OCP^{ΔIKKβ} cells (Supplementary Figure 3, panel d).

Whether the absence of IKKβ protein is essential for the gain-of-function of JNK in response to RANKL is unknown. For example, it is probable that a downstream effector of IKKβ signaling and not IKKβ itself, is responsible for inhibition of JNK after RANKL stimulation. In any case, we demonstrate that fine-tuned inhibition of JNK in

OCP^{ΔIKKβ} cells rescues osteoclastogenesis. Our data suggest a model whereby RANKL stimulation of OCP's leads to activation and eventual downregulation of JNK through MAP kinase phosphatase synthesis. In the absence of IKKβ, RANKL-mediated MKP1 and MKP5 synthesis are defective leading to enhancement and prolongation of JNK phosphorylation and activation resulting in apoptosis. One may postulate that blockade of JNK-downregulation through inhibition of the JNK phosphatases will result in enhanced and prolonged RANKL-induced JNK activity that is anti-osteoclastogenic.

The mechanism of JNK-mediated apoptosis in response to RANKL is not well defined. It has previously been demonstrated that in response to TNF-α in NF-κB-deficient cells, JNK activation leads to caspase-8 - independent cleavage of the pro-apoptotic protein, bid, resulting in mitochondrial release of smac and apoptosis (24). Since RANKL stimulation of OCP's does not result in caspase-8 activation, it is likely that enhanced JNK activity in the absence of IKKβ directly leads to apoptosis of OCP's after RANKL stimulation. Because lower expression of IKKβ in OCP^{ΔIKKβ} cells prevents osteoclast differentiation, it is unlikely that inhibition of JNK-mediated apoptosis will rescue osteoclastogenesis in the complete absence of IKKβ. Observing the rescuing effect of a low-dose JNK inhibitor on osteoclastogenesis in OCP^{ΔIKKβ}, therefore, requires a permissive level of IKKβ expression that allows differentiation to occur but does not inhibit apoptosis. We believe our CD11b Cre-mediated deletion of IKKβ was a successful tool in this regard.

In addition to MAP kinase phosphatases, several potential connections between the absence of IKKβ and enhanced JNK activation exist. For example, known target

genes of NF- κ B serve to downregulate JNK activation such as Gadd45 β , which specifically inhibits TNF- α -mediated MKK7 activation of JNK (25). Additionally, XIAP is a target of NF- κ B which downregulates JNK activation in response to TNF- α (26). Furthermore, A20 has been postulated to play a role in NF- κ B-mediated inhibition of JNK activation by downregulating TRAF2 (27), although this hypothesis has never been validated. Since OCP ^{Δ IKK β} display reduced XIAP and A20 expression, it will be interesting to test whether these mechanisms of crosstalk between IKK β and JNK hold true in RANKL signaling during osteoclastogenesis.

It is important to note that JNK-mediated c-jun activation is required for efficient osteoclastogenesis (19). c-jun activation leads to a partnership between AP-1 and NFAT1 which induces expression of NFAT2 and differentiation of osteoclasts (20). Therefore, inhibition of the RANKL-RANK-JNK pathway is a candidate for treatment of osteoporosis (28). In light of the opposing effects of the two arms of JNK activation in the osteoclast, it will be critical to sort out the pro and anti-osteoclastogenic means of RANKL-mediated JNK activation.

Our results highlight the necessity of IKK β in osteoclastogenesis. We demonstrate that IKK β is important for both differentiation and survival of osteoclasts. Given that we are able to rescue osteoclastogenesis in OCP ^{Δ IKK β} cells through inhibition of JNK-induced apoptosis, we conclude that IKK β acts, at least partially, through down-modulation of JNK activity to support cell survival during osteoclastogenesis. Our results, therefore, suggest that hyperactivation of JNK and inhibition of IKK β in OCP's are potential means to treat osteoclast-mediated disease.

REFERENCES

1. Kong, Y. Y., Yoshida, H., Sarosi, I., Tan, H. L., Timms, E., Capparelli, C., Morony, S., Oliveira, d. S. A., Van, G., Itie, A., Khoo, W., Wakeham, A., Dunstan, C. R., Lacey, D. L., Mak, T. W., Boyle, W. J., and Penninger, J. M. (1999) *Nature* **397**(6717), 315-323
2. Yoshida, H., Hayashi, S.-I., Kunisada, T., Ogawa, M., Nishikawa, S., Okamura, H., Sudo, T., Shultz, L. D., and Nishikawa, S.-I. (1990) *Nature* **345**, 442-443
3. Anderson, D. M., Maraskovsky, E., Billingsley, W. L., Dougall, W. C., Tometsko, M. E., Roux, E. R., Teepe, M. C., DuBose, R. F., Cosman, D., and Galibert, L. (1997) *Nature* **390**, 175-179
4. Iotsova, V., Caamano, J., Loy, J., Young, Y., Lewin, A., and Bravo, R. (1997) *Nature Med* **3**, 1285-1289
5. Yamashita, T., Yao, Z., Li, F., Zhang, Q., Badell, I. R., Schwarz, E. M., Takeshita, S., Wagner, E. F., Noda, M., Matsuo, K., Xing, L., and Boyce, B. F. (2007) *The Journal of biological chemistry* **282**(25), 18245-18253
6. Senftleben, U., Cao, Y., Xiao, G., Greten, F. R., Krahm, G., Bonizzi, G., Chen, Y., Hu, Y., Fong, A., Sun, S. C., and Karin, M. (2001) *Science* **293**(5534), 1495-1499
7. Vaira, S., Johnson, T., Hirbe, A. C., Alhawagri, M., Anwisye, I., Sammut, B., O'Neal, J., Zou, W., Weilbaecher, K. N., Faccio, R., and Novack, D. V. (2008) *Proceedings of the National Academy of Sciences of the United States of America* **105**(10), 3897-3902

8. Zandi, E., Rothwarf, D. M., Delhase, M., Hayakawa, M., and Karin, M. (1997) *Cell* **91**, 243-252
9. Chaisson, M. L., Branstetter, D. G., Derry, J. M., Armstrong, A. P., Tometsko, M. E., Takeda, K., Akira, S., and Dougall, W. C. (2004) *J Biol Chem* **279**(52), 54841-54848
10. Ruocco, M. G., Maeda, S., Park, J. M., Lawrence, T., Hsu, L.-C., Cao, Y., Schett, G., Wagner, E. F., and Karin, M. (2005) *J. Exp. Med.* **201**(10), 1677-1687
11. Abbas, S., and Abu-Amer, Y. (2003) *Journal of Biological Chemistry* **278**(22), 20077-20082
12. Dai, S., Hirayama, T., Abbas, S., and Abu-Amer, Y. (2004) *Journal of Biological Chemistry* **279**(36), 37219-37222
13. Ferron, M., and Vacher, J. (2005) *Genesis* **41**(3), 138-145
14. Pasparakis, M., Courtois, G., Hafner, M., Schmidt-Supprian, M., Nenci, A., Toksoy, A., Krampert, M., Goebeler, M., Gillitzer, R., Israel, A., Krieg, T., Rajewsky, K., and Haase, I. (2002) *Nature* **417**(6891), 861-866
15. Bharti, A. C., Takada, Y., Shishodia, S., and Aggarwal, B. B. (2004) *Journal of Biological Chemistry* **279**(7), 6065-6076
16. Liu, Y., Gorospe, M., Yang, C., and Holbrook, N. J. (1995) *The Journal of biological chemistry* **270**(15), 8377-8380
17. Theodosiou, A., Smith, A., Gillieron, C., Arkinstall, S., and Ashworth, A. (1999) *Oncogene* **18**(50), 6981-6988

18. Barr, R. K., Kendrick, T. S., and Bogoyevitch, M. A. (2002) *The Journal of biological chemistry* **277**(13), 10987-10997
19. David, J. P., Sabapathy, K., Hoffmann, O., Idarraga, M. H., and Wagner, E. F. (2002) *Journal of Cell Science* **115**(22), 4317-4325
20. Ikeda, F., Nishimura, R., Matsubara, T., Tanaka, S., Inoue, J. i., Reddy, S. V., Hata, K., Yamashita, K., Hiraga, T., Watanabe, T., Kukita, T., Yoshioka, K., Rao, A., and Yoneda, T. (2004) *Journal of Clinical Investigation* **114**(4), 475-484
21. Li, Z. W., Chu, W., Hu, Y., Delhase, M., Deerinck, T., Ellisman, M., Johnson, R., and Karin, M. (1999) *The Journal of experimental medicine* **189**(11), 1839-1845
22. Yagi, M., Miyamoto, T., Sawatani, Y., Iwamoto, K., Hosogane, N., Fujita, N., Morita, K., Ninomiya, K., Suzuki, T., Miyamoto, K., Oike, Y., Takeya, M., Toyama, Y., and Suda, T. (2005) *The Journal of Experimental Medicine* **202**(3), 345-351
23. Lee, S. H., Rho, J., Jeong, D., Sul, J. Y., Kim, T., Kim, N., Kang, J. S., Miyamoto, T., Suda, T., Lee, S. K., Pignolo, R. J., Koczon-Jaremko, B., Lorenzo, J., and Choi, Y. (2006) *Nature medicine* **12**(12), 1403-1409
24. Deng, Y., Ren, X., Yang, L., Lin, Y., and Wu, X. (2003) *Cell* **115**(1), 61-70
25. Papa, S., Zazzeroni, F., Pham, C. G., Bubici, C., and Franzoso, G. (2004) *Journal of Cell Science* **117**(22), 5197-5208
26. Tang, G., Minemoto, Y., Dibling, B., Purcell, N. H., Li, Z., Karin, M., and Lin, A. (2001) *Nature* **414**(6861), 313-317
27. Perkins, N. D. (2007) *Nature reviews. Molecular cell biology* **8**(1), 49-62

28. Teitelbaum, S. L. (2004) *Journal of Clinical Investigation* **114**(4), 463-465

FOOTNOTES

* This work was funded by a Ruth L. Kirschstein Predoctoral National Research Service Award: AR055392-01 (to J.E.O), National Institutes of Health Grants: AR049192, AR054326 (to Y. A.-A.) and by grants #8570, #8510 from the Shriners Hospital for Children (to Y. A.-A)

¶ To whom correspondence should be addressed: Washington University School of Medicine, Department of Orthopaedic Surgery, One Barnes Jewish Hospital Plaza, Suite 11300, Campus Box 8233, St. Louis, MO 63110. Fax: 314-362-0334; E-mail: abuamery@wudosis.wustl.edu

¹ Abbreviations used are: m-CSF, macrophage colony stimulating factor; RANKL, Receptor Activator of NF- κ B Ligand; OCP, osteoclast precursor; wt, wild-type; TRAP, tartrate-resistant acid phosphatase; CtR, calcitonin receptor; NFAT, nuclear factor and activator of T-cells; MMP, matrix metalloproteinase; cIAP, cellular inhibitor of apoptosis; XIAP, X-linked inhibitor of apoptosis; MKP, MAP kinase phosphatase; PARP, poly (ADP-ribose) polymerase; TUNEL, TdT-mediated dUTP Nick End Labeling; JIP, JNK-interacting protein

FIGURE LEGENDS

Figure 1. Mice with IKK β -deleted osteoclast precursors possess a defect in *in vivo* and *in vitro* osteoclastogenesis. (A) Histochemical TRAP stain at growth plate of femur of CD11b Cre-positive wt/wt IKK β and CD11b Cre-positive floxed/floxed IKK β (OCP Δ IKK β) mice to visualize osteoclasts. Arrows indicate osteoclasts. (B) Western blot for indicated proteins in total cell lysates of osteoclast precursors from CD11b Cre-negative, CD11b Cre-positive wt/floxed IKK β , and CD11b Cre-positive floxed/floxed IKK β mice. (C and D) Osteoclast precursors from CD11b Cre-positive wt/wt IKK β , CD11b Cre-positive wt/floxed IKK β , and CD11b Cre-positive floxed/floxed IKK β mice were cultured in osteoclastogenic conditions. (C) Cells were either not stimulated (a, d, g), or were further stimulated with 10 ng/ml TNF- α (b, e, h) or 100 ng/ml LPS (c, f, i) on day 4 of culture. Cells were fixed and histochemically stained for TRAP to visualize osteoclasts on day 6 of culture. (D) Quantification of C. TRAP-positive multinucleated cells (MNC's) with 3 or more nuclei were scored as osteoclasts. Asterisk indicates $p < 0.005$ for difference between number of TRAP-positive MNC's in wells represented by d and g.

Figure 2. OCP Δ IKK β are defective in osteoclast differentiation and demonstrate increased susceptibility to apoptosis. OCP Δ IKK β and control OCP's were plated in whole media supplemented with 10 ng/ml m-CSF. Cells were either not stimulated or were stimulated with 10 ng/ml RANKL for 5 days to induce osteoclast differentiation. mRNA was

collected and analyzed by real-time PCR for markers of osteoclast differentiation: (A) β_3 -Integrin, (B) Cathepsin K (Cath K), (C) Calcitonin Receptor (CtR), (D) Matrix Metalloproteinase 9 (MMP9), and (E) Tartrate-Resistant Acid Phosphatase (TRAP) as well as (F) IKK β (IKK2). GAPDH served as the internal standard for cDNA normalization. Data are presented as relative quantification with WT non-stimulated levels serving as the reference point (relative expression value of 1). Values represent mean quantification plus the standard error of the mean. (G) OCP Δ IKK β and control OCP's were plated in whole media supplemented with 10 ng/ml m-CSF. mRNA was collected and analyzed by real-time PCR for the indicated NF- κ B-regulated anti-apoptotic proteins: A20, cIAP2 (cellular inhibitor of apoptosis 2), cIAP1 (cellular inhibitor of apoptosis 1), XIAP (X-linked inhibitor of apoptosis), and Bcl-x_L. β -Actin served as the internal standard for cDNA normalization. Data are presented as relative quantification with control levels serving as the reference point (relative expression value of 1). Values represent mean quantification plus the standard error of the mean. Data are representative of three independent experiments. (H) OCP Δ IKK β and control OCP's were serum starved and were either not stimulated or were stimulated with 10 ng/ml RANKL for 15, 30, 45, 60, or 240 minutes. Total cell lysates were analyzed by Western blot for integrity of full length PARP (f-PARP). β -Actin served as the loading control.

Figure 3. Apoptosis contributes to the *in vivo* deficiency of osteoclasts in OCP Δ IKK β mice.

(A) Immunoperoxidase TUNEL stain and hematoxylin counterstain of histological sections of growth plate of humerus from OCP Δ IKK β and control mice to visualize

apoptosis of peritrabecular osteoclasts and OCP's. Upper images taken at 10X magnification, and lower images are panels from upper images taken at 40X magnification. (B) Graph depicting quantification of TUNEL positive peritrabecular nuclei per 40X field visualized by light microscopy. Arrows indicate apoptotic nuclei. Asterisk denotes $p < 0.001$. (C) TRAP stain of sections taken from same paraffin embedded bones used for TUNEL stain in (A) to demonstrate correlation between apoptosis and defective *in vivo* osteoclastogenesis.

Figure 4. Loss of IKK β in OCP's results in a gain-of-function in JNK phosphorylation. OCP Δ IKK β and control OCP's were serum starved for 4-6 hours. (A) Cells were either not stimulated or were stimulated with 10 ng/ml RANKL or TNF- α for 5, 10, or 30 minutes. (B) Cells were either not stimulated or were stimulated with 10 ng/ml RANKL for 7.5, 15, 30, or 60 minutes. Total cell lysates were then analyzed by Western blot for the indicated phosphorylated proteins and whole proteins. Equal loading for phosphorylated proteins was determined by stripping the membrane and re-probing for the respective whole protein (A and B). (C) Cells were stimulated with 10 ng/ml RANKL for 10, 15, 30, or 120 min. Total cell lysates were then analyzed by Western blot for MKP5 and MKP1. β -Actin served as the loading control.

Figure 5. Inhibition of RANKL-mediated JNK-induced apoptosis rescues osteoclastogenesis defect in OCP's deficient in IKK β . (A) OCP's from Cre $^{+}$ wild-type/floxed IKK β mice were plated in whole media supplemented with 10 ng/ml m-CSF.

Four groups of cells were treated at the time of plating with either no TAT-TI-JIP or with 0.4 μ M, 1.0 μ M, or 2.0 μ M TAT-TI-JIP. Also at the time of plating, one sample in each group was stimulated with 20 ng/ml RANKL. Cells were lysed after 24 hours of stimulation and total cell lysates were analyzed by Western blot for cleaved PARP (c-PARP), phosphorylated c-jun (p-c jun), and total c-jun. Cleaved PARP and phospho-c jun quantification in the different conditions is shown in numerical and graph form under the corresponding blot image. (B) OCP Δ IKK β and control OCP's were plated in osteoclastogenic conditions. At the time of plating, one group of cells from each population was either left untreated (a and c) or treated with 0.4 μ M TAT-TI-JIP (b and d). Cells were fixed and histochemically stained for TRAP to visualize osteoclasts on day 6 of culture. Quantification is shown in graph below. TRAP-positive multinucleated cells (MNC's) with 3 or more nuclei were scored as osteoclasts. Data are representative of three independent experiments, and error bars represent standard error of the mean. Asterisk indicates $p < 0.0001$ for difference between number of TRAP-positive MNC's in wells represented by a and c. No significant difference exists between a and d.

Figure 6. Inhibition of JNK in OCP Δ IKK β cells rescues bone resorption. Control (panels a and c) and OCP Δ IKK β (panels b and d) osteoclast precursors were plated onto BD Biocoat Osteologic tissue culture slides in osteoclastogenic conditions in the absence (panels a and b) or presence (panels c and d) of 0.4 μ M TAT-TI-JIP. Cells were removed from the slides with deionized water, and resorption pits were noted as clear areas. Images were taken at 10X magnification.

Supplementary Figure 1. Deletion of IKK β in multiple hematopoietic tissues. Southern blot for IKK β gene from DNA of bone, thymus (thym), and spleen of CD11b Cre + floxed/floxed IKK β mice. Floxed; loxP-flanked, Δ ; deleted by Cre.

Supplementary Figure 2. OCP Δ IKK β with insufficient suppression of IKK β mRNA show defective osteoclast phenotype *in vitro* despite normal induction of osteoclast markers. Control and OCP Δ IKK β osteoclast precursors were either not treated (unstim) or were treated with RANKL for 5 days. At day 5, mRNA was collected from cells for analysis of gene expression for (A) β_3 -Integrin, (B) TRAP, (C) Calcitonin Receptor, and (D) IKK β . RANKL-treated cells were also TRAP-stained (E) for visualization of osteoclasts.

Supplementary Figure 3. Requirement for early inhibition of JNK for rescue of osteoclastogenesis in OCP Δ IKK β . Control (a) and OCP Δ IKK β (b-d) osteoclast precursors were treated with RANKL for 5 days. For JNK inhibition, OCP Δ IKK β cells were either not treated (b) or were treated with 0.4 μ M TAT-TI-JIP at the same time as the first RANKL stimulation (c) or 48 hours later (d).

FIGURES

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5







Figure 6




Supplementary Figure 1



Supplementary Figure 2



Supplementary Figure 3



CHAPTER 3

IKK β ACTIVATION IS SUFFICIENT FOR RANK-INDEPENDENT OSTEOCLAST DIFFERENTIATION AND OSTEOLYSIS

IKK β Activation is Sufficient for RANK-Independent Osteoclast Differentiation and Osteolysis

Jesse E Otero¹, Simon Dai¹, Muhammad A Alhawagri¹, Isra Darwech¹, and Yousef Abu-Amer^{1, 2}

¹Orthopedics, ²Department of Cell Biology & Physiology; Washington University
School of Medicine, St. Louis, Missouri 63110

Correspondence: abuamery@wustl.edu

Running Title: RANK-independent osteoclastogenesis by IKK β

SUMMARY:

Osteoclasts differentiate from monocytes through stimulation of Receptor-Activator of NF- κ B (RANK). Many downstream effectors of RANK play a positive role in osteoclastogenesis, but their relative importance in osteoclast differentiation is unclear. We report the discovery that introduction of constitutively activated IKK β (IKK β^{SSEE}) into monocytes stimulates differentiation of *bona-fide* osteoclasts in the absence of RANK Ligand (RANKL). This phenomenon is independent of upstream signals, since IKK β^{SSEE} induced the development of bone-resorbing osteoclasts from RANK and IKK α -knockout monocytes and in conditions in which NEMO-IKK β association was inhibited.

NF- κ B p100 and p105 -but not RelB- were critical mediators of this effect. More importantly, adenoviral gene transfer of IKK β ^{SSEE} induced osteoclasts and osteolysis in calvariae and knees of mice. Our data establish the sufficiency of IKK β activation for osteolysis and suggest that IKK β gain-of-function may be a causative factor in conditions of pathological bone destruction refractory to RANK/RANKL proximal therapeutic interventions.

INTRODUCTION:

Healthy bone balance is dependent on the concerted activity of osteoblasts, bone forming cells, and osteoclasts, bone resorbing cells. In pathological conditions such as rheumatoid arthritis, osteoporosis, and osteolytic cancer metastasis, bone balance tips in favor of increased osteoclast activity, stemming from heightened osteoclast differentiation and activation¹. These conditions result in significant bone pain and increased risk of fracture. Therefore, therapies which target the osteoclast are in the armament for treatment of these conditions². On the other hand, gene mutations that disrupt osteoclast differentiation lead to development of osteopetrotic dense bones compromising bone homeostasis³. This class of bone diseases is incurable owing to osteoclast deficiency and lack of bone resorption. Undoubtedly, increasing understanding of the factors which regulate the osteoclast in health and disease will offer important insight into new effective therapies for bone loss associated with pathological conditions and for osteopetrosis.

The osteoclast is the sole bone resorbing cell, and it differentiates from a monocyte precursor through the concerted action of two cytokines, Ligand for the Receptor Activator for NF- κ B (RANKL) and Macrophage Colony Stimulating Factor (M-CSF)¹. Upon stimulation of their cognate receptors, RANK and c-Fms respectively, a series of signaling events induces activation of transcription factors such as NF- κ B, AP-1, and NFATc1 which results in fusion of precursors and expression of genes required for osteoclast function, including β_3 -Integrin, Cathepsin K, Tartrate Resistant Acid Phosphatase (TRAP), and Matrix Metalloproteinase 9 (MMP9)⁴. With expression of all necessary genes for osteoclast differentiation, the ability of the osteoclast to resorb bone requires tight regulation of the actin cytoskeleton. Indeed, genetic murine models have revealed a number of proteins such as c-Src⁵, β_3 -Integrin⁶, ITAM containing adaptors^{7,8}, and the small GTPase Rac⁹ whose activity is required for cytoskeletal regulation and bone resorption. These molecules contribute to formation of the actin ring which is the signature of a polarized osteoclast capable of resorbing bone¹⁰.

The complement of proteins whose expression and activation are important for osteoclast differentiation and function make up a growing list, but the relative importance of these genes remains unclear given the varied phenotypes of osteoclasts or osteoclast precursors devoid of any of them. A well-studied family of transcription factors which is required for osteoclastogenesis is NF- κ B. Recent findings have revealed that NF- κ B p100 and p105 are both required together for osteoclast differentiation¹¹. Additionally, p65/RelA¹² and RelB¹³ have been shown to play complementary roles in osteoclast survival and differentiation, respectively. The complex interplay between NF- κ B family

members in the context of osteoclast differentiation remains to be worked out, but it is clear that factors which activate NF- κ B are logical targets for the treatment of osteoclast-mediated disease.

The I κ B Kinase (IKK) Complex is responsible for NF- κ B activation downstream of RANK. Upstream signals lead to association of two catalytically active kinases, IKK α and IKK β with the non-catalytic member, IKK γ /NEMO. This association is required for activation of IKK through phosphorylation of two IKK activation loop serines, via an unidentified upstream kinase. IKK then phosphorylates I κ B targeting it for proteasomal degradation allowing NF- κ B to enter the nucleus and regulate gene transcription¹⁴⁻¹⁶. We and others have shown that inhibition of IKK activation through pharmacological inhibition of IKK association with NEMO abrogates osteoclastogenesis and inflammatory osteolysis^{17,18}. Furthermore, mice devoid of IKK α ¹⁹ or IKK β ^{20,21} demonstrate an impaired ability for osteoclast development *in vitro*. In a study comparing the relative contributions of the catalytic IKK members to osteoclast development *in vivo*, mice devoid of IKK β displayed osteopetrosis and resistance to inflammatory bone erosion, while mice lacking active IKK α showed no obvious skeletal phenotype²⁰. This finding implicates IKK β as an important target for therapy in osteoclast-mediated disease.

We now report that IKK β is not only necessary for RANKL-mediated osteoclastogenesis, but its activation is sufficient for RANK-independent osteoclast formation. Using retroviral delivery of constitutively active IKK β (IKK β ^{SSEE}), we reveal a signal for differentiation of functional osteoclasts that occurs downstream of RANK. IKK β ^{SSEE}-but not wild-type IKK β nor IKK α ^{SSEE}-induces osteoclast differentiation from

bone marrow, spleen, and fetal liver monocytes. These osteoclasts express all markers for normal osteoclasts, they form actin rings, and they resorb bone demonstrating that they are indeed authentic osteoclasts. Importantly, RANK is not a requirement since IKK β ^{SSEE} induces formation of bone resorbing osteoclasts from RANK-null spleen monocytes. Furthermore, we show that the classical IKK complex is not a requirement for active IKK β to drive osteoclastogenesis, since IKK β ^{SSEE} induces formation of bone-resorbing osteoclasts from IKK α null fetal liver monocytes and when NEMO binding is inhibited. Finally, adenoviral gene transfer of IKK β ^{SSEE} in knees and calvariae of mice is sufficient for development of massive osteolysis. In summary, our findings demonstrate for the first time that a single activated kinase is sufficient for RANK-independent osteoclast differentiation and that active IKK β alone leads to the development of osteolytic disease. These data highlight the centrality of IKK β in osteoclast differentiation and implicate gain-of-function of IKK β in pathological bone destruction.

RESULTS:

Constitutively Active IKK β Induces RANKL-Independent Osteoclast Differentiation from Monocytes

Recently, we and others have demonstrated the necessity for IKK β in osteoclast differentiation^{20,21}. In an effort to identify mutations in IKK β which could prevent or enhance its ability to rescue osteoclast differentiation in IKK β knockout (KO) osteoclast precursors, we made the surprising observation that introduction of the constitutively activated form of IKK β (IKK β ^{SSEE}), but not the wild-type (IKK β ^{WT}) form, into wild-type

or IKK β KO bone marrow-derived macrophages induced the formation of TRAP-positive osteoclasts in the absence of RANKL administration (**Fig. 1A, and Supplementary Figures 1 and 2**). These cells were morphologically indistinguishable from RANKL-induced osteoclasts. Levels of IKK β^{WT} and IKK β^{SSEE} protein were comparable (**Fig. 1B**), whereas IKK β^{SSEE} but not IKK β^{WT} was recognized by an antibody specific for IKK β phosphorylated at activation loop serines (**Fig. 1C**). These observations suggest that the kinase domain of IKK β^{SSEE} exists in an active conformation and further assert that mutation of IKK β activation loop serines 177 and 181 to glutamic acid, and not overexpression of IKK β *per se*, is the factor responsible for the formation of osteoclasts in the absence of RANKL.

Further characterization showed that IKK β^{SSEE} , but not GFP or IKK β^{WT} , induced expression of RelB and c-fos, two transcription factors known to be critical for normal osteoclast differentiation^{13,22}. IKK β^{SSEE} but not IKK β^{WT} , also induced the expression of β_3 -Integrin and Cathepsin K, two markers for mature osteoclasts and genes whose products are required for osteoclast bone resorption^{6, 23}, (**Fig. 1C**). Quantitative real-time PCR analysis revealed that IKK β^{SSEE} induced expression of mRNA for calcitonin receptor, cathepsin K, TRAP, and β_3 -integrin, indicating that these cells possess the molecular signature for true osteoclasts (**Fig. 1D**). This notion was further supported by experiments showing that, similar to RANKL-induced cells, osteoclasts derived through introduction of IKK β^{SSEE} into precursors form actin rings and are capable of resorbing artificial (**Supplementary Figure 3**) and authentic bone matrix (**Fig. 1E**). Expression of IKK β^{SSEE} by RANKL-independent osteoclasts was demonstrated using IKK β^{SSEE} -GFP

fusion construct (**Fig. 1F**). These data provide evidence that the TRAP+ multinucleated cells induced through expression of constitutively active IKK β in macrophages are authentic osteoclasts. Furthermore, the fact that both bone marrow and spleen-derived macrophages were susceptible to osteoclast induction by IKK β^{SSEE} argued against the theoretical possibility that IKK β^{SSEE} may induce osteoclastogenesis in a paracrine fashion.

Given the implications of this finding in studying osteoclast signaling in various genetic models for osteoclast impairment which result in embryonic lethality, we sought to examine whether stimulation of osteoclast differentiation through introduction of IKK β^{SSEE} was a phenomenon restricted to precursors obtained from adult tissue. To this end, IKK β^{SSEE} -infected but not GFP or IKK β^{WT} -infected fetal liver cells formed authentic osteoclasts with visible actin rings, a critical step in osteoclast polarization¹⁰, which are capable of resorbing dentin slices (**Fig. 1E**). Actin rings and resorption pits were observed in IKK β^{WT} -infected cells only after RANKL administration (**Fig. 1E, Supplementary Figure 4**). These observations reveal that IKK β^{SSEE} is sufficient to induce an authentic program for functional osteoclasts from adult and fetal precursor cells independent from RANKL. To verify the specificity of the osteoclastogenic effect of the phosphomimetic mutation, we mutated IKK β activation loop Serines to Alanine (IKK β^{SSAA}). This mutation resulted in an activation deficient molecule which failed to rescue basal and IL-1-induced osteoclastogenesis in IKK β KO monocytes (**Fig. 1G and H**). This result indicates that phosphomimetic mutation of IKK β activation loop Serines is a specific inducer of the osteoclast program.

IKK β ^{SSEE} Rescues RANK Knockout Osteoclast Phenotype

Having established that RANKL is dispensable for IKK β ^{SSEE}-mediated osteoclastogenesis, we sought to determine whether intrinsic RANK signaling played a role in this phenomenon. To accomplish this, the RANKL decoy molecule osteoprotegerin (OPG-Fc)^{10,24} and RANK-null cells were employed. OPG-Fc completely inhibited RANKL-induced osteoclastogenesis in IKK β ^{WT}-infected macrophages but had absolutely no effect on IKK β ^{SSEE}-induced osteoclast differentiation indicating that IKK β ^{SSEE} induces osteoclastogenesis without RANKL (**fig. 2A**). Furthermore, IKK β ^{SSEE}, but not IKK β ^{WT} nor GFP, induced the formation of osteoclasts from RANK knockout cells (**Fig. 2B**), excluding the possible necessity for an intrinsic effect of RANK. Importantly, RANK KO spleen-derived macrophages expressing GFP or IKK β ^{WT} failed to form osteoclasts in response to RANKL (**Fig. 2B**). IKK β ^{SSEE}-induced osteoclasts were also observed to form actin rings and resorb dentin (**Fig. 2C**). Consistent with this result, Western blot revealed that IKK β ^{SSEE} introduction into, but not RANKL treatment of, RANK KO cells resulted in expression of c-fos and RelB as well as c-src, β_3 -Integrin, and Cathepsin K (**Fig. 2D**), indicating that IKK β ^{SSEE}-induced RANK-KO osteoclasts are indeed *bona fide* osteoclasts which appear molecularly identical to those derived from RANKL treatment of wild-type precursors. Furthermore, quantitative real-time PCR revealed that IKK β ^{SSEE} induces expression of mRNA for TRAP, Calcitonin Receptor, Cathepsin K, and β_3 -Integrin in RANK KO cells (**Fig. 2E**). These data prove that IKK β ^{SSEE} functions independent of RANK to induce a program for differentiation of functional osteoclasts.

IKK β ^{SSEE} Acts Independently from the Classical IKK Complex to Drive Osteoclastogenesis

Activation of IKK β by upstream signals requires its association, via two carboxyl-terminal tryptophans (W739 and W741), with the non-catalytic IKK member, NEMO^{25, 26}. We and others have shown that inhibition of this association blocks RANKL-induced IKK activity and inhibits osteoclastogenesis and osteolysis^{17,18}. Since IKK β ^{SSEE} induces osteoclastogenesis independent from RANK signaling, we tested if IKK β ^{SSEE} could also induce osteoclastogenesis in the absence of NEMO binding. We employed pharmacologic and molecular approaches to test this hypothesis. First, we determined that while administration of cell-permeable NBD peptides, which inhibit the association of IKK β with NEMO, blocks RANKL-induced osteoclast differentiation, NBD did not inhibit osteoclastogenesis in response to transduction of IKK β ^{SSEE} (**Fig. 3A**). Second, while compound mutations of W739 and W741 to Alanine in the presence of the S177 and S181 to Glutamic Acid (IKK β ^{SSEE/WA}) prevent IKK β ^{SSEE} from binding to NEMO (**Fig. 3B,C**), IKK β ^{SSEE/WA} is still capable of inducing RANKL-independent osteoclastogenesis from bone marrow macrophages to the same degree as IKK β ^{SSEE} (**figure 3D**). This quadruple IKK mutant is expressed properly and retains its kinase activity (**Fig 3E, F**). Collectively, these results solidify the conclusion that IKK β ^{SSEE} induces RANKL-independent osteoclastogenesis without binding to NEMO, uncoupling the mechanism of IKK β ^{SSEE} – induced osteoclastogenesis from virtually all known upstream stimuli important for osteoclast differentiation and activation. Furthermore, this result suggests that in the setting of osteoclast differentiation, IKK β binding to NEMO is

only important for IKK β activation loop phosphorylation, after which point the association is not required for IKK β to induce osteoclastogenesis.

Since NEMO association was not required for this phenomenon, we hypothesized that IKK β^{SSEE} could induce osteoclastogenesis without formation of the classical IKK complex which includes IKK α , a kinase that has been shown required for osteoclastogenesis *in vitro*¹⁹. First, we confirmed that IKK α -null fetal liver-derived macrophages (FLC) transduced with GFP do not differentiate into osteoclasts (**Fig. 4A**) and fail to express mRNA for the osteoclast markers TRAP, Cathepsin K, and calcitonin receptor in response to RANKL stimulation while induction of these markers is normal in littermate control cells treated with RANKL (**Fig. 4C**). However, transduction of IKK α knockout FLCs with IKK β^{SSEE} restores osteoclastogenesis even in the absence of RANKL administration, rescues the ability of these cells to form normal actin rings and to resorb bone (**Fig. 4A**), and induces expression of typical signaling proteins (**Fig. 4B**) and expression of mRNA for Cathepsin K, TRAP, and Calcitonin Receptor (**Fig. 4C**). These data indicate that formation of the classical IKK complex and the IKK α -mediated non-canonical NF- κ B signaling pathway are not a requirement for IKK β^{SSEE} to stimulate RANK-independent osteoclastogenesis.

Requirement for Coordinated NF- κ B Activation in IKK β^{SSEE} -Induced Osteoclastogenesis

In an effort to identify the mechanism underlying IKK β^{SSEE} -induced osteoclastogenesis, we examined the status of essential NF- κ B subunits compared with RANKL-treated

conditions. We observed elevated total levels of RelB in the cytosol of IKK β ^{SSEE} – expressing cells at all time points assessed, including non-stimulated, compared with GFP and IKK β ^{WT} expressing cells. RelB translocation into the nucleus was only slightly stimulated by RANKL in the time course of one hour. We also observed reduced levels of I κ B α which coincided with a dramatically increased level of RelA protein in the nucleus in the absence of RANKL stimulation and at all time points tested in IKK β ^{SSEE} compared with GFP and IKK β ^{WT} expressing cells, indicating that the constitutively activated form of IKK β induces continuous I κ B α processing (**Fig. 5A**). These data suggest that IKK β ^{SSEE} may act through an NF- κ B-dependent mechanism to induce RANK-independent osteoclast differentiation. To test this hypothesis, we began by challenging RelB knockout cells with IKK β ^{SSEE}, since we repeatedly observed induction of RelB protein expression in response to IKK β ^{SSEE} in macrophages and since a positive role for RelB in osteoclast differentiation was recently described¹³. To our surprise, RelB knockout bone marrow-derived macrophages were capable of differentiating into TRAP+ osteoclasts which express Cathepsin K in the absence of RANKL-administration when expressing IKK β ^{SSEE} but not IKK β ^{WT} (**Fig. 5B,C**). Real-time PCR analysis also revealed that while induction of expression of mRNA for Calcitonin Receptor and TRAP in response to RANKL administration was impaired in RelB knockout cells, IKK β ^{SSEE} rescued the induction to levels equivalent to that seen in WT cells expressing IKK β ^{SSEE} (**Fig. 5D**). These data indicate that IKK β ^{SSEE} does not require RelB to induce osteoclast differentiation.

Given the observation that IKK β ^{SSEE} induces nuclear translocation of RelA and induces increased expression of RelB, we further explored the possibility that these NF- κ B subunits may act as mediators of the IKK β ^{SSEE} effect. However, overexpression of RelA, RelB, or a combination of RelA and RelB (**Fig. 5E**) did not induce osteoclast differentiation of bone marrow-derived macrophages. To verify activity of the RelA and RelB in this setting, we observed that RelA induced expression of I κ B α and that RelA and RelB as well as the combination of RelA and RelB induced expression of p100. (**Fig. 5F**). Collectively, these results indicate that IKK β ^{SSEE} is a specific activator of NF- κ B capable of inducing osteoclast differentiation and simple ectopic overexpression of RelA plus RelB is insufficient to coordinate this effect.

Phosphorylation of T-loop residues is a hallmark of activation for many kinases²⁷. Given the specificity of IKK β T-loop activation as a mediator of osteoclast differentiation, we asked whether constitutive activation of other kinases through phosphomimetic mutations could induce osteoclast differentiation or whether this effect is specific to IKK β . IKK α and IKK β share significant primary and secondary structural homology¹⁵, so we reasoned that, in contrast to other less-related kinases, constitutive activation of IKK α through phosphomimetic mutation (S176/180E) would be most likely to induce an osteoclast program like IKK β ^{SSEE}. We found that when expressed at comparable levels (**Fig. 5E**), IKK β ^{SSEE} induces osteoclast differentiation from bone marrow macrophages, whereas IKK α ^{SSEE} had no such effect (**Fig. 5F**), demonstrating that IKK β is the specific kinase activator of the osteoclast program.

It has been established that a combination of both NF- κ B1/p50 and NF- κ B2/p52 subunits are absolutely required for osteoclast differentiation¹¹. We wished to determine whether IKK β ^{SSEE}-induced RANK-independent osteoclastogenesis also requires NF- κ B1 and 2. To accomplish this, we transduced control and *NF- κ B1*^{-/-} / *NF- κ B2*^{-/-} (NF- κ B dKO) spleen macrophages with GFP, IKK β ^{WT}, and IKK β ^{SSEE} (**Fig. 5G**) and performed TRAP staining for osteoclasts in the absence of RANKL administration. While control cells expressing IKK β ^{SSEE} produced a significant number of osteoclasts capable of resorbing bone coinciding with expression of mRNA for Cathepsin K, no osteoclasts were observed in NF- κ B dKO cells (**Fig. 5H,I**) despite constitutive I κ B α processing (**Supplementary Figure 5**). These results indicate that IKK β ^{SSEE}-mediated induction of osteoclastogenesis requires NF- κ B-mediated gene regulation.

Constitutively Active IKK β is Sufficient for the Establishment of *in vivo* Osteolysis

To determine the relevance of active IKK β to osteoclastogenesis and osteolysis *in vivo*, we performed gene transfer experiments in mice. We injected mice with adenovirus expressing IKK β ^{SSEE} or lacZ supracalvarially or intra-articularly into the knee joint (**Supplementary Figure 6**). While lacZ did not induce an osteoclast response in either calvariae or knees, IKK β ^{SSEE} stimulated a massive local osteolytic response in both settings characterized by bone destruction and the appearance of osteoclasts at sites of bone erosion (**Fig. 6A,B**). To support the role of kinase activity of IKK β in mediating this effect, joints injected with adenoviral IKK β ^{SSEE} showed intense immunostaining for phosphorylated I κ B α at sites of synovial inflammation and osteoclastic articular bone

erosion, while LacZ-infected knees stained negatively for articular osteoclasts and phosphorylated I κ B α (**Fig. 6B**).

DISCUSSION:

We provide novel evidence that osteoclast differentiation from monocyte progenitors can be triggered by an autonomous intracellular signal downstream, yet independent of the RANK receptor. The IKK complex has been implicated in RANKL-induced osteoclast differentiation¹⁷⁻²¹, but the sufficiency of this single enzyme to independently induce osteoclastogenesis is surprising. The fact that constitutively activated IKK β induces osteoclast differentiation raises several questions. First and foremost, phosphorylation of IKK β is not unique to the RANKL/RANK signaling complex, so why do other receptor signaling complexes which activate IKK β fail to induce osteoclast differentiation? The answer to this question, most likely, lies in the tuning of IKK-mediated NF- κ B activation by RANK. It has recently been demonstrated that at the level of promoter binding and gene activation, the timing of NF- κ B oscillations in concert with AP-1 determines transcriptional output²⁸. These oscillations are differentially regulated by TNF and RANKL, despite their activation by both cytokines, resulting in transcription at different promoters. Our data predicts that NF- κ B activation through IKK β in monocyte progenitors is more sustained and prolonged by RANKL than other cytokines and that prolonged activation of IKK/NF- κ B results in transcription at osteoclast-specific gene promoters. Second, in light of its osteoclastogenic function, it is interesting to consider how closely IKK β ^{SSEE} mimics the molecule when activated

through NEMO association-dependent phosphorylation. It is possible that IKK β ^{SSEE} takes on functions not performed by IKK β in normal settings. In support of this speculation, we observe that infection of monocytes with IKK β ^{SSEE} results in p100 processing to p52, which is usually considered to be a function of IKK α ²⁹. Perhaps atypical functions like this contribute to its osteoclastogenic activity. Nevertheless, the ability of IKK β ^{SSEE} to induce the osteoclast is entirely dependent on kinase activity, since mutation of the ATP-binding lysine to methionine in the kinase domain completely abrogated the IKK β ^{SSEE} osteoclastogenic function (**Supplementary Figure 7**). Another explanation of the high specificity with which active IKK β ^{SSEE} prompts osteoclastogenesis in monocytes despite the fact that this kinase can be activated by numerous stimuli in other systems devoid of osteoclasts, can be attributed to the fact that upstream ligands prompt complex stimulatory and inhibitory circuits to modulate their responses. These complex circuits emanating from ligand/receptor interactions are absent from the IKK β ^{SSEE} response, suggesting that the immediate IKK response is induction of osteoclastogenesis whereas upstream receptor-based regulatory signals induced by various stimuli, such as TNF, lipopolysaccharide, IL-1, etc, provide networks that counteract the IKK β ^{SSEE} osteoclastogenic effect.

In addition to IKK β , several kinases have been demonstrated to play a role in osteoclast differentiation including ERK and p38 MAP Kinases³⁰, PI3K³¹, Akt³², c-Src³³, PKC³⁴, and JNK³⁵. Many of these kinases have been demonstrated to be essential to osteoclastogenesis, but it has been difficult to sort out their individual contributions to differentiation for two main reasons. First, survival defects mask the effect of null

mutations on differentiation. Second, no kinase has ever been studied for its sufficiency to activate the osteoclast program. Our discovery that constitutively activated IKK β stimulates osteoclast differentiation led us to question the uniqueness of IKK β in accomplishing this function. To address this, we mutated IKK α to create a constitutively active mutant with significant structural and sequence similarity to IKK β^{SSEE} . This molecule was insufficient for osteoclastogenesis, which led us to conclude that IKK β is uniquely situated to stimulate the osteoclast program. In this regard, it is interesting that IKK β^{SSEE} did not require IKK α or NEMO, its members in the traditional IKK complex¹⁵. This observation strongly suggests that the function of IKK α and NEMO in the setting of osteoclast differentiation is to facilitate activation of IKK β .

It is important to consider the extent to which IKK β^{SSEE} -induced osteoclasts resemble those induced by RANKL. With regard to their ability to resorb bone, they are indeed *bone fide* osteoclasts. This is supported by the fact that the same transcription factors which are important for RANKL-induced osteoclast differentiation are also upregulated by IKK β^{SSEE} , including RelB, c-Fos, and nuclear p65/RelA. Furthermore, our analysis revealed that IKK β^{SSEE} potentially induced expression of markers for RANKL-induced osteoclasts, TRAP, Cathepsin K, Calcitonin Receptor, and β_3 -Integrin. In addition to these, preliminary mRNA expression array revealed significant upregulation of DC-STAMP, OSCAR, as well as MMP9, further validating the IKK β^{SSEE} -induced osteoclast phenotype.

Differentiation of the osteoclast requires NF- κ B¹¹. To determine whether the phenotype we observed similarly requires NF- κ B we tested the ability of IKK β^{SSEE} to

drive osteoclastogenesis in *NF-κB1/2* double knockout spleen monocytes, in which it failed. In addition to NF-κB, other transcription factors may play a role in the IKKβ^{SSEE} effect. c-Fos has been implicated downstream of NF-κB for osteoclastogenesis, and in the *NF-κB1/2* double knockout, failure of c-Fos upregulation in response to RANKL has been shown to lead to impaired differentiation³⁶. We saw no defect in c-Fos upregulation by IKKβ^{SSEE} in the *NF-κB1/2*-null setting meaning that c-Fos induction is not sufficient for osteoclastogenesis (Unpublished data, J.O. and Y.A.). Therefore, NF-κB must serve functions other than c-Fos upregulation which are necessary for osteoclast differentiation. Identification of these targets will lead to a better understanding of NF-κB in the osteoclast.

Another puzzling question prompted by our data regards the mechanism through which IKKβ^{SSEE} induces formation of the Actin ring. It is known that complicated signaling at the membrane of osteoclasts associated with integrin stimulation ultimately results in formation of the actin ring which allows formation of the sealing zone and bone resorption^{7,37}. Our data suggests that the initial requirements for actin ring formation are transcriptional and are downstream of IKK, since RANK knockout cells can be induced to form actin rings and resorb bone when expressing IKKβ^{SSEE}. In this setting, integrin signaling at the bone-osteoclast interface most likely leads to actin organization. Our discovery provides a direct approach to identify the essential components for establishment of the actin ring.

NF-κB is a critical regulator of the inflammatory cellular program³⁸, and inflammatory cytokines have been linked to enhanced osteoclast function^{39,40}. Since

TNF- α has been shown to induce osteoclast differentiation in certain settings⁴¹, we sought to determine whether this inflammatory factor was required for IKK β ^{SSEE} to induce osteoclast differentiation. Using IKK β ^{SSEE}-transduced TNF- α knockout bone marrow monocytes, we found that TNF- α is not required for IKK β ^{SSEE} to accomplish its effect in osteoclast differentiation (Unpublished data, J.O. and Y.A.). Therefore, the mechanism we observe for IKK β ^{SSEE}-induced osteoclastogenesis is uncoupled from inflammatory signaling with respect to TNF. However, IKK β ^{SSEE} is capable of inducing secretion of TNF by wild-type cells suggesting that this kinase may modulate osteoclastogenesis as well as inflammatory osteolysis at varying levels.

Consistent with our *in vitro* findings, adenoviral gene transfer experiments revealed that IKK β ^{SSEE} is also sufficient for the establishment of osteolysis *in vivo*. The clinical significance of our findings is highlighted by our observations that IKK β ^{SSEE}-induced osteoclastogenesis is refractory to intervention with OPG and deletion of RANK/RANKL. In this regard, a number of conditions in human patients are associated with heightened bone turnover in the setting of inflammation for which a cause has not been identified⁴². Given the potency with which activated IKK β induces osteoclast appearance and bone destruction in this model, it is important to consider IKK β gain-of-function as an independent cause and a target in therapy for these and all conditions of inflammatory bone destruction. Further, given the potency at which IKK β ^{SSEE} induces bone resorption, this molecule positions itself as a strong therapeutic strategy for osteopetrotic diseases.

In summary, our data highlight the critical role of IKK β in osteoclast differentiation and osteolysis. We have found that constitutively active IKK β unfolds the osteoclast program in the absence of upstream signals. This result raises the possibility that other kinase effectors of RANK in osteoclast differentiation may be involved in IKK β activation. We report the first evidence of RANK-independent osteoclast differentiation that is induced through a single kinase, and we propose that gain-of-function in human IKK β may lead to a subset of genetic diseases resulting in bone destruction which would be refractory to treatments targeting proximal RANK and TNF signaling molecules.

METHODS:

Reagents. Antibodies against IKK β , IKK α , I κ B α , NEMO, Actin, RelA, RelB, c-Fos, c-Src, β_3 -Integrin, Histone H1, and horseradish peroxidase (HRP)-conjugated secondary antibodies were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Antibodies against phospho- IKK β , p100, and p105 were from Cell Signaling Technologies, Inc. (Danvers, MA). Antibodies against Flag epitope were from Sigma (St. Louis, MO). Antibody against V5 epitope was from Novus (Littleton, CO). Antibody against Cathepsin K was from Millipore/Chemicon (Temecula, CA). HRP-conjugated secondary antibody for immunohistochemistry was from Vector Laboratories (Burlingame, CA). Cytokines were purchased from R&D Systems (Minneapolis, MN). All other chemicals were purchased from Sigma (St. Louis, MO) unless otherwise indicated.

Animals and Cells. All mice were housed in a controlled barrier facility at Washington University (St. Louis, MO). TRAP Cre mice ⁴³ were from Dr. Roodman (University of Pittsburgh, PA). Floxed IKK β ⁴⁴ mice were from Dr. Pasparakis (University of Cologne, Germany). TRAP Cre floxed/floxed IKK β mice were generated by crossing TRAP Cre transgenic mice with floxed IKK β mice. IKK α heterozygous mice ¹⁹ were obtained from Dr. Akira (Osaka University, Japan). RelB KO ⁴⁵ and control bone marrow was from Dr. Novack (Washington University, St. Louis, MO). RANK KO ⁴⁶ and control spleens as well as NF- κ B double KO ³⁶ and control spleens were provided by Dr. Xing (University of Rochester Medical Center, N.Y.) For *in vivo* experiments, wild-type C57BL/6 mice at 5-6 weeks of age were used.

Plasmids. pMxs retroviral expression plasmid was from Dr. T. Kitamura (University of Tokyo, Japan). Mouse cDNA for IKK α was kindly provided by Dr. Kenneth Marcu (Stony Brook, NY). IKK β and RelB cDNA were purchased from ATCC. RelA cDNA was provided by Dr. C. Sasaki (NIA, Baltimore, MD). All expression constructs were subcloned into pMxs using standard techniques. The following mutations were generated using the QuickChange II Site Directed Mutagenesis Kit (Stratagene, La Jolla, CA) with primer pairs in parentheses: IKK β ^{SSEE} (IKK β _S177_181E_f, GAGCTGGATCAGGGCGAACTGTGCACGGAATTTGTGGGGACTCTGC, and IKK β _S177_181E_r, GCAGAGTCCCCACAAATTCCGTGCACAGTTCGCCCTGATCCAGCTC). Note that the constitutive activating effect of this mutation of IKK β has been established

previously^{47,48}. $IKK\beta^{SSAA}$ (IKK β _S177_181A_f, GAGCTGGATCAGGGCGCTCTGTGCACGGCATTGTGGGGACTCTGC, and IKK β _S177_181A_r, GCAGAGTCCCCACAAATGCCGTGCACAGAGCGCCCTGATCCAGCTC); $IKK\beta^{WWAA}$ (IKK β _W739_741A_f, GACTCTAGACGCGAGCGCGTTACAGATGGAGGATG, and IKK β _W739_741A_r, CATCCTCCATCTGTAACGCGCTCGCGTCTAGAGTC); $IKK\beta^{KM}$ (IKK β _K44M_f, GTGAACAGATCGCCATCATGCAATGCCGACAGGAGC, and IKK β _K44M_r, GCTCCTGTCGGCATTGCATGATGGCGATCTGTTACAC); $IKK\alpha^{SSEE}$ (IKK α _S176_180E_f, GATGTTGATCAAGGAGAGCTCTGTACAGAATTTGTGGGAACATTGC, and IKK α -S176_180E_r, GCAATGTTCCCACAAATTCTGTACAGAGCTCTCCTTGATCAACATC).

Generation of Bone Marrow, Spleen, and Fetal Liver-Derived Monocyte/Macrophages. Whole marrow was flushed from long bones into α - Minimum Essential Medium (MEM). Spleens and d18.5 fetal livers were crushed into cell suspensions in α -MEM and were centrifuged at 453 rcf. Cell pellets were resuspended in whole media (α -MEM with 1X penicillin/streptomycin, 10% heat-inactivated fetal bovine serum (FBS)). Monocytes/ macrophages were produced by growing cell suspensions in the presence of 10 ng/ml M-CSF. Monocytes/ macrophages were allowed to proliferate

for 3 days at 37 °C in 5% CO₂ at which point they were infected with retrovirus. See below.

Generation and Use of Retrovirus. The use of Plat-E retrovirus packaging cells stably expressing retroviral structural proteins gag-pol and env for transient production of high titer retrovirus was described previously⁴⁹. Briefly, 8µg pMx vectors expressing our gene of interest were transfected into 5 million plat-E cells (grown in DMEM supplemented with 10% FBS, 10ng/ml M-CSF, and penicillin/streptomycin) using Eugene 6 (Roche, Palo Alto, CA) according to manufacturer's instructions. Twenty-four hrs post transfection, media was exchanged to remove transfection reagent. Twenty-four and 48 hrs post media exchange, supernatant was collected and pooled. In parallel, monocyte/macrophage cultures from bone marrow, spleen, or fetal liver were developed on petri dishes, washed with PBS, and infected with retrovirus in infection mix (50% virus supernatant, 50% αMEM containing 10% FBS, 10ng/ml M-CSF, penicillin/streptomycin, and 4µg/ml hexadimethrine bromide). Twenty-four hrs post infection, cells were selected in αMEM containing 10% FBS, 10ng/ml M-CSF, penicillin/streptomycin, and 2µg/ml puromycin for 72 hrs, at which point selection media was removed, cells were washed, and grown for 24 additional hrs without puromycin. At this point, cells were lifted, counted, and plated for downstream experiments. Of note, IKKβ^{SSEE}-expressing cells fused, spread, and assumed osteoclast morphology within 30 minutes of plating on a tissue culture-treated surface, indicating that gene expression which occurred during viral transduction and selection contributed to osteoclast differentiation. A representative image depicting this phenomenon 30 min. post-plating is depicted in supplementary figure 2.

***In vitro* Osteoclastogenesis.** IKK β ^{SSEE} expressing cells were cultured in 10ng/ml M-CSF, while GFP and IKK β ^{WT}-expressing cells were cultured in 10ng/ml M-CSF plus 100ng/ml RANKL for 4 days. IKK β ^{SSEE} induced spontaneous osteoclastogenesis in the absence of RANKL, while RANKL was required for osteoclasts to form from monocyte/macrophages expressing GFP or IKK β ^{WT}. At this point, cells were fixed and TRAP stained using the Leukocyte Acid Phosphatase Kit (Sigma, St. Louis, MO). TRAP-positive cells with three or more nuclei were scored as osteoclasts.

Inhibitor Studies. For inhibition of osteoclastogenesis, cells were treated with 100ng/ml OPG/Fc Chimera (R&D Systems, Minneapolis, MN), 25 μ M TAT-NBD (YGRKKRRQRRR-G-TTLDWSWLQME) or 25 μ M TAT-mutant NBD (YGRKKRRQRRR-G-TTLDASALQME) during the entire course of retroviral transduction and *in vitro* osteoclast differentiation. The efficacy of TAT-NBD in inhibition of RANKL-induced osteoclastogenesis has been established previously¹⁷.

RNA Isolation and cDNA Production. RNA was isolated from macrophage or osteoclast cultures using the Total RNA Isolation Mini Kit (Agilent Technologies, Santa Clara, CA) according to manufacturer's instructions. Reverse transcription was performed as follows: 1.0 μ g RNA and 1.0 μ g random hexamer primer in 10 μ l nuclease-free deionized H₂O in PCR tubes were heated to 70 °C for 5 minutes, cooled to 42 °C, and set on ice. The following components were then added at the indicated amounts or concentrations for a total reaction volume of 20 μ l: 1x AMV RT buffer (Roche, Palo

Alto, CA), 40U RNaseIn (Promega, San Luis Obispo, CA), 1.25 mM dNTPs, 5 mM Sodium Pyruvate, 5 U Reverse Transcriptase Enzyme, AMV (Roche). To produce cDNA, tubes were placed in a thermocycler programmed as follows: 42 °C for 60 minutes, 50 °C for 10 minutes, and 95 °C for 5 minutes.

Quantitative Real-Time PCR. Triplicate samples of 4 µl cDNA product (5X diluted), 10 µl Sybr Green PCR Master Mix (Applied Biosystems, Inc. Foster City, CA), 0.1 µl each of 10 µM forward and reverse primer stocks, and 6 µL nuclease-free deionized H₂O were subjected to real-time PCR according to the following program in an ABI 7300 Real Time PCR System: 50 °C for 2 minutes, 95 °C for 10 minutes, (95 °C for 15 seconds, 60 °C for 1 minute) x 40 cycles. Results were analyzed using AB RQ Study Software. Real Time PCR primers were designed using Primer Express Software (Applied Biosystems, Inc.) mouse RANK Forward 5'-CTGCCTCCTGGGCTTCTTCT-3', mouse RANK Reverse 5'-CCCCTGGTGTGCTTCTAGCT-3', mouse TRAP Forward 5'-CGACCATTTGTTAGCCACATACG-3', mouse TRAP Reverse 5'-CACATAGCCCACACCGTTCTC-3', mouse Calcitonin Receptor Forward 5'-CAAGAACCTTAGCTGCCAGAG-3', mouse Calcitonin Receptor Reverse 5'-CAAGCACGCGGACAATGTTG-3', mouse Cathepsin K Forward 5'-GGAAGAAGACTCACCAGAAGC-3', mouse Cathepsin K Reverse 5'-GTCATATAGCCGCCTCCACAG-3', mouse β_3 Integrin Forward 5'-TTACCCCGTGGACATCTACTA-3', mouse β_3 Integrin Reverse 5'-AGTCTTCCATCCAGGGCAATA-3', mouse GAPDH Forward 5'-

CTTCACCACCATGGAGAAGGC-3', mouse GAPDH Reverse 5'-
GACGGACACATTGGGGGTAG-3'.

Western Blotting. Equivalent amounts of total cell protein were boiled in the presence of an equal volume of 2X SDS sample buffer consisting of (0.5 M Tris-HCl, pH 6.8, 10% (w/v) SDS, 10% glycerol, 0.05% (w/v) bromphenol blue, 3% β -Mercaptoethanol (v/v), and distilled water) for 5 min. and subjected to electrophoresis on 8–10% SDS-PAGE. Proteins were transferred to nitrocellulose membranes using a semi-dry blotter (Bio-Rad, Hercules, CA) and incubated in blocking solution (10% skim milk prepared in phosphate-buffered saline containing 0.05% Tween 20) to reduce nonspecific binding. The membranes were washed with PBS/Tween buffer and exposed to primary antibodies (16 h at 4 °C), washed (4 x 15 min.), and incubated with the appropriate secondary horseradish peroxidase-conjugated antibodies (1 h at room temperature). The membranes were washed extensively (4 X 15 min.), and an ECL detection assay was performed following the manufacturer's instructions.

Co-Immunoprecipitation. Cells expressing GFP, flag IKK β^{WT} , flag IKK β^{WA} , flag IKK β^{SSEE} , or flag IKK $\beta^{\text{SSEE/WA}}$ were lysed in immunoprecipitation (IP) buffer (10mM Tris pH 7.4, 150mM NaCl, 0.5% NP-40 (IGEPAL) 1mM EDTA, 1mM NaF, 1mM PMSF, 1mM Na₃VO₄, and 1X protease inhibitor cocktail) at 4°C. Protein was measured by BCA Assay (Pierce, Rockford, IL) and normalized. Non-specific binding was removed by rocking total cell lysate at 4°C with GammaBind G Sepharose beads (GE

Lifesciences) and 100ng normal mouse IgG for 2 hrs at 4°C. Beads and normal antibody were centrifuged and supernatant was incubated with GammaBind G Sepharose beads and 1 µg/ml mouse anti-Flag M2 antibody (Sigma, St. Louis, MO) at 4°C for 16 hrs. Immune complexes were centrifuged with beads. Supernatant was removed by vacuum suction, and 2X sample buffer (0.5 M Tris-HCl, pH 6.8, 10% (w/v) SDS, 10% glycerol, 0.05% (w/v) bromphenol blue, 3% β-Mercaptoethanol, and distilled water) was added to beads which were boiled for 5 minutes to elute the complex components.

***In vitro* Kinase Assay.** Plat E cells expressing indicated flag-tagged IKKβ constructs were lysed in IP buffer. IKKβ was immunoprecipitated with M2 antibody, washed twice with IP buffer, once with kinase assay buffer (Cell Signaling Technologies Danvers, MA), and incubated for 30 minutes at 30°C in 30 µl kinase assay buffer with 1µg GST-IκBα, 2.5mM MgCl₂, and 16µM ATP. Reaction was terminated with 30 µl reducing sample buffer. Samples were analyzed by Western blot.

Bone Resorption Assays. Osteoclasts were cultured on 5mm² 100µm thick dentin slices for 5 days in a 48-well tissue culture plate. To visualize resorption pits and tracks, slices were exposed to 0.5N NaOH, and cells were removed by mechanical agitation. Slices were washed in PBS three times and stained with 0.1% toluidine blue (w/v) in PBS for 10 minutes. Stained slices were rinsed with PBS and blotted dry, and pits were visualized by light microscopy. For assessment of resorption of artificial bone matrix, macrophages or osteoclasts were cultured on BD Biocoat Osteologic tissue culture slides (BD

Biosciences, San Jose, CA) for 4 days, and resorption areas were determined as clear areas in the osteologic matrix as visualized by light microscopy.

Actin Ring Staining. Macrophages expressing IKK β ^{SSEE} cultured on dentin in M-CSF (IKK β ^{SSEE}-induced osteoclasts) or expressing GFP or IKK β ^{WT} cultured on dentin in M-CSF or M-CSF + RANKL were fixed in 4% paraformaldehyde in PBS for 5 minutes at room temperature. Fixed macrophages or osteoclasts on dentin slices were washed with PBS three times and permeabilized in 0.2% Triton X 100 in PBS for 10 minutes at room temperature. Dentin slices were washed three times with PBS and then incubated in a 1:40 dilution of Alexa Fluor-488 phalloidin (Invitrogen Molecular Probes, Eugene, OR) for 10 minutes in a dark humidified chamber at room temperature. Slices were washed with PBS and mounted onto microscope slides for visualization of actin rings with fluorescent microscopy.

Generation and Use of Adenovirus. Adenovirus expressing IKK β ^{SSEE} was generated by subcloning from the pMx parental vector into Ad5 CMV K-NpA Shuttle using EcoR1 and Not1 restriction endonucleases (New England Biolabs, Ipswich, MA). Recombination⁵⁰, production and characterization (pfu/particle) of virus was provided by Viraquest, Inc. (North Liberty, IA). For local *in vivo* gene transfer in mice, 1 x 10⁷ pfu of virus diluted in 10 μ l sterile PBS were injected intra-articularly into the knee joint capsule. Contralateral knees on the same mouse served as experimental (Ad IKK β ^{SSEE}) and control (AdntLacZ). For calvarial osteolysis, 1 x 10⁷ pfu of virus diluted in 50 μ l

sterile PBS were injected supracalvarially. Seven days post-injection, knees and calvariae were fixed, decalcified, and analyzed histologically for osteoclasts and osteolysis. In calvarial injection experiment, RANKL and LPS were used as positive controls for osteolysis. 1µg mouse RANKL diluted in 50µl sterile PBS or 20µg LPS (055:B5 Sigma, St. Louis, MO) diluted in 50µl sterile PBS were injected over calvaria. LPS and RANKL were injected every-other-day.

X-Gal Staining. Bones were incubated at 37° C for 15 minutes in staining buffer consisting of 2mM MgCl₂, 5mM K₃Fe(CN)₆, 5mM K₄Fe(CN)₆, and 1mg/ml X-Gal in PBS, pH 7.4.

Histology. Long bones and calvariae were collected from mice and fixed in 10% buffered formalin for 24 hours. Bones were then decalcified for 7 days in decalcification buffer consisting of (14% (w/v) EDTA, H₄NOH pH 7.2), dehydrated in graded ethanol (30%-70%), cleared through xylene, and embedded in paraffin. Paraffin sections were stained histochemically for TRAP to visualize osteoclasts or H&E to assess tissue architecture. Immunohistochemistry was performed according to antibody manufacturer's instructions for immunoperoxidase staining.

Microscopy. Cells and histological sections were imaged under white or ultraviolet light on an inverted microscope (Olympus IX-51). For f-actin visualization, ultraviolet light

was passed through a FITC filter cube to localize green phalloidin. Digital images were captured using a CCD camera (Olympus DP70, 12 mega-pixel resolution).

Author contributions

J.E.O., S.D., Y.A.A, planned and designed experiments. M.A.A. maintained animal colony. J.E.O and S.D. designed DNA constructs. J.E.O. performed experiments. I.D. assisted with tissue culture experiments. J.E.O. and Y.A.A. analyzed, interpreted data, and wrote manuscript.

Acknowledgments

We thank Drs. L. Xing for providing RANK-null cells, NF- κ B double knockout cells, Y. Choi for providing RANKL-null mice, D. Novack for RelB-null cells, M. Pasparakis for IKK β -floxed mice, J. Vacher for CD11b-cre mice, C. Idleburg for superb histology work, and R. Aurora for helpful discussions. This research was supported by a Ruth L. Kirschstein Predoctoral NRSA: AR055392-01 (to J.E.O), NIH Grants: AR049192, AR054326 (to Y. A.-A.) and by grants #8570, #8510 from the Shriners Hospital for Children (to Y. A.-A.)

REFERENCES:

1. Teitelbaum, S.L. Osteoclasts: what do they do and how do they do it? *The American journal of pathology* **170**, 427-35 (2007).
2. Abu-Amer, Y. Advances in osteoclast differentiation and function. *Current drug targets. Immune, endocrine and metabolic disorders*. **5**, 347-55 (2005).
3. Teitelbaum, S.L. & Ross, F.P. Genetic regulation of osteoclast development and function. *Nat Rev Genet* **4**, 638-49 (2003).
4. Takayanagi, H. Mechanistic insight into osteoclast differentiation in osteoimmunology. *Journal of molecular medicine (Berlin, Germany)* **83**, 170-9 (2005).
5. Destaing, O. et al. The tyrosine kinase activity of c-Src regulates actin dynamics and organization of podosomes in osteoclasts. *Molecular biology of the cell* **19**, 394-404 (2008).
6. McHugh, K.P. et al. Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts. *The Journal of clinical investigation* **105**, 433-40 (2000).
7. Zou, W. et al. Syk, c-Src, the alphavbeta3 integrin, and ITAM immunoreceptors, in concert, regulate osteoclastic bone resorption. *The Journal of cell biology* **176**, 877-88 (2007).

8. Zou, W., Reeve, J.L., Liu, Y., Teitelbaum, S.L. & Ross, F.P. DAP12 couples c-Fms activation to the osteoclast cytoskeleton by recruitment of Syk. *Molecular cell* **31**, 422-31 (2008).
9. Wang, Y. et al. Identifying the relative contributions of Rac1 and Rac2 to osteoclastogenesis. *Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research* **23**, 260-70 (2008).
10. Teitelbaum, S.L. Bone resorption by osteoclasts. *Science (New York, N.Y.)* **289**, 1504-8 (2000).
11. Iotsova, V. et al. Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. *Nature medicine* **3**, 1285-9 (1997).
12. Vaira, S. et al. RelA/p65 promotes osteoclast differentiation by blocking a RANKL-induced apoptotic JNK pathway in mice. *The Journal of clinical investigation* **118**, 2088-97 (2008).
13. Vaira, S. et al. RelB is the NF- κ B subunit downstream of NIK responsible for osteoclast differentiation. *Proceedings of the National Academy of Sciences* **105**, 3897-3902 (2008).
14. Rothwarf, D.M. & Karin, M. The NF-kappa B activation pathway: a paradigm in information transfer from membrane to nucleus. *Science's STKE : signal transduction knowledge environment* **1999**, RE1 (1999).
15. Hèacker, H. & Karin, M. Regulation and function of IKK and IKK-related kinases. *Science's STKE : signal transduction knowledge environment* **2006**, re13 (2006).

16. Rossi, A. et al. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of I κ B kinase. *Nature* **403**, 103-18 (2000).
17. Dai, S., Hirayama, T., Abbas, S. & Abu-Amer, Y. The I κ B kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks osteoclastogenesis and bone erosion in inflammatory arthritis. *The Journal of biological chemistry* **279**, 37219-22 (2004).
18. Jimi, E. et al. Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. *Nature medicine* **10**, 617-24 (2004).
19. Chaisson, M.L. et al. Osteoclast differentiation is impaired in the absence of I κ B kinase- α . *J Biol Chem* **279**, 54841-8 (2004).
20. Ruocco, M.G. et al. I κ B kinase- β , but not IKK- α , is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss. *J. Exp. Med.* **201**, 1677-1687 (2005).
21. Otero, J.E. et al. Defective osteoclastogenesis by IKK β -null precursors is a result of receptor activator of NF-kappaB ligand (RANKL)-induced JNK-dependent apoptosis and impaired differentiation. *The Journal of biological chemistry* **283**, 24546-53 (2008).
22. Grigoriadis, A.E. et al. c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. *Science (New York, N.Y.)* **266**, 443-8 (1994).
23. Saftig, P. et al. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. *Proc Natl Acad Sci U S A* **95**, 13453-8 (1998).

24. Khosla, S. Minireview: the OPG/RANKL/RANK system. *Endocrinology* **142**, 5050-5 (2001).
25. Rudolph, D. et al. Severe liver degeneration and lack of NF-kappaB activation in NEMO/IKKgamma-deficient mice. *Genes & development* **14**, 854-62 (2000).
26. May, M.J., Marienfeld, R.B. & Ghosh, S. Characterization of the Ikappa B-kinase NEMO binding domain. *The Journal of biological chemistry* **277**, 45992-6000 (2002).
27. Hanks, S.K. & Hunter, T. Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. *The FASEB journal : official publication of the Federation of American Societies for Experimental Biology* **9**, 576-96 (1995).
28. Sun, L., Yang, G., Zaidi, M. & Iqbal, J. TNF-induced oscillations in combinatorial transcription factor binding. *Biochemical and biophysical research communications* **371**, 912-6 (2008).
29. Senftleben, U. et al. Activation by IKKalpha of a Second, Evolutionary Conserved, NF-kappa B Signaling Pathway. *Science* **293**, 1495-1499 (2001).
30. Lee, S.E. et al. The phosphatidylinositol 3-kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation. *Bone* **30**, 71-7 (2002).
31. Munugalavadla, V. et al. The p85{alpha} Subunit of Class IA Phosphatidylinositol 3-Kinase Regulates the Expression of Multiple Genes

- Involved in Osteoclast Maturation and Migration. *Molecular and cellular biology* **28**, 7182-98 (2008).
32. Sugatani, T. & Hruska, K.A. Akt1/Akt2 and mammalian target of rapamycin/Bim play critical roles in osteoclast differentiation and survival, respectively, whereas Akt is dispensable for cell survival in isolated osteoclast precursors. *The Journal of biological chemistry* **280**, 3583-9 (2005).
 33. Schwartzberg, P.L. et al. Rescue of osteoclast function by transgenic expression of kinase-deficient Src in src^{-/-} mutant mice. *Genes & development* **11**, 2835-44 (1997).
 34. Lee, S.W. et al. Participation of protein kinase C beta in osteoclast differentiation and function. *Bone* **32**, 217-27 (2003).
 35. David, J.P., Sabapathy, K., Hoffmann, O., Idarraga, M.H. & Wagner, E.F. JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms. *Journal of Cell Science* **115**, 4317-4325 (2002).
 36. Yamashita, T. et al. NF-kappaB p50 and p52 regulate receptor activator of NF-kappaB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1. *The Journal of biological chemistry* **282**, 18245-53 (2007).
 37. Faccio, R. et al. Vav3 regulates osteoclast function and bone mass. *Nat Med* **11**, 284-90 (2005).
 38. Bonizzi, G. & Karin, M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. *Trends in immunology* **25**, 280-8 (2004).

39. Lam, J. et al. Tumor necrosis factor superfamily cytokines and the pathogenesis of inflammatory osteolysis. *Ann.Rheum.Dis.* **61**, 82-83 (2002).
40. Wei, S., Kitaura, H., Zhou, P., Ross, F.P. & Teitelbaum, S.L. IL-1 mediates TNF-induced osteoclastogenesis. *J Clin Invest* **115**, 282-90 (2005).
41. Kim, N. et al. Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis. *The Journal of experimental medicine* **202**, 589-95 (2005).
42. Simsek, S. et al. Sporadic hyperphosphatasia syndrome featuring periostitis and accelerated skeletal turnover without receptor activator of nuclear factor-kappaB, osteoprotegerin, or sequestosome-1 gene defects. *The Journal of clinical endocrinology and metabolism* **92**, 1897-901 (2007).
43. Chiu, W.S. et al. Transgenic mice that express Cre recombinase in osteoclasts. *Genesis (New York, N.Y. : 2000)* **39**, 178-85 (2004).
44. Pasparakis, M. et al. TNF-mediated inflammatory skin disease in mice with epidermis-specific deletion of IKK2. *Nature* **417**, 861-6 (2002).
45. Vaira, S. et al. RelB is the NF-kappaB subunit downstream of NIK responsible for osteoclast differentiation. *Proceedings of the National Academy of Sciences of the United States of America* **105**, 3897-902 (2008).
46. Hsu, H. et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. *Proceedings of the National Academy of Sciences of the United States of America* **96**, 3540-5 (1999).

47. Mercurio, F. et al. IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation. *Science (New York, N.Y.)* **278**, 860-6 (1997).
48. Delhase, M., Hayakawa, M., Chen, Y. & Karin, M. Positive and negative regulation of IkappaB kinase activity through IKKbeta subunit phosphorylation. *Science (New York, N.Y.)* **284**, 309-13 (1999).
49. Morita, S., Kojima, T. & Kitamura, T. Plat-E: an efficient and stable system for transient packaging of retroviruses. *Gene therapy* **7**, 1063-6 (2000).
50. Anderson, R.D., Haskell, R.E., Xia, H., Roessler, B.J. & Davidson, B.L. A simple method for the rapid generation of recombinant adenovirus vectors. *Gene therapy* **7**, 1034-8 (2000).

FIGURE LEGENDS

Figure 1. IKK β ^{SSEE} Induces *bona fide* Osteoclasts from Bone Marrow, Spleen, and Fetal Liver Progenitors

(A) Bone marrow macrophages from IKK β -KO and littermate mice were infected with retroviruses expressing GFP, IKK β ^{WT} or IKK β ^{SSEE} and cultured with M-CSF alone or M-CSF+RANKL for 4 days. Cells were fixed and TRAP stained to determine osteoclastogenesis. Arrows denote osteoclasts. Lower panel, quantification; flx, loxP flanked.

(B) Expression levels of IKK β ^{WT} and IKK β ^{SSEE} in control and IKK β KO macrophages were measured by Western blot. Expression of endogenous NEMO is shown as control.

(C) Western blot for expression of NF- κ B molecules and osteoclast markers in total cell lysates of spleen cells infected with indicated viruses. Actin expression indicates equal loading. OC+, osteoclast positive control total cell lysate. (B and C) pMx, retroviral expression vector.

(D) Relative expression of mRNA for osteoclast markers assessed by quantitative real-time PCR. GAPDH served as internal standard for cDNA normalization. Values are expressed as relative quantity plus the standard error of the mean.

(E) Fetal liver cells (FLCs) were plated on dentin slices to determine bone resorbing activity. Slices were stained with toluidine (Tol.) blue and phalloidin to visualize resorption tracks (darker staining areas) and actin ring formation, respectively. Cells were cultured in M-CSF alone except where indicated. Scale bars indicate magnification of actin images.

(F) Spleen macrophages infected with retrovirus expressing IKK β ^{SSEE}-EGFP Fusion cultured in M-CSF were visualized by fluorescent microscopy (lower panel) and then TRAP stained to visualize osteoclasts (upper panel). (G) Control and IKK β KO monocytes were transduced with viruses expressing GFP or the indicated forms of IKK β . These cells were treated with M-CSF and RANKL and TRAP stained to visualize osteoclasts. (H) Western blot to demonstrate expression of the indicated IKK β constructs.

Figure 2. IKK β ^{SSEE}-induced Osteoclastogenesis does not Require RANKL/RANK Upstream Signals

(A) Bone marrow macrophages were cultured in the presence of M-CSF alone or in the presence of M-CSF plus RANKL each in the absence or presence of OPG/Fc chimera. IKK β ^{SSEE}- expressing cells were cultured with M-CSF in the absence or presence of OPG/Fc chimera. Cells were TRAP stained to visualize osteoclasts.

(B) WT, RANK +/?, or RANK^{-/-} spleen-derived macrophages were infected with a retrovirus expressing GFP, IKK β ^{WT}, or IKK β ^{SSEE}. These cells were cultured in the presence of M-CSF alone or in combination with RANKL for four days and TRAP stained to visualize osteoclasts.

(C) WT and RANK^{-/-} spleen-derived macrophages were infected with a retrovirus expressing IKK β ^{WT} or IKK β ^{SSEE}. These cells were cultured in the presence of M-CSF alone or in combination with RANKL for four days on dentin and were stained with phalloidin or toluidine (Tol.) blue to visualize actin rings and resorption pits, respectively. Scale bars indicate relative magnification of images.

(D) WT (+/+) or RANK KO (-/-) spleen cells infected with the indicated viruses were cultured in the presence of M-CSF or M-CSF + RANKL (RL), and total cell lysates were analyzed by Western blot for expression of indicated proteins. Lower panel, quantitative real-time PCR analysis to verify absence of RANK mRNA expression in RANK KO cells. (E) Relative expression of mRNA for osteoclast markers assessed by quantitative real-time PCR. GAPDH served as internal standard for cDNA normalization. Values are expressed as relative quantity plus the standard error of the mean.

Figure 3. IKK β ^{SSEE} Induces Osteoclastogenesis Independent from NEMO Association

(A) Bone marrow macrophages expressing IKK β ^{SSEE} were cultured in the presence of M-CSF without NBD or with NBD or mutant NBD (mNBD). Cells expressing IKK β ^{WT} were treated with RANKL to induce osteoclast differentiation in the absence of NBD or in the presence of NBD or mNBD. Cells were TRAP stained for osteoclasts. Right panel, quantification.

(B) Schematic diagram of IKK β constructs utilized in (C and D). Kinase, kinase domain; LZ, leucine zipper; HLH, helix-loop-helix; NBD, NEMO-binding domain. Not shown to scale.

(C) Co-immunoprecipitation depicting ability of Tryptophan 739 and 741 to Alanine mutations to prevent binding of IKK β ^{WT} and IKK β ^{SSEE} to NEMO.

(D) TRAP stain of cells expressing GFP or the IKK β constructs shown in (B).

(E) Luciferase assay for NF- κ B induction by constructs shown in (B).

(F) Kinase assay for constructs shown in B. p-I κ B α , phosphorylated I κ B α .

Figure 4. IKK β ^{SSEE} Induction of Osteoclasts does not Require IKK α

(A) WT and IKK α -null FLCs expressing GFP were cultured with M-CSF in the absence or presence of RANKL, or IKK β ^{SSEE} with M-CSF alone. TRAP staining for osteoclastogenesis; phalloidin staining for actin ring formation; toluidine (Tol.) blue staining for dentin resorption. Scale bars indicate magnification of actin image. (B) Western blot for expression of selected NF- κ B pathway markers. Actin blot shows equal loading. OC+, osteoclast positive control. n.s., non-specific band. (C) Relative expression of mRNA for selected markers of osteoclastogenesis assessed by quantitative real-time PCR. Levels normalized to GAPDH.

Figure 5. IKK β ^{SSEE} Induction of Osteoclastogenesis Requires Coordinated NF- κ B Signaling

(A) Western blot for expression levels of key NF- κ B signaling molecules in total cell lysates (left panel) and cytosol and nuclear fractions (right panel) of spleen-derived macrophages expressing GFP, IKK β ^{WT}, or IKK β ^{SSEE} not treated or treated with RANKL for the indicated times.

(B) TRAP stain of WT and RelB KO bone marrow macrophages expressing IKK β ^{SSEE} cultured in the presence of M-CSF without RANKL.

(C) Western blot for the indicated proteins in WT and RelB KO cells expressing GFP, IKK β ^{WT}, or IKK β ^{SSEE} cultured with M-CSF. OC+, osteoclast positive control.

(D) Relative mRNA expression of selected osteoclast markers in WT and Rel B KO cells treated with RANKL or expressing IKK β ^{SSEE} not treated with RANKL.

(E and F) Protein expression and osteoclastogenesis, respectively, were measured following expression of GFP, IKK β ^{WT}, IKK β ^{SSEE}, IKK α ^{SSEE}, p65(RelA), RelB, or p65+RelB in bone marrow macrophages cultured with M-CSF.

(G-I) Control or NF- κ B double knockout (dKO) spleen cells transduced with GFP, IKK β ^{WT}, or IKK β ^{SSEE} were analyzed to determine (G) protein expression levels, (H) osteoclastogenesis and bone resorption, and (I) Cathepsin K mRNA expression. Cells in (I) were cultured in the presence of M-CSF without RANKL.

Figure 6. Active IKK β is Sufficient for Osteolysis

(A) Images of TRAP stained histological slides of calvarial bones of mice injected supracalvarially with adenovirus expressing lac Z (Ad LacZ) or IKK β ^{SSEE} (Ad IKK β ^{SSEE}), LPS, or RANKL. Arrows indicate areas of osteoclastic bone erosion. Scale bars, 200 μ m.

(B) Images of H&E, TRAP, and Immunoperoxidase-phospho-I κ B α stained histological slides of knees of mice injected intra-articularly with adenovirus expressing lac Z (Ad LacZ) or IKK β ^{SSEE} (Ad IKK β ^{SSEE}). Arrows indicate areas of pathological osteoclastic bone erosion at the articular surface (osteoclasts stain pink). Asterisks denote areas of inflammatory cell infiltrate into the synovial space. Arrowheads show positive stain for phosphorylated I κ B α , indicative of active IKK β . Objective used for capturing image is labeled above panels. Scale bars, 200 μ m.

Supplementary Figure 1. High Resolution Image Demonstrating RANKL-Independent Osteoclastogenic Effect of $\text{IKK}\beta^{\text{SSEE}}$ in the Absence of Endogenous $\text{IKK}\beta$. In an independent experiment from figure 1A of main text, $\text{IKK}\beta$ KO cells were retrovirally transduced with GFP, $\text{IKK}\beta^{\text{WT}}$, or $\text{IKK}\beta^{\text{SSEE}}$ and were either cultured in M-CSF or M-CSF + RANKL. Cells were TRAP stained to visualize osteoclasts (indicated with arrows).

Supplementary Figure 2. $\text{IKK}\beta^{\text{SSEE}}$ -Transduced cells 30 min. Post-Plating. Image capturing the phenomenon of the assumption of osteoclast morphology (arrows) by $\text{IKK}\beta^{\text{SSEE}}$ but not GFP - expressing cells 30 minutes after plating on a tissue culture surface. This observation indicates that gene expression which occurs during the retroviral infection and selection process is responsible for osteoclast differentiation.

Supplementary Figure 3. Resorption of Artificial Matrix by Osteoclasts Generated by Expression of $\text{IKK}\beta^{\text{SSEE}}$. Spleen cells expressing $\text{IKK}\beta^{\text{WT}}$ and $\text{IKK}\beta^{\text{SSEE}}$ were grown in M-CSF alone or in combination with RANKL and were TRAP stained or plated on osteologic (Osteo.) substrate to assess osteoclast activity. Clear areas indicated by arrowheads represent osteoclastic resorption of substrate.

Supplementary Figure 4. High Resolution Image of Resorption Pits Generated by RANKL and IKK β ^{SSEE} – Induced Osteoclasts. Monocytes were retrovirally transduced with either IKK β ^{WT} or IKK β ^{SSEE}. Cells were then plated on dentin slices and grown in the presence of M-CSF (IKK β ^{SSEE}) or M-CSF + RANKL (IKK β ^{WT}) for 5 days. Slices were stained with toluidine blue and visualized by light microscopy. This high resolution image depicts the regular pattern of the dentin slice best visualized when not resorbed (IKK β ^{WT} in M-CSF). Arrows indicate resorption pits and tracks which appear as dark staining irregularities in the dentin slice.

Supplementary Figure 5. Constitutive I κ B α Processing Induced by IKK β ^{SSEE} in Control and NF- κ B dKO Cells. Monocytes were retrovirally transduced with either GFP, IKK β ^{WT}, or IKK β ^{SSEE}. Total cell lysates were immunoblotted for the indicated proteins. This data indicates that basal I κ B α level is normal in the absence of subunits NF- κ B1 and 2. IKK β ^{SSEE} induces constitutive processing of I κ B α independently from these two subunits, but this phenomenon is insufficient to induce osteoclasts without NF- κ B1 and 2. OC+, osteoclast positive control.

Supplementary Figure 6. Adenoviral Gene Transfer *in vivo*. Knees of mice were intra-articularly injected with adenovirus expressing LacZ or IKK β ^{SSEE}. One week post-injection, legs were analyzed by X-gal staining for LacZ expression. Retro-patellar location of blue stain (arrowhead) indicates the intra-joint localization of gene expression. Scale bar, 1 cm.

Supplementary Figure 7. Kinase Activity is responsible for IKK β^{SSEE} -induced osteoclastogenesis. (A) Spleen macrophages were infected with retrovirus expressing GFP, IKK β , IKK β^{SSEE} , or IKK $\beta^{\text{SSEE KM}}$. Cells were TRAP-stained to visualize osteoclasts. (B) NF- κ B luciferase and (C) *in vitro* kinase assays for indicated constructs.

FIGURES:

Figure 1




Figure 2





Figure 3





A

| IKK β | | Cytosol | | | | | | | | | | | | Nuclear | | | | | | | | | | | |
|-----------------------|------|-------------|----|----|----|----------------|----|----|----|------------------|----|----|----|---------|----|----|----|----------------|----|----|----|------------------|----|----|----|
| | | GFP | | | | IKK β WT | | | | IKK β SSEE | | | | GFP | | | | IKK β WT | | | | IKK β SSEE | | | |
| WT | SSEE | 0 | 15 | 30 | 60 | 0 | 15 | 30 | 60 | 0 | 15 | 30 | 60 | 0 | 15 | 30 | 60 | 0 | 15 | 30 | 60 | 0 | 15 | 30 | 60 |
| IKK β | | min RANKL | | | | | | | | | | | | | | | | | | | | | | | |
| p-IKK β | | IKK β | | | | | | | | | | | | | | | | | | | | | | | |
| c-Fos | | RelA | | | | | | | | | | | | | | | | | | | | | | | |
| RelB | | RelB | | | | | | | | | | | | | | | | | | | | | | | |
| NEMO | | RelB | | | | | | | | | | | | | | | | | | | | | | | |
| I κ B α | | RelB | | | | | | | | | | | | | | | | | | | | | | | |
| β_3 -Integrin | | Histone H1 | | | | | | | | | | | | | | | | | | | | | | | |

B

M-CSF + IKK β SSEE

WT

RelB KO

C

| WT | | RelB KO | | | | |
|----------------|-----------------|---------|-----------------|----|------|-----|
| pMx | pMx IKK β | pMx | pMx IKK β | | | |
| GFP | WT | SSEE | GFP | WT | SSEE | OC+ |
| RelB | | | | | | |
| IKK β | | | | | | |
| Cathepsin K | | | | | | |
| β -Actin | | | | | | |

D

Relative Calcitonin Receptor Expression

IKK β WT + RANKL

IKK β SSEE

WT

RelB KO

E

β -Actin

p100

I κ B α

RelB

RelA endo+

V5

IKK α

Flag

IKK β

GFP

Flag IKK β WT

Flag IKK β SSEE

V5 IKK α SSEE

p65

RelB

p65 + RelB

F

M-CSF

GFP

IKK β WT

IKK β SSEE

IKK α SSEE

p65

RelB

p65 + RelB

G

| Control | | | | NF- κ B dKO | | | |
|----------------|-----------------|-----------------|-----------------|--------------------|-----------------|-----------------|-----------------|
| pMx | pMx IKK β | pMx IKK β | pMx IKK β | pMx | pMx IKK β | pMx IKK β | pMx IKK β |
| GFP | WT | SSEE | GFP | WT | SSEE | OC+ | OC+ |
| p100 | | | | | | | |
| p105 | | | | | | | |
| IKK β | | | | | | | |
| β -Actin | | | | | | | |

H

IKK β SSEE (No RANKL)

GFP

IKK β WT

IKK β WT + RANKL

TRAP

Dentin

NF- κ B dKO Control

NF- κ B dKO

I

Relative Cathepsin K Expression

GFP

WT


IKK β

IKK β SSEE


WT

NF- κ B dKO


Figure 6




Supplementary Figure 1




Supplementary Figure 2




Supplementary Figure 3




Supplementary Figure 4




Supplementary Figure 5



Supplementary Figure 6



Supplementary Figure 7



CHAPTER 4

INFLAMMATORY CYTOKINE SECRETION AND
OSETOCLAST DIFFERENTIATION INDUCED BY ACTIVATION
OF IKK β IN MACROPHAGES ARE UNCOUPLED EVENTS

ABSTRACT

We have previously demonstrated that constitutively active IKK β (IKK β^{SSEE}) induces a program for differentiation of fully functional osteoclasts in the absence of RANK signaling. This finding, coupled with the fact that IKK β is required for normal osteoclast differentiation in response to RANKL treatment of macrophages, argues that IKK β activation is necessary for osteoclast differentiation and constitutive activation of IKK β is sufficient. It is known that IKK β activates NF- κ B which is an inducer of both osteoclastogenic and inflammatory signals. We sought to determine whether inflammatory signals contribute to the osteoclastogenic effect of constitutively active IKK β in macrophages. We confirmed that, in conjunction with induction of osteoclastogenesis, IKK β^{SSEE} induces expression of both TNF α and IL-1 β , two pro-inflammatory cytokines linked to osteoclastogenesis and inflammatory osteolysis. However, using macrophages genetically deficient in TNF α or the IL-1 type 1 receptor, we determined that neither TNF α nor IL-1 β are required for osteoclast differentiation induced by IKK β^{SSEE} . These results confirm that *in vitro*, osteoclast differentiation and the cellular inflammatory response, with respect to TNF α and IL-1 are uncoupled. Furthermore, we confirm that pure activation IKK β is capable of inducing osteoclastogenesis from macrophages in an autocrine stimulation-independent, cell-autonomous manner.

INTRODUCTION

Rheumatoid Arthritis (RA) is an autoimmune disease characterized by chronic inflammation of the joints resulting in joint pain, swelling, immobility, and deformity. Although the initiating event responsible for RA is unknown, several factors are believed to play a role in the pathogenesis of the disease. It is known that several cell types interact in the inflamed joint and contribute to the progression of RA including synovial fibroblasts and lymphocytes, which secrete pro-inflammatory factors, and osteoclasts which degrade bone in response to these factors ¹. The role of cytokines in progression of RA is well established ². For example, synovial mononuclear cell cultures from patients affected by RA were demonstrated to produce the pro-inflammatory cytokine, TNF α ³, which was later localized to the inflamed synovial membrane in tissue sections of RA patients⁴. Further, mice engineered to express high levels of human TNF α develop spontaneous arthritis with cartilage and bone destruction ⁵, and neutralizing antibodies against TNF α significantly reduced the clinical severity of arthritis in a murine model for the disease ⁶. It is believed that TNF α contributes to the bone destruction mediated by osteoclasts in arthritis ⁷. Whether TNF itself is sufficient for osteoclast differentiation ^{8,9} or whether TNF enhances established osteoclastogenesis ¹⁰ is controversial, but it is clear that osteoclasts are necessary for TNF-mediated bone destruction ¹¹. IL-1 is another cytokine known to contribute to the pathogenesis of arthritis as IL-1 gene expression has been demonstrated in the synovium of patients with RA ¹², and IL-1 blockade ameliorates the joint destruction associated with experimental arthritis in mice ¹³. The role of IL-1 in

mediating bone destruction in arthritis has been suggested based on the observation that IL-1 knockout mice were resistant to TNF-mediated bone destruction¹⁴ and that IL-1 is essential for TNF-mediated osteoclastogenesis *in vitro*¹⁵. Factors that influence TNF and IL-1 expression in the setting of RA are candidate targets in the treatment of the bone destruction associated with the disease.

NF- κ B is a family of transcription factors that plays a critical role in the inflammatory response¹⁶. It is known that TNF and IL-1 are gene targets for NF- κ B^{17,18} and that these cytokines also activate NF- κ B^{19,20} creating a positive feedback loop which may contribute to chronic inflammatory diseases. It has been shown in mice that disruption of NF- κ B or upstream activators of NF- κ B are resistant to different models for inflammatory arthritis and bone destruction²¹⁻²⁵. Given the therapeutic value of TNF and IL-1 blockade in arthritis², it is likely that NF- κ B mediated activation of TNF and IL-1 contributes to the inflammation and bone destruction associated with arthritis. We wondered whether osteoclastogenesis driven by constitutive activation of NF- κ B (reported in Chapter 3 of this thesis) was a result of continuous secretion and therefore autocrine stimulation of monocytes by TNF or IL-1.

We used retrovirus mediated delivery of constitutively activated IKK β (IKK β ^{SSEE}) into monocytes to activate NF- κ B, and we demonstrated that in response to IKK β ^{SSEE}, TNF α and IL-1 β are upregulated at both mRNA and protein levels. However, TNF α and IL-1R knockout monocytes were stimulated to become osteoclasts in response to IKK β ^{SSEE},

which demonstrates that pro-inflammatory autocrine signaling does not contribute to spontaneous osteoclast differentiation driven by constitutively active IKK β . These observations suggest that IKK β -driven transcriptional activity within IKK β^{SSEE} – expressing monocytes leads to osteoclast differentiation in a cell-autonomous manner, which provides strong evidence that osteoclast differentiation can be stimulated by a single signaling pathway downstream of RANK.

RESULTS

Constitutively Active IKK β Induces both Pro-Inflammatory and Osteoclastogenic Programs

NF- κ B is an important stimulator of the production of the inflammatory cytokines, TNF and IL-1^{17,18}. We have shown that constitutively active IKK β (IKK β^{SSEE}), which is an upstream activator of NF- κ B, triggers osteoclast differentiation from monocytes in the absence of RANKL. Since TNF and IL-1 have been demonstrated to induce osteoclastogenesis in certain settings independent from the RANKL/RANK signaling pathway⁹, we sought to determine whether IKK β^{SSEE} induces production of TNF and IL-1 in macrophages and, further, whether these molecules are responsible for triggering spontaneous osteoclast differentiation promoted by IKK β^{SSEE} . We confirmed by Western blot that IKK β^{SSEE} but not WT IKK β induced nuclear translocation of p65/RelA in macrophages, which demonstrates the ability of phosphomimetic Serine to Glutamic

Acid mutations in the t-loop of IKK β to activate NF- κ B in macrophages (**Fig. 1**). In a culture system in which wild-type bone marrow macrophages were induced by IKK β ^{SSEE} to differentiate into mature osteoclasts (**Fig. 2A**), we measured production of the mRNA for the osteoclastogenic cytokine, RANKL, and its receptor RANK. We determined that RANKL mRNA was not detectable in our culture system in GFP, WT IKK β , or IKK β ^{SSEE} expressing cells (**Fig. 2B**), suggesting that IKK β ^{SSEE} induces osteoclastogenesis without positive feedback by RANKL. Furthermore, mRNA for the receptor RANK was not induced by IKK β ^{SSEE} (**Fig. 2B**), which argued against the possibility that IKK β ^{SSEE} – expressing cells may be more sensitive to undetectable levels of RANKL in the culture through receptor upregulation. This result is consistent with our previous findings in which we show that the osteoclastogenic effect of IKK β ^{SSEE} is a RANK/RANKL-independent event. Next, to determine whether activation of IKK β in macrophages results in production of pro-inflammatory cytokines, we measured mRNA levels for the pro-inflammatory cytokines, TNF α and IL-1 β . We determined that IKK β ^{SSEE} induces increased expression of mRNA for both TNF α and IL-1 β compared with GFP and WT IKK β – expressing macrophages (**Fig. 2C**). Interestingly, TNF α mRNA level was only induced 3 fold, while mRNA for IL-1 β was increased by more than 1000 fold (**Fig. 2C**). Nevertheless, the level of TNF α protein secreted into the culture media measured by ELISA was 7.8 fold greater in IKK β ^{SSEE} – expressing cells compared with GFP expressing cells (p<0.005), and IL-1 β protein measured in the media of IKK β ^{SSEE} – expressing cells was 22.6 fold greater than in the media of GFP – expressing cells (p<0.005) (**Fig. 2D**). WT IKK β did not induce increased TNF α or IL-1 β protein secretion

from macrophages compared with GFP. These results demonstrate that in macrophages, constitutively active IKK β induces secretion of pro-inflammatory cytokines, which have been shown to contribute to osteoclast differentiation^{8-10,15}.

TNF α is Dispensable for Induction of Spontaneous Osteoclast Formation by IKK β^{SSEE}

Whether TNF α or IL-1 β was a causative factor for osteoclastogenesis in response to activation of IKK β was unclear. To address this question, we tested the ability of IKK β^{SSEE} to induce osteoclastogenesis from bone marrow macrophages isolated from TNF α knockout mice, which are defective in TNF α production²⁶. We retrovirally expressed either GFP, WT IKK β , or IKK β^{SSEE} in WT and TNF α KO macrophages. Western blot revealed equivalent expression of IKK β constructs (**Fig. 3A**). However, although IKK β^{SSEE} induced secretion of TNF α from WT macrophages, this induction did not occur in TNF α KO macrophages (**Fig. 3B**). Nevertheless, TNF α KO macrophages were induced by IKK β^{SSEE} to become osteoclasts to the same extent as WT macrophages (**Fig. 3C**), indicating that IKK β^{SSEE} – induced TNF α autocrine stimulation of macrophages is not responsible for the spontaneous osteoclast differentiation induced by constitutive activation of IKK β . Interestingly, we observed reduced IL-1 β secretion by TNF α KO compared with WT macrophages expressing IKK β^{SSEE} ($p < 0.005$) (**Fig. 3D**). Therefore, active IKK β partially relies on TNF α for maximal IL-1 β production, but reduced IL-1 β production in the TNF α – null setting does not result in impaired spontaneous osteoclast differentiation.

IL-1 Does Not Mediate the Osteoclastogenic Effect of Constitutively Active IKK β

To determine whether constitutively active IKK β requires IL-1 β autocrine stimulation to induce osteoclastogenesis, we tested the ability of IKK β^{SSEE} to induce osteoclasts from macrophages lacking the IL-1 α/β type 1 receptor ²⁷. IL-1 signaling is required for osteoclast bone erosion in response to systemic inflammation ¹⁴, so the possibility exists that IKK β^{SSEE} may induce osteoclast differentiation through production of IL-1. We observed that although IL-1 β failed to enhance RANKL-mediated osteoclastogenesis from IL-1 receptor knockout macrophages (**Fig 4 A. B**), these cells were not defective in osteoclastogenesis induced by expression of IKK β^{SSEE} (**Fig 4 B**), despite equivalent expression of IKK β constructs in WT and IL-1 receptor knockout macrophages (**Fig 4 C**). These results indicate that IL-1 does not mediate the osteoclastogenic effect of constitutive activation of IKK β .

DISCUSSION

Osteoclastogenesis in the setting of inflammation has been widely documented ²⁸⁻³⁰, and it is known that NF- κ B is a critical mediator of both inflammatory as well as osteoclastogenic signaling ³¹. We discovered that constitutively activating NF- κ B by expressing active IKK β (IKK β^{SSEE}) in monocytes induces osteoclast differentiation without upregulating RANKL or its receptor, RANK. We therefore hypothesized that

constitutively active IKK β induced osteoclast differentiation either from within the monocyte in a cell-autonomous fashion or through secretion of and autocrine stimulation by pro-inflammatory mediators. Although RANKL, the most important osteoclastogenic cytokine, is required for inflammatory osteoclastogenesis in response to certain *in vivo* models of arthritis ³², it has been proposed that the inflammatory cytokines TNF and IL-1 may compensate for RANKL to induce osteoclast differentiation from isolated monocytes ^{8,9}. Since activation of NF- κ B is associated with production of TNF and IL-1 ^{17,18}, we sought to determine whether IKK β ^{SSEE} induced osteoclast differentiation through these pro-inflammatory cytokines. In addition to stimulation of osteoclast differentiation, we observed induction of both TNF α and IL-1 β secretion by macrophages expressing constitutively active IKK β . However, genetic disruption of TNF or the IL-1 type 1 receptor had no effect on the osteoclastogenic phenotype induced by IKK β ^{SSEE}. Therefore, we have demonstrated that there are separate and exclusive programs for osteoclast differentiation and inflammation induced downstream of IKK β activation. Furthermore, the fact that autocrine stimulation by TNF α and IL-1 β does not mediate osteoclast differentiation induced by constitutively active IKK β strongly suggests that the program for osteoclastogenesis can be encoded entirely through NF- κ B downstream of IKK β . This finding, in addition to the fact that IKK β is required for osteoclast differentiation induced by RANKL ³³, supports the notion that IKK β is a critical target in treating inflammatory bone erosion and other osteoclast – mediated diseases.

METHODS

Reagents: Antibodies against IKK β , Actin, and RelA as well as horseradish peroxidase-conjugated secondary antibodies were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Antibody against Flag epitope was purchased from Sigma (St. Louis, MO). Cytokines were purchased from R&D Systems (Minneapolis, MN). Enhanced Chemiluminescence kit was purchased from Pierce Biotechnology, Inc (Rockford, IL). All other chemicals were purchased from Sigma (St. Louis, MO) unless otherwise indicated.

Animals: All mice were purchased from Jackson Laboratories (Bar Harbor, Maine) and were housed in a controlled barrier facility at Washington University (St. Louis, MO).

Plasmids: pMxs retroviral expression plasmid was a generous gift from Dr. Toshio Kitamura (University of Tokyo, Japan). IKK β cDNA was purchased from ATCC, I.M.A.G.E. Clone ID #4482634. All expression constructs were subcloned into pMxs using standard techniques. The following mutations were generated using the QuickChange II Site Directed Mutagenesis Kit (Stratagene, La Jolla, CA) with primer pairs in parentheses: IKK β ^{SSEE} (IKK β _S177_181E_f, GAGCTGGATCAGGGCGAACTGTGCACGGAATTTGTGGGGACTCTGC, and IKK β _S177_181E_r, GCAGAGTCCCCACAAATTCCGTGCACAGTTCGCCCTGATCCAGCTC). Note that

the constitutive activating effect of this mutation of IKK β has been established previously^{34,35}.

Macrophage Culture: Whole marrow was flushed from long bones into α - Minimum Essential Medium (MEM). Spleens were crushed into cell suspensions in α -MEM and were centrifuged at 453 rcf. Cell pellets were resuspended in whole media (α -MEM with 1X penicillin/streptomycin, 10% heat-inactivated fetal bovine serum (FBS)). Monocytes/macrophages were produced by growing cell suspensions in the presence of 10 ng/ml M-CSF. Monocytes/ macrophages were allowed to proliferate for 3 days at 37 °C in 5% CO₂ at which point they were infected with retrovirus. See below.

Infection of Macrophages: The use of Plat-E retrovirus packaging cells stably expressing retroviral structural proteins gag-pol and env for transient production of high titer retrovirus was described previously³⁶. Briefly, 8 μ g pMx vectors expressing our gene of interest were transfected into 5 million plat-E cells (grown in DMEM supplemented with 10% FBS, 10ng/ml M-CSF, and penicillin/streptomycin) using Fugene 6 (Roche, Palo Alto, CA) according to manufacturer's instructions. Twenty-four hrs post transfection, media was exchanged to remove transfection reagent. Twenty-four and 48 hrs post media exchange, supernatant was collected and pooled. In parallel, monocyte/macrophage cultures from bone marrow, spleen, or fetal liver were developed on petri dishes, washed with PBS, and infected with retrovirus in infection mix (50% virus supernatant, 50% α MEM containing 10% FBS, 10ng/ml M-CSF, penicillin/streptomycin, and 4 μ g/ml hexadimethrine bromide). Twenty-four hrs post infection, cells were selected in α MEM containing 10% FBS, 10ng/ml M-CSF,

penicillin/streptomycin, and 2 μ g/ml puromycin for 72 hrs, at which point selection media was removed, cells were washed, and grown for 24 additional hrs without puromycin. At this point, cells were lifted, counted, and plated for downstream experiments.

Osteoclast Differentiation: IKK β ^{SSEE} expressing cells were cultured in 10ng/ml M-CSF, while GFP and IKK β ^{WT}-expressing cells were cultured in 10ng/ml M-CSF plus 100ng/ml RANKL for 4 days. IKK β ^{SSEE} induced spontaneous osteoclastogenesis in the absence of RANKL, while RANKL was required for osteoclasts to form from monocyte/macrophages expressing GFP or IKK β ^{WT}. At this point, cells were fixed and TRAP stained using the Leukocyte Acid Phosphatase Kit (Sigma, St. Louis, MO). TRAP-positive cells with three or more nuclei were scored as osteoclasts.

Western Blot: Equivalent amounts of total cell protein were boiled in the presence of an equal volume of 2X SDS sample buffer consisting of (0.5 M Tris-HCl, pH 6.8, 10% (w/v) SDS, 10% glycerol, 0.05% (w/v) bromphenol blue, 3% β -Mercaptoethanol (v/v), and distilled water) for 5 min. and subjected to electrophoresis on 8–10% SDS-PAGE. Proteins were transferred to nitrocellulose membranes using a semi-dry blotter (Bio-Rad, Hercules, CA) and incubated in blocking solution (10% skim milk prepared in phosphate-buffered saline containing 0.05% Tween 20) to reduce nonspecific binding. The membranes were washed with PBS/Tween buffer and exposed to primary antibodies (16 h at 4 °C), washed (4 x 15 min.), and incubated with the appropriate secondary horseradish peroxidase-conjugated antibodies (1 h at room temperature). The membranes

were washed extensively (4 X 15 min.), and an ECL detection assay was performed following the manufacturer's instructions.

Enzyme Linked Immunosorbent Assay: Supernatants were collected from 6-well plates of 1×10^6 cells expressing various constructs and were rapidly frozen at -80°C . TNF α or IL-1 β concentrations were measured in thawed supernatants by ELISA using Quantikine kits from R&D Systems (Minneapolis, MN).

Isolation of RNA and cDNA Production: RNA was isolated from macrophage or osteoclast cultures using the Total RNA Isolation Mini Kit (Agilent Technologies, Santa Clara, CA) according to manufacturer's instructions. Reverse transcription was performed as follows: 1.0 μg RNA and 1.0 μg random hexamer primer in 10 μl nuclease-free deionized H_2O in PCR tubes were heated to 70°C for 5 minutes, cooled to 42°C , and set on ice. The following components were then added at the indicated amounts or concentrations for a total reaction volume of 20 μl : 1x AMV RT buffer (Roche, Palo Alto, CA), 40U RNaseIn (Promega, San Luis Obispo, CA), 1.25 mM dNTPs, 5 mM Sodium Pyruvate, 5 U Reverse Transcriptase Enzyme, AMV (Roche). To produce cDNA, tubes were placed in a thermocycler programmed as follows: 42°C for 60 minutes, 50°C for 10 minutes, and 95°C for 5 minutes.

Quantitative Real-Time PCR: Triplicate samples of 4 µl cDNA product (5X diluted), 10 µl Sybr Green PCR Master Mix (Applied Biosystems, Inc. Foster City, CA), 0.1 µl each of 10 µM forward and reverse primer stocks, and 6 µL nuclease-free deionized H₂O were subjected to real-time PCR according to the following program in an ABI 7300 Real Time PCR System: 50 °C for 2 minutes, 95 °C for 10 minutes, (95 °C for 15 seconds, 60 °C for 1 minute) x 40 cycles. Results were analyzed using AB RQ Study Software. Real Time PCR primers were designed using Primer Express Software (Applied Biosystems, Inc.) mouse RANK Forward 5'-CTGCCTCCTGGGCTTCTTCT-3', mouse RANK Reverse 5'-CCCCTGGTGTGCTTCTAGCT-3'; mouse RANKL Forward 5'-CCTGAGGCCAGCCATTT-3' mouse RANKL Reverse 5'-AGCCTCGATCGTGGTACCAA-3'; mouse TNF α Forward 5'-GACACCATGAGCACAGAAAGCATGATCCGC-3' mouse TNF α Reverse 5'-CGAAGTTCAGTAGACAGAAGAGCGTGGTGG-3'; mouse IL-1 β Forward 5'-GCTTCCTTGTGCAAGTGTCTGA-3' mouse IL-1 β Reverse 5'-TCAAAAGGTGGCATTTCACAGT-3'.

Microscopy: Cells were imaged under white light on an inverted microscope (Olympus IX-51). Digital images were captured using a CCD camera (Olympus DP70, 12 mega-pixel resolution).

Statistics: Students two-tailed T-test for comparison between means was used for all analyses.

REFERENCES

1. Schett, G. Review: Immune cells and mediators of inflammatory arthritis. *Autoimmunity* **41**, 224-9 (2008).
2. McInnes, I.B. & Schett, G. Cytokines in the pathogenesis of rheumatoid arthritis. *Nature Reviews. Immunology* **7**, 429-42 (2007).
3. Brennan, F.M., Chantry, D., Jackson, A.M., Maini, R.N. & Feldmann, M. Cytokine production in culture by cells isolated from the synovial membrane. *Journal of Autoimmunity* **2 Suppl**, 177-86 (1989).
4. Chu, C.Q., Field, M., Feldmann, M. & Maini, R.N. Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. *Arthritis & Rheumatism* **34**, 1125-32 (1991).
5. Keffer, J. et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. *EMBO Journal* **10**, 4025-31 (1991).
6. Williams, R.O., Feldmann, M. & Maini, R.N. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. *Proceedings of the National Academy of Sciences of the United States of America* **89**, 9784-8 (1992).
7. Abu-Amer, Y., Erdmann, J., Alexopoulos, L., Kollias, G. & Teitelbaum, S. Tumor necrosis factor receptors types 1 and 2 differentially regulate osteoclastogenesis. *J Biol Chem* **275**, 27307-27310 (2001).

8. Kobayashi, K. et al. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. *J Exp Med* **191**, 275-285 (2000).
9. Kim, N. et al. Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis. *The Journal of experimental medicine* **202**, 589-95 (2005).
10. Lam, J. et al. TNF induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. *J Clin Invest* **106**, 1481-1488 (2000).
11. Redlich, K. et al. Osteoclasts are essential for TNF- α -mediated joint destruction. *Journal of Clinical Investigation* **110**, 1419-1427 (2002).
12. Firestein, G.S., Alvaro-Gracia, J.M. & Maki, R. Quantitative analysis of cytokine gene expression in rheumatoid arthritis.[erratum appears in J Immunol 1990 Aug 1;145(3):1037 Note: Alvaro-Garcia JM [corrected to Alvaro-Gracia JM]]. *Journal of Immunology* **144**, 3347-53 (1990).
13. Joosten, L.A. et al. IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation. *Journal of Immunology* **163**, 5049-55 (1999).
14. Zwerina, J. et al. TNF-induced structural joint damage is mediated by IL-1. *Proceedings of the National Academy of Sciences of the United States of America* **104**, 11742-7 (2007).

15. Wei, S., Kitaura, H., Zhou, P., Ross, F.P. & Teitelbaum, S.L. IL-1 mediates TNF-induced osteoclastogenesis. *J Clin Invest* **115**, 282-90 (2005).
16. Barnes, P.J. & Karin, M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. *New England Journal of Medicine* **336**, 1066-71 (1997).
17. Liu, H. et al. TNF-alpha gene expression in macrophages: regulation by NF-kappa B is independent of c-Jun or C/EBP beta. *Journal of Immunology* **164**, 4277-85 (2000).
18. Hiscott, J. et al. Characterization of a functional NF-kappa B site in the human interleukin 1 beta promoter: evidence for a positive autoregulatory loop. *Molecular & Cellular Biology* **13**, 6231-40 (1993).
19. Beg, A.A. & Baldwin, A.S., Jr. Activation of multiple NF-kappa B/Rel DNA-binding complexes by tumor necrosis factor. *Oncogene* **9**, 1487-92 (1994).
20. Beg, A.A., Finco, T.S., Nantermet, P.V. & Baldwin, A.S., Jr. Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of I kappa B alpha: a mechanism for NF-kappa B activation. *Molecular & Cellular Biology* **13**, 3301-10 (1993).
21. Campbell, I.K., Gerondakis, S., O'Donnell, K. & Wicks, I.P. Distinct roles for the NF-kappaB1 (p50) and c-Rel transcription factors in inflammatory arthritis. *Journal of Clinical Investigation* **105**, 1799-806 (2000).

22. Vaira, S. et al. RelA/p65 promotes osteoclast differentiation by blocking a RANKL-induced apoptotic JNK pathway in mice. *The Journal of clinical investigation* **118**, 2088-97 (2008).
23. Dai, S., Hirayama, T., Abbas, S. & Abu-Amer, Y. The IkappaB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks osteoclastogenesis and bone erosion in inflammatory arthritis. *The Journal of biological chemistry* **279**, 37219-22 (2004).
24. Ruocco, M.G. et al. Ikb kinase-beta, but not IKK-alpha, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss. *J. Exp. Med.* **201**, 1677-1687 (2005).
25. Xing, L. et al. Expression of Either NF-B p50 or p52 in Osteoclast Precursors Is Required for IL-1-Induced Bone Resorption. *J Bone Miner Res* **18**, 260-269 (2003).
26. Pasparakis, M., Alexopoulou, L., Episkopou, V. & Kollias, G. Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response.[see comment]. *Journal of Experimental Medicine* **184**, 1397-411 (1996).
27. Glaccum, M.B. et al. Phenotypic and functional characterization of mice that lack the type I receptor for IL-1. *Journal of Immunology* **159**, 3364-71 (1997).

28. Bromley, M. & Woolley, D.E. Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint. *Arthritis & Rheumatism* **27**, 968-75 (1984).
29. Gravallesse, E. et al. Identification of cell types responsible for bone resorption in RA and JRA. *Am J Pathol* **152**, 943-951 (1998).
30. Teitelbaum, S.L. Osteoclasts; culprits in inflammatory osteolysis. *Arthritis Research & Therapy* **8**, 201 (2006).
31. Abu-Amer, Y., Darwech, I. & Otero, J. Role of the NF-kappaB axis in immune modulation of osteoclasts and bone loss. *Autoimmunity* **41**, 204-11 (2008).
32. Pettit, A.R. et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. *Am J Pathol* **159**, 1689-99 (2001).
33. Otero, J.E. et al. Defective osteoclastogenesis by IKKbeta-null precursors is a result of receptor activator of NF-kappaB ligand (RANKL)-induced JNK-dependent apoptosis and impaired differentiation. *The Journal of biological chemistry* **283**, 24546-53 (2008).
34. Mercurio, F. et al. IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation. *Science (New York, N.Y.)* **278**, 860-6 (1997).
35. Delhase, M., Hayakawa, M., Chen, Y. & Karin, M. Positive and negative regulation of IkappaB kinase activity through IKKbeta subunit phosphorylation. *Science (New York, N.Y.)* **284**, 309-13 (1999).
36. Morita, S., Kojima, T. & Kitamura, T. Plat-E: an efficient and stable system for transient packaging of retroviruses. *Gene therapy* **7**, 1063-6 (2000).

FIGURE LEGENDS

Figure 1: Constitutively Active IKK β Induces NF- κ B Nuclear Translocation

WT macrophages were infected (infx) with retroviruses expressing GFP or flag-tagged WT IKK β or IKK β^{SSEE} for either 0, 1, 2, 4, or 6 days. Nuclei were extracted and blotted for p65/RelA (lower two panels). Cytosolic fraction was blotted with flag antibody to detect retrovirally expressed IKK β (upper pannel). ns, non-specific antibody reactivity; N, nucleus; C, cytosol.

Figure 2: Induction of Osteoclastogenesis and Inflammatory Cytokine Secretion by IKK β^{SSEE}

WT macrophages were infected with retroviruses expressing GFP, WT IKK β (WT), or IKK β^{SSEE} (SSEE). (A) Cells were plated for osteoclastogenesis. GFP, WT IKK β , and IKK β^{SSEE} expressing cells were cultured in M-CSF alone. Where indicated, WT IKK β – expressing cells were treated with RANKL to induce osteoclastogenesis. Cells were TRAP-stained to visualize osteoclasts. (B) mRNA was collected from cells, and RANK and RANKL gene expression were measured by quantitative real-time PCR. MC3T3, mouse bone stromal cell line. Values are expressed as mean quantitation plus standard error of the mean. (C) TNF α and IL-1 β gene expression levels were measured by quantitative real-time PCR. Values are expressed as mean quantitation plus standard error of the mean. (D) Media supernatants were harvested from cultures of macrophages (or osteoclasts in the case with IKK β^{SSEE} -expressing cells) expressing the indicated

constructs. TNF α and IL-1 β protein concentrations were measured by ELISA. (*), p<0.005.

Figure 3: TNF α Autocrine Stimulation is not Responsible for IKK β ^{SSEE} – Induced Osteoclastogenesis. (A) Macrophages from TNF KO and WT littermates were collected and infected with retroviruses expressing either GFP, WT IKK β , or IKK β ^{SSEE}. Cells were lysed and total IKK β protein was detected by Western blot. Actin was blotted as a loading control. (B) Media supernatant was collected from cultures of cells expressing either GFP, WT IKK β , or IKK β ^{SSEE}. TNF α protein concentration in media was measured by ELISA. (**), p<0.001. (C) Cells were grown in media supplemented with M-CSF (without RANKL) and were TRAP-stained to visualize osteoclasts. (D) Media supernatant was collected from cultures of WT and TNF α KO cells expressing either GFP, WT IKK β , or IKK β ^{SSEE}. IL-1 β protein concentration in media was measured by ELISA. (*), p<0.005

Figure 4: IL-1 Receptor Autocrine Stimulation is not an Essential Mediator of the Osteoclastogenic Effect of Constitutively Active IKK β . (A) Macrophages were isolated from WT or IL-1 receptor knockout mice and were infected with retroviruses expressing either GFP, WT IKK β (WT), or IKK β ^{SSEE} (SSEE). Cells were grown in the presence M-CSF (without RANKL) or were supplemented with RANKL or RANKL and IL-1 β as

indicated. Cells were TRAP-stained to visualize osteoclasts. (B) Quantification of (A).
(C) Expression of IKK β constructs in cells from (A).

FIGURES

Figure 1




Figure 2




Figure 3





Figure 4



CHAPTER 5

ACTIVATION OF THE ALTERNATIVE NF- κ B PATHWAY

BY CONSTITUTIVELY ACTIVE IKK β

INTRODUCTION

NF- κ B is a family of transcription factors which serves diverse functions in development, immunity, and bone metabolism. Traditionally, NF- κ B signaling is divided into two pathways, classical (canonical) and alternative (non-canonical) ^{1,2}. In classical NF- κ B signaling, extracellular signals such as TNF or IL-1, activate an IKK complex comprising IKK α , IKK β , and IKK γ (NEMO). IKK then phosphorylates I κ B α , which holds NF- κ B in the cytoplasm in an inactive state. Upon phosphorylation, I κ B α becomes ubiquitinated and rapidly degraded by the proteasome. Classical NF- κ B heterodimers consisting of p50 and p65/RelA are released from cytoplasmic sequestration, enter the nucleus, and activate gene transcription. In the alternative signaling pathway, signals from cytokines such as BAFF and lymphotoxin β lead to activation of IKK α which phosphorylates the C-terminal I κ B portion of NF- κ B p100. This event results in ubiquitination and proteosomal processing of p100 to p52 leading to nuclear translocation of the p52/RelB heterodimer and gene transcription ³.

The ability of the two NF- κ B pathways to interact or be coordinated at multiple levels has been suggested. For example, RANKL, the pro-osteoclastogenic cytokine, is known to activate both classical and alternative NF- κ B ^{4,5}. In addition, the kinase, NIK, has been shown to activate both IKK β ⁶ and IKK α ^{7,8}, responsible for activation of classical and alternative NF- κ B signaling, respectively. Furthermore, the level and activity of RelB, the alternative NF- κ B signaling pathway transactivator, are set by activity of the classical

pathway⁹. The inability of these two pathways to compensate for each other in development highlights the notion that they are indeed separate signaling modules¹⁰, but whether they are coordinated in disease states is unknown. Interestingly, constitutive activation of classical NF- κ B has been demonstrated to compensate for absence of alternative signaling through BAFFR in B-cell development¹¹, raising the possibility that activation of IKK β may regulate alternative signaling in certain settings.

We have shown that constitutively active IKK β is capable of inducing osteoclastogenesis from monocytes in the absence of IKK α , a setting in which alternative NF- κ B signaling induced by RANKL is inhibited. We now demonstrate that constitutively active IKK β (IKK β^{SSEE}) induces nuclear translocation of RelB in monocytes. This event is likely a result of processing of p100 to p52, which we show can be induced by IKK β^{SSEE} in the absence of IKK α . Whether the activation of RelB by IKK β^{SSEE} contributes to the osteoclast differentiation observed in the absence of IKK α is unclear. Further, it is uncertain whether alternative NF- κ B can be activated by IKK β in pathological settings. It will be important to identify the mechanism by which constitutive activation of IKK β leads to RelB nuclear translocation, as this will lead to a better understanding of NF- κ B regulation in the setting of normal physiology and disease.

RESULTS

Constitutively Active IKK β Induces RelB Nuclear Translocation

A signature of RANKL-induced osteoclast differentiation is activation of both Classical and Alternative NF- κ B signaling^{4,5,12}. We have shown that constitutive activation of NF- κ B by IKK β^{SSEE} results in differentiation of osteoclasts. Although this phenomenon was also observed in the absence of RelB, we noted that RelB protein levels were constitutively increased in cells expressing IKK β^{SSEE} , but not WT IKK β . We sought to determine whether in addition to increased RelB expression, IKK β^{SSEE} also induced RelB nuclear translocation. We performed nuclear/cytosolic fractionation in monocytes, which we infected with retroviruses expressing GFP, WT IKK β , or IKK β^{SSEE} . We observed that indeed, RelB was induced to enter the nucleus after 4 days of infection with IKK β^{SSEE} , but not WT IKK β or GFP (**Fig. 1**). This indicates that constitutive activation of IKK β , normally considered an activator of the Classical NF- κ B pathway, can also activate the Alternative NF- κ B pathway in monocytes.

Constitutively Active IKK β Induces p100 Processing to p52

We sought to determine the mechanism responsible for IKK β^{SSEE} – induced RelB nuclear translocation. It is known that p100 processing to p52 is required for activation of the Alternative NF- κ B pathway^{2,8}. We hypothesized that IKK β^{SSEE} may induce processing

of p100 to p52 resulting in RelB activation. We expressed GFP, WT IKK β , and IKK β^{SSEE} in WT and NF- κ B1/2 double knockout (DKO) monocytes. We observed that IKK β^{SSEE} , but not WT IKK β or GFP, induced production of p52 in WT but not NF- κ B1/2 DKO monocytes (**Fig. 2**). The absence of p52 in cells lacking the precursor, p100, suggests the authenticity of the p52 product. The ability of WT IKK β and IKK β^{SSEE} to induce processing of I κ B α even in the absence of *NF- κ B1* and *NF- κ B2* demonstrates that NF- κ B is not required for IKK β activity.

Production of p52 by IKK β^{SSEE} does not require IKK α

It is known that NIK activates the alternative NF- κ B pathway through IKK α ¹³. We wondered whether IKK α is required for IKK β^{SSEE} mediated p52 processing. We expressed GFP or IKK β^{SSEE} in WT and IKK α KO fetal liver – derived monocytes and detected p52 expression by Western blot. We observed that even in the absence of IKK α , IKK β^{SSEE} induced the processing of p100 to p52 (**Fig. 3**). This result suggests that active IKK β may act on p100 directly to produce p52 and activate the alternative NF- κ B pathway. It will be important to determine whether this crosstalk between classical and alternative NF- κ B signaling has functional significance in the setting of bone pathology.

METHODS

Reagents: Antibodies against IKK β , Actin, I κ B α , and RelB as well as horseradish peroxidase-conjugated secondary antibodies were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Antibody against Flag epitope was purchased from Sigma (St. Louis, MO). Antibodies against IKK α and p100/p52 were from Cell Signaling Technologies, Inc (Danvers, MA). Cytokines were purchased from R&D Systems (Minneapolis, MN). Enhanced Chemiluminescence kit was purchased from Pierce Biotechnology, Inc (Rockford, IL). All other chemicals were purchased from Sigma (St. Louis, MO) unless otherwise indicated.

Animals and Cells: All mice were housed in a controlled barrier facility at Washington University (St. Louis, MO). IKK α heterozygous mice ¹² were obtained from Dr. Akira (Osaka University, Japan). RelB KO ⁵ and control bone marrow was obtained from Dr. Novack (Washington University, St. Louis, MO). NF- κ B double KO ¹⁴ and control spleens were a generous gift from Dr. Lianping Xing (University of Rochester Medical Center, N.Y.)

Plasmids: pMxs retroviral expression plasmid was a generous gift from Dr. Toshio Kitamura (University of Tokyo, Japan). IKK β cDNA was purchased from ATCC, I.M.A.G.E. Clone ID #4482634. All expression constructs were subcloned into pMxs using standard techniques. The following mutations were generated using the

QuickChange II Site Directed Mutagenesis Kit (Stratagene, La Jolla, CA) with primer pairs in parentheses: $\text{IKK}\beta^{\text{SSEE}}$ ($\text{IKK}\beta_{\text{S177-181E_f}}$, GAGCTGGATCAGGGCGAACTGTGCACGGAATTTGTGGGGACTCTGC, and $\text{IKK}\beta_{\text{S177-181E_r}}$, GCAGAGTCCCCACAAATTCCGTGCACAGTTCGCCCTGATCCAGCTC). Note that the constitutive activating effect of this mutation of $\text{IKK}\beta$ has been established previously^{6,15}.

Macrophage Culture: Whole marrow was flushed from long bones into α - Minimum Essential Medium (MEM). Spleens and Fetal livers were crushed into cell suspension in α -MEM and were centrifuged at 453 rcf. Cell pellets were resuspended in whole media (α -MEM with 1X penicillin/streptomycin, 10% heat-inactivated fetal bovine serum (FBS)). Monocytes/ macrophages were produced by growing cell suspensions in the presence of 10 ng/ml M-CSF. Monocytes/ macrophages were allowed to proliferate for 3 days at 37 °C in 5% CO₂ at which point they were infected with retrovirus. See below.

Infection of Macrophages: The use of Plat-E retrovirus packaging cells stably expressing retroviral structural proteins gag-pol and env for transient production of high titer retrovirus was described previously¹⁶. Briefly, 8 μ g pMx vectors expressing our gene of interest were transfected into 5 million plat-E cells (grown in DMEM supplemented with 10% FBS, 10ng/ml M-CSF, and penicillin/streptomycin) using Fugene 6 (Roche, Palo Alto, CA) according to manufacturer's instructions. Twenty-four hrs post transfection, media was

exchanged to remove transfection reagent. Twenty-four and 48 hrs post media exchange, supernatant was collected and pooled. In parallel, monocyte/macrophage cultures from bone marrow, spleen, or fetal liver were developed on petri dishes, washed with PBS, and infected with retrovirus in infection mix (50% virus supernatant, 50% α MEM containing 10% FBS, 10ng/ml M-CSF, penicillin/streptomycin, and 4 μ g/ml hexadimethrine bromide). Twenty-four hrs post infection, cells were selected in α MEM containing 10% FBS, 10ng/ml M-CSF, penicillin/streptomycin, and 2 μ g/ml puromycin for 72 hrs, at which point selection media was removed, cells were washed, and grown for 24 additional hrs without puromycin. At this point, cells were lifted, counted, and plated for downstream experiments.

Western Blot: Equivalent amounts of total cell protein were boiled in the presence of an equal volume of 2X SDS sample buffer consisting of (0.5 M Tris-HCl, pH 6.8, 10% (w/v) SDS, 10% glycerol, 0.05% (w/v) bromphenol blue, 3% β -Mercaptoethanol (v/v), and distilled water) for 5 min. and subjected to electrophoresis on 8–10% SDS-PAGE. Proteins were transferred to nitrocellulose membranes using a semi-dry blotter (Bio-Rad, Hercules, CA) and incubated in blocking solution (10% skim milk prepared in phosphate-buffered saline containing 0.05% Tween 20) to reduce nonspecific binding. The membranes were washed with PBS/Tween buffer and exposed to primary antibodies (16 h at 4 °C), washed (4 x 15 min.), and incubated with the appropriate secondary horseradish peroxidase-conjugated antibodies (1 h at room temperature). The membranes were washed extensively (4 X 15 min.), and an ECL detection assay was performed following the manufacturer's instructions.

REFERENCES

1. Brown, K.D., Claudio, E. & Siebenlist, U. The roles of the classical and alternative nuclear factor-kappaB pathways: potential implications for autoimmunity and rheumatoid arthritis. *Arthritis Research & Therapy* **10**, 212 (2008).
2. Bonizzi, G. & Karin, M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. *Trends in immunology* **25**, 280-8 (2004).
3. Hayden, M.S. & Ghosh, S. Signaling to NF-kB. *Genes and Development* **18**, 2195-2224 (2004).
4. Vaira, S. et al. RelA/p65 promotes osteoclast differentiation by blocking a RANKL-induced apoptotic JNK pathway in mice. *The Journal of clinical investigation* **118**, 2088-97 (2008).
5. Vaira, S. et al. RelB is the NF-kappaB subunit downstream of NIK responsible for osteoclast differentiation. *Proceedings of the National Academy of Sciences of the United States of America* **105**, 3897-902 (2008).
6. Delhase, M., Hayakawa, M., Chen, Y. & Karin, M. Positive and negative regulation of IkappaB kinase activity through IKKbeta subunit phosphorylation. *Science (New York, N.Y.)* **284**, 309-13 (1999).
7. Ling, L., Cao, Z. & Goeddel, D.V. NF-kappa B-inducing kinase activates IKK-alpha by phosphorylation of Ser-176. *Proceedings of the National Academy of Sciences* **95**, 3792-3797 (1998).

8. Senftleben, U. et al. Activation by IKKalpha of a Second, Evolutionary Conserved, NF-kappa B Signaling Pathway. *Science* **293**, 1495-1499 (2001).
9. Basak, S., Shih, V.F. & Hoffmann, A. Generation and activation of multiple dimeric transcription factors within the NF-kappaB signaling system. *Molecular & Cellular Biology* **28**, 3139-50 (2008).
10. Beg, A.A., Sha, W.C., Bronson, R.T., Ghosh, S. & Baltimore, D. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B. *Nature* **376**, 167-70 (1995).
11. Sasaki, Y. et al. Canonical NF-kappaB activity, dispensable for B cell development, replaces BAFF-receptor signals and promotes B cell proliferation upon activation.[see comment]. *Immunity* **24**, 729-39 (2006).
12. Chaisson, M.L. et al. Osteoclast differentiation is impaired in the absence of Ikb kinase-alpha. *J Biol Chem* **279**, 54841-8 (2004).
13. Xiao, G., Fong, A. & Sun, S.C. Induction of p100 processing by NF-kappaB-inducing kinase involves docking IkappaB kinase alpha (IKKalpha) to p100 and IKKalpha-mediated phosphorylation. *Journal of Biological Chemistry* **279**, 30099-105 (2004).
14. Yamashita, T. et al. NF-kappaB p50 and p52 regulate receptor activator of NF-kappaB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1. *The Journal of biological chemistry* **282**, 18245-53 (2007).

15. Mercurio, F. et al. IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation. *Science (New York, N.Y.)* **278**, 860-6 (1997).
16. Morita, S., Kojima, T. & Kitamura, T. Plat-E: an efficient and stable system for transient packaging of retroviruses. *Gene therapy* **7**, 1063-6 (2000).

FIGURE LEGENDS

Figure 1. Expression of IKK β ^{SSEE} in Monocytes results in RelB Activation

Wild-type monocytes were infected with retroviruses expressing either GFP or flag-tagged WT IKK β or IKK β ^{SSEE} for either 0, 1, 2, 4, or 6 days. Nuclear fractions were separated from cytosolic fractions. Retroviral IKK β was detected in the cytosolic fraction by Western blot for flag. RelB was detected in nuclear fraction by Western blot. N, nuclear. C, cytosolic. ns, non-specific background band.

Figure 2. IKK β ^{SSEE} induces p100 processing to p52

Wildtype and NF- κ B1/2 double knockout (DKO) monocytes were infected with retroviruses expressing either GFP or flag-tagged WT IKK β or IKK β ^{SSEE}. Expression of indicated proteins was detected in total cell lysates by Western Blot. OC+, osteoclast positive control total cell lysate.

Figure 3. IKK α – independent p52 production by IKK β ^{SSEE}

WT and IKK α KO monocytes were infected with retroviruses expressing either GFP or flag-tagged IKK β ^{SSEE}. Expression of the indicated proteins was detected by Western blot. OC+, osteoclast positive control total cell lysate.

FIGURES

Figure 1




Figure 2





Figure 3



CHAPTER 6
CONCLUSION

SUMMARY OF RESULTS

IKK β is Necessary for Osteoclast Differentiation and Prevents JNK-Mediated Apoptosis in Differentiating Pre-Osteoclasts

We began with the hypothesis that since NF- κ B activity is absolutely critical for osteoclast differentiation ¹, then upstream activators of NF- κ B would play an important role in osteoclastogenesis. We focused on IKK β to build on previous work in our laboratory which demonstrated that the NEMO – IKK β interaction is important for osteoclast differentiation ². Further, an osteoclast defect resulting in resistance to inflammatory osteolysis was noted in mice lacking IKK β in hematopoietic tissues ³. This fact, coupled with the observation that IKK α activation is dispensable for osteoclastogenesis ³ led us to investigate the role IKK β plays in response to RANKL in the setting of osteoclastogenesis.

To this end, we used Cre/loxP technology to produce a mouse lacking IKK β specifically in osteoclast precursors (OCPs) by crossing mice possessing homozygous floxed IKK β alleles ⁴ with mice transgenically expressing Cre recombinase under the control of the CD11b promoter ⁵. Initial observation of Cre-expressing, homozygous floxed IKK β (OCP ^{Δ IKK β}) mice revealed a defect in bone metabolism, since OCP ^{Δ IKK β} demonstrated shorter and more radio-dense bones on x-ray. Macrophages from these mice isolated from both spleen and bone marrow showed decreased IKK β expression at both mRNA

and protein levels. This confirmed that our genetic targeting of IKK β in osteoclast precursors was successful and resulted in defects in bone metabolism.

To determine whether deletion of IKK β in OCPs affects osteoclast differentiation, we cultured control and OCP Δ IKK β cells in the presence of M-CSF and RANKL to induce osteoclast differentiation *in vitro*. Differentiation of OCP Δ IKK β cells into osteoclasts *in vitro* was severely impaired, and long bones of OCP Δ IKK β mice possessed significantly fewer osteoclasts than control littermates. We demonstrated a defect in RelA nuclear translocation in response to RANKL in OCP Δ IKK β cells as well, confirming that IKK β mediated NF- κ B activation in response to RANKL is important for osteoclastogenesis. In order to determine the cause for impaired osteoclastogenesis in OCP Δ IKK β cells, we performed quantitative real-time PCR for osteoclast-specific gene expression after treatment of WT and OCP Δ IKK β cells with M-CSF and RANKL, we noted significantly reduced induction of osteoclast genes in OCP Δ IKK β cells compared with control cells. This finding correlated well with our observation that absence of IKK β results in defective differentiation of monocytes into osteoclasts. We also determined by real-time PCR that OCP Δ IKK β cells showed reduced expression of NF- κ B-controlled anti-apoptotic proteins. We hypothesized that perhaps RANKL induced apoptosis of OCP Δ IKK β cells as a result. Indeed, RANKL treatment of OCP Δ IKK β but not control cells for 4 hrs resulted in PARP cleavage, an indicator of apoptosis. Furthermore, OCP Δ IKK β mice possessed many apoptotic osteoclasts associated with bony trabeculae in long bones, suggesting that osteoclast lineage cells in OCP Δ IKK β mice were susceptible to apoptosis *in vivo*.

Analysis of kinase signaling downstream of RANK stimulation in OCP^{ΔIKKβ} cells revealed a gain-of-function of JNK compared with WT cells. Since JNK hyperactivity has been linked to apoptosis in response to RANKL in differentiating osteoclasts ⁶, we hypothesized that inhibition of JNK may rescue the osteoclast defect in OCP^{ΔIKKβ} cells. Indeed, treatment of OCP^{ΔIKKβ} monocytes with low doses of a cell-permeable peptide inhibitor of JNK restored osteoclastogenesis in OCP^{ΔIKKβ}. This rescue phenomenon was only observed with incomplete deletion of IKKβ, whereas OCPs with more efficient deletion of IKKβ (with less IKKβ mRNA expression) could not be differentiated into osteoclasts even with JNK inhibition. We concluded that IKKβ serves two functions which are important for osteoclastogenesis. First, IKKβ inhibits JNK-mediated apoptosis in response to RANKL. Second, IKKβ facilitates the osteoclast differentiation program downstream of RANKL.

Constitutive Activation of IKKβ is Sufficient for Osteoclastogenesis

With an established genetic model for deficiency of IKKβ in osteoclast precursors in hand, our next step was to identify the residues and domains of IKKβ which are important for its function in the setting of osteoclast differentiation. We took the approach of retroviral re-introduction of WT IKKβ or mutant forms of IKKβ into OCP^{ΔIKKβ} cells to attempt to rescue osteoclastogenesis. We chose K44M as a negative control, since this molecule lacks kinase activity ⁷. Also, in order to test phosphorylation – dependent loss-of-function and gain-of-function, we tested S177/181A (IKKβ^{SSAA}) and

S177/181E (IKK β ^{SSEE}), respectively. Mutation of T-loop Serines to Alanine renders IKK β refractory to signal-induced activation, while mutation to Glutamic Acid creates a constitutively active form of IKK β ⁸. In response to RANKL, WT IKK β restored osteoclastogenesis in OCP Δ IKK β . IKK β ^{K44M} and IKK β ^{SSAA} failed to rescue osteoclastogenesis, indicating that RANKL-induced serine phosphorylation of IKK β is required for osteoclast differentiation. IKK β ^{SSEE} also rescued osteoclastogenesis from OCP Δ IKK β , and upon closer examination, we made the surprising discovery that IKK β ^{SSEE} induced osteoclast differentiation in the absence of RANKL administration.

This finding led to the hypothesis that phosphorylation of IKK β at Serines 177 and 181 in response to RANK stimulation by RANKL represents a molecular switch that activates the osteoclast differentiation program. Our subsequent investigation was focused on challenging this hypothesis. First, we characterized the osteoclasts induced by IKK β ^{SSEE} to determine if they met the criteria for authentic osteoclasts derived by RANKL stimulation of M-CSF-dependent monocytes. Our examination revealed that IKK β ^{SSEE} – induced osteoclasts expressed all markers of mature osteoclasts, formed actin rings, and resorbed bone. We determined that, indeed, constitutively active IKK β induces differentiation of *bona fide* osteoclasts.

We further demonstrated that IKK β ^{SSEE} induced osteoclasts in the absence of the receptor, RANK, and in the presence of inhibitory concentrations of OPG-fc (which

interferes with RANKL stimulation of monocytes). These results led us to conclude that $\text{IKK}\beta^{\text{SSEE}}$ induces differentiation of osteoclasts in a RANK – independent manner.

Next, we desired to dissect the molecular environment surrounding $\text{IKK}\beta$ in the monocyte. Since $\text{IKK}\beta$ is a member of the IKK complex ⁷, and all the members of this complex play an essential role in osteoclastogenesis ^{2,9-11}, we wondered if the integrity of the IKK complex was critical for $\text{IKK}\beta^{\text{SSEE}}$ to induce osteoclastogenesis. We found that constitutively active $\text{IKK}\beta$ could induce osteoclastogenesis in the absence of endogenous $\text{IKK}\beta$ and $\text{IKK}\alpha$ and in conditions in which NEMO- $\text{IKK}\beta$ association were inhibited pharmacologically and genetically. We concluded that $\text{IKK}\beta^{\text{SSEE}}$ acts independently and autonomously with respect to the IKK complex to induce osteoclastogenesis. This result suggests that the function of the IKK complex downstream of RANKL is to allow for phosphorylation and activation of $\text{IKK}\beta$, which then triggers osteoclast differentiation.

We looked downstream to determine which factors were necessary for $\text{IKK}\beta^{\text{SSEE}}$ to induce RANK-independent osteoclastogenesis. Nuclear/cytosol fractionation experiments revealed that $\text{IKK}\beta^{\text{SSEE}}$ induces nuclear translocation of NF- κ B subunits RelA and RelB and also stimulates increased production of total RelB. Although RelB plays a role in RANKL-induced osteoclast differentiation ¹², $\text{IKK}\beta^{\text{SSEE}}$ induced bone resorbing osteoclasts from RelB knockout spleen monocytes. Importantly, *NF- κ B1/NF- κ B2* double knockout macrophages did not become osteoclasts when expressing $\text{IKK}\beta^{\text{SSEE}}$, demonstrating a pivotal role for NF- κ B in this phenomenon. These results suggested that

constitutive activation of NF- κ B by IKK β ^{SSEE} is sufficient for RANK-independent osteoclast differentiation. Overexpression of IKK α ^{SSEE}, RelB, or RelA failed to induce osteoclast differentiation, highlighting the specificity of IKK β as an inducer of osteoclastogenesis.

Importantly, kinase activity of IKK β ^{SSEE} was critical for mediating its osteoclastogenic effect, since mutation of Lysine 44 to Methionine in the presence of S177/181E mutations abrogated the effect. IKK β ^{SSEE} demonstrated some qualities which were surprising. For example, it induced processing of p100 to p52 in monocytes, a function which is thought to be mediated by IKK α . The role of this phenomenon in inducing osteoclasts in response to IKK β ^{SSEE} is unclear at this point.

We wished to determine whether activation of IKK β in an *in vivo* setting possesses pathological significance. Indeed, adenoviral gene transfer of IKK β ^{SSEE} into knees of mice results in massive inflammation and bone erosion, mimicking the findings in rheumatoid arthritis.

These data provide evidence that IKK β is a specific inducer of osteoclast differentiation and that gain-of-function in IKK β may contribute to the pathogenesis of inflammatory osteolysis. Therefore, therapy targeting the activation of IKK β may represent a successful approach to ameliorate pathological bone loss.

Inflammation and Osteoclastogenesis Induced by Constitutively Active IKK β are Uncoupled

It is well known that NF- κ B is a crucial mediator of osteoclastogenic^{1,13} as well as inflammatory signaling¹⁴⁻¹⁶. Inflammatory inducers such as TNF α and IL-1 β have been shown to contribute to osteoclast differentiation^{17,18}, so we wondered whether IKK β ^{SSEE} – mediated induction of osteoclastogenesis required these inflammatory modulators. We demonstrated by quantitative real-time PCR and ELISA that in addition to stimulating osteoclastogenesis, IKK β ^{SSEE} induced expression of the pro-inflammatory cytokines, TNF α and IL-1 β , by monocytes. Since these two cytokines have been shown to induce RANK-independent osteoclast differentiation from monocytes in the presence of TGF- β ¹⁹, we wondered if TNF α and IL-1 β were responsible for inducing osteoclast differentiation in our system. We demonstrated in TNF α knockout and IL-1 receptor knockout monocytes that IKK β ^{SSEE} was still capable of inducing osteoclast differentiation *in vitro*. Whether the inflammatory component downstream of IKK β ^{SSEE} plays a role in the arthritis pathogenesis in the adenoviral IKK β ^{SSEE} *in vivo* model is still to be investigated, but it is absolutely clear that constitutively active IKK β can drive osteoclastogenesis in a cell-autonomous, NF- κ B-dependent, inflammatory cytokine-independent manner.

Altogether, our work has identified IKK β as a central regulator of the osteoclast program. It is essential for normal differentiation of osteoclasts in response to RANKL, and gain-of-function results in spontaneous osteoclast formation in the absence of RANKL. It is

likely that IKK β gain-of-function – whether mutational or signal-induced - plays a role in osteolysis in patients with inflammatory diseases, and our work leads us to strongly support targeting of IKK β for amelioration of these conditions.

FUTURE DIRECTIONS

Screening Patients with Inflammatory Bone Loss for IKK β Gain-of-Function Mutations

Our results strongly suggest that gain-of-function in IKK β results in spontaneous osteoclastogenesis that occurs in the absence of upstream signals. Since IKK β is an essential downstream component in RANKL-induced osteoclast differentiation ¹⁰, and since gain-of-function in the RANKL/RANK pathway results in pathological conditions of heightened bone turnover ^{20,21}, it is likely that gain-of-function mutations in IKK β could cause osteolysis in human patients. Currently, genetic diagnosis of many of these conditions remains elusive ^{22,23}. A diagnostic approach which involves screening for IKK β mutations may lend insight into the pathogenesis of these and other inflammatory conditions involving heightened bone turnover.

Identification of Substrates of IKK β Important in Osteoclastogenesis

IKK β has recently been shown to phosphorylate several proteins in addition to its canonical target, I κ B α ²⁴. When we overexpressed p65/RelA in monocytes, mimicking the outcome of phosphorylation-dependent degradation of I κ B α , we did not observe

induction of osteoclastogenesis. However, given that $\text{IKK}\beta^{\text{SSEE}}$ induces osteoclastogenesis in a kinase-dependent manner, it is likely that there are additional targets of $\text{IKK}\beta$ in the monocyte which mediate this effect. We propose a high-power approach to screen multiple targets of $\text{IKK}\beta^{\text{SSEE}}$ with the use of phosphoprotein detection by mass spectrometry ²⁵. Identification of these molecules will lead to a better understanding of the mechanisms through which $\text{IKK}\beta$ activates the osteoclast program. Furthermore, identification of these molecules will lend insight into potential modes of therapy for inflammatory conditions.

Structure Function Analysis of $\text{IKK}\beta$ for Therapeutic Peptide Design

We have demonstrated that constitutively active $\text{IKK}\beta$ is an extremely specific inducer of osteoclast differentiation. Constitutively active $\text{IKK}\alpha$, although possessing more than 50% sequence conservation with $\text{IKK}\beta$ ⁷, fails to induce osteoclastogenesis. We rationalize that we can take advantage of the differences between $\text{IKK}\beta$ and $\text{IKK}\alpha$ in order to learn which unique regions in $\text{IKK}\beta$ confer its osteoclast – inducing properties. This can be accomplished through domain swapping by PCR to generate chimeric molecules. Also, structurally unique regions in $\text{IKK}\beta$ can be sequentially mutated to determine the minimum essential structure which preserves $\text{IKK}\beta$ function. Important regions may be further investigated biochemically to determine how they regulate $\text{IKK}\beta$ activity, and they can be targeted or mimicked molecularly to interfere with $\text{IKK}\beta$ function. This approach will lead to novel therapeutic modalities in inflammatory diseases.

Amelioration of Osteopetrosis

Osteopetrosis is a condition of dense brittle bone owing mostly to defective osteoclast function or differentiation²⁶. Most forms of clinical and experimental osteopetrosis are amenable to bone marrow transplantation, which means that correction of a defect in the hematopoietic compartment rescues the osteoclast defect. We have identified a potential approach using viral gene transfer of constitutively active IKK β to correct an osteoclast differentiation defect in cells. Theoretically, using this approach, osteoclast precursors from an osteopetrotic mouse or congenic mouse, and perhaps a patient whose osteopetrosis results from defective osteoclast differentiation, may be infected with a virus expressing active IKK β and then reintroduced locally into bone. IKK β would trigger osteoclast differentiation in progenitors and would correct the osteopetrosis. There are potential pitfalls of this approach related to NF- κ B-mediated inflammation. Nevertheless, exploring new means to cure this disease may prove to be therapeutically beneficial in the future.

PERSPECTIVES

Given the wide range of pathological conditions in which NF- κ B activity is believed to play a role, an intense effort to develop drugs which target the NF- κ B signaling pathway is logical and justified. Our data provide evidence that these drugs may prove to be beneficial in reducing bone – destructive effects of inflammatory conditions. Exciting progress has been made toward discovery of selective small-molecule inhibitors of IKK β , which are now in the pre-clinical phase of testing ²⁷. Given the central role for IKK β in differentiation of the osteoclast, the continued effort to target this molecule provides hope for effective therapy in patients with conditions of inflammatory osteolysis and other conditions of pathologically heightened bone turnover.

REFERENCES

1. Iotsova, V. et al. Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. *Nature medicine* **3**, 1285-9 (1997).
2. Dai, S., Hirayama, T., Abbas, S. & Abu-Amer, Y. The IkappaB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks osteoclastogenesis and bone erosion in inflammatory arthritis. *The Journal of biological chemistry* **279**, 37219-22 (2004).
3. Ruocco, M.G. et al. Ikb kinase-beta, but not IKK-alpha, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss. *J. Exp. Med.* **201**, 1677-1687 (2005).
4. Pasparakis, M. et al. TNF-mediated inflammatory skin disease in mice with epidermis-specific deletion of IKK2. *Nature* **417**, 861-6 (2002).
5. Ferron, M. & Vacher, J. Targeted expression of Cre recombinase in macrophages and osteoclasts in transgenic mice. *Genesis* **41**, 138-45 (2005).
6. Bharti, A.C., Takada, Y., Shishodia, S. & Aggarwal, B.B. Evidence That Receptor Activator of Nuclear Factor (NF)-kB Ligand Can Suppress Cell Proliferation and Induce Apoptosis through Activation of a NF-kB-independent and TRAF6-dependent Mechanism. *Journal of Biological Chemistry* **279**, 6065-6076 (2004).
7. Mercurio, F. et al. IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation. *Science (New York, N.Y.)* **278**, 860-6 (1997).

8. Delhase, M., Hayakawa, M., Chen, Y. & Karin, M. Positive and negative regulation of IkappaB kinase activity through IKKbeta subunit phosphorylation. *Science (New York, N.Y.)* **284**, 309-13 (1999).
9. Chaisson, M.L. et al. Osteoclast differentiation is impaired in the absence of IkB kinase-alpha. *J Biol Chem* **279**, 54841-8 (2004).
10. Otero, J.E. et al. Defective osteoclastogenesis by IKKbeta-null precursors is a result of receptor activator of NF-kappaB ligand (RANKL)-induced JNK-dependent apoptosis and impaired differentiation. *The Journal of biological chemistry* **283**, 24546-53 (2008).
11. Ruocco, M.G. & Karin, M. IKK{beta} as a target for treatment of inflammation induced bone loss. *Annals of the Rheumatic Diseases* **64 Suppl 4**, iv81-5 (2005).
12. Vaira, S. et al. RelB is the NF-kappaB subunit downstream of NIK responsible for osteoclast differentiation. *Proceedings of the National Academy of Sciences of the United States of America* **105**, 3897-902 (2008).
13. Franzoso, G. et al. Requirement for NF-kB in osteoclast and B-cell development. *Genes & Development* **11**, 3482-3496 (1997).
14. Barnes, P.J. & Karin, M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. *New England Journal of Medicine* **336**, 1066-71 (1997).
15. Liu, H. et al. TNF-alpha gene expression in macrophages: regulation by NF-kappa B is independent of c-Jun or C/EBP beta. *Journal of Immunology* **164**, 4277-85 (2000).

16. Hiscott, J. et al. Characterization of a functional NF-kappa B site in the human interleukin 1 beta promoter: evidence for a positive autoregulatory loop. *Molecular & Cellular Biology* **13**, 6231-40 (1993).
17. Wei, S., Kitaura, H., Zhou, P., Ross, F.P. & Teitelbaum, S.L. IL-1 mediates TNF-induced osteoclastogenesis. *J Clin Invest* **115**, 282-90 (2005).
18. Lam, J. et al. TNF induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. *J Clin Invest* **106**, 1481-1488 (2000).
19. Kim, N. et al. Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis. *The Journal of experimental medicine* **202**, 589-95 (2005).
20. Whyte, M.P. & Hughes, A.E. Expansile skeletal hyperphosphatasia is caused by a 15-base pair tandem duplication in TNFRSF11A encoding RANK and is allelic to familial expansile osteolysis. *Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research* **17**, 26-9 (2002).
21. Whyte, M.P. Paget's disease of bone and genetic disorders of RANKL/OPG/RANK/NF-kappaB signaling. *Annals of the New York Academy of Sciences* **1068**, 143-64 (2006).
22. Simsek, S. et al. Sporadic hyperphosphatasia syndrome featuring periostitis and accelerated skeletal turnover without receptor activator of nuclear factor-kappaB, osteoprotegerin, or sequestosome-1 gene defects. *The Journal of clinical endocrinology and metabolism* **92**, 1897-901 (2007).

23. Wenkert, D., Mumm, S., Wiegand, S.M., McAlister, W.H. & Whyte, M.P. Absence of MMP2 mutation in idiopathic multicentric osteolysis with nephropathy. *Clinical Orthopaedics & Related Research* **462**, 80-6 (2007).
24. Perkins, N.D. Integrating cell-signalling pathways with NF-kappaB and IKK function. *Nature Reviews Molecular Cell Biology* **8**, 49-62 (2007).
25. Yang, F. et al. Applying a targeted label-free approach using LC-MS AMT tags to evaluate changes in protein phosphorylation following phosphatase inhibition. *Journal of Proteome Research* **6**, 4489-97 (2007).
26. Tolar, J., Teitelbaum, S.L. & Orchard, P.J. Osteopetrosis. *New England Journal of Medicine* **351**, 2839-49 (2004).
27. Karin, M., Yamamoto, Y. & Wang, M. The IKK NF-kB system: A treasure trove for drug development. *Nat.Rev.* **3**, 17-26 (2004).